Amphiphilic Polymers as Enhanced Drug Delivery Systems by Aibani, Noorjahan
 Amphiphilic Polymers as Enhanced Drug 
Delivery Systems 
 
 
 
 
 
 
 
 
 
 
Noorjahan Aibani (M. Pharm) 
 
Faculty of Life and Health Sciences 
Ulster University 
 
A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
May 2018 
I confirm that the word count of this thesis is less than 100,000 words. 
2 
 
Declaration 
I hereby declare that with effect from the date on which the thesis is deposited in the 
library of Ulster University, I permit, 
1. The librarian of the university to allow the thesis to be copied in whole or in part 
without reference to me on the understanding that such authority applies to the 
provision of single copies made for study purposes or for inclusion within the stock of 
another library. 
2. The thesis to be made available through the Ulster institutional repository and/or 
EthOS under the terms of the Ulster eTheses deposit agreement which I have signed. 
This thesis is the sole work of the author and has not been submitted for any previous 
application for a higher degree.  
 
 
Noorjahan Aibani  
3 
 
Acknowledgements 
I would like to take this opportunity to thank my supervisor Dr. Bridgeen Callan for her 
unwavering support. Dr. Callan made me feel right at home from the very first day and 
has been the same until the last. I couldn’t have asked for a better supervisor and as I 
always say- You are the best! Thanks to Dr. Susan Fetherston, who left me in such capable 
hands. 
To my second supervisor, Prof. Anthony McHale, for the in-vivo studies- I can’t imagine 
going through them without his guidance and support and his honest appreciation of my 
work makes me fill up with pride. 
Special note of thanks to my third supervisor, Prof. John Callan for all the dinners and 
summer trips! And for his direct and indirect support towards the successful completion 
of my research work. 
Thanks to Dr. Sukanta Kamila and Dr. Colin Fowley for teaching me the basic techniques 
that helped shape the early days of my PhD and who I always look up to. 
To all my colleagues and friends who have endured my happy chirpy days and my 
demotivated days- Dean, Conor, David, Jordan, Scarlett, Fernanda, Chloe, Jason, Kieran, 
Nino, Ivana, Heather, Federica, Siman, Bernie and particularly Varun- you all deserve a 
special accolade. Thank you so much. 
Thanks to Ulster University Vice Chancellor Research Scholarship for giving me this unique 
opportunity of pursuing a fully funded PhD in an international environment. I am grateful 
for the kind and supportive nature of all the people of Northern Ireland who made me 
feel accepted in this foreign place away from home. 
Lastly, I would like to extend a heartfelt thank you to my lifeline- my little brother, Tausif- 
who has stood by me like a pillar at all times since childhood and throughout my PhD 
journey. He is my pride and joy and he deserves the best in life. 
  
4 
 
Summary 
This thesis involves the application of different amphiphilic copolymers as self-assembling 
nanoparticulate drug delivery systems such as micelles and polymersomes. The first 
chapter starts with the introduction to nanoparticulate drug delivery systems and the 
significance of liposomes to nanoparticulate drug delivery research. It describes the 
advantages of polymeric systems as future contenders in the preparation of 
nanoparticles. Later, different types of self-assembling copolymers and the methods of 
preparation of different nanoparticles are discussed. The chapter concludes with the 
recent applications of polymeric micelles and polymersomes in several areas of drug 
delivery and diagnostics. 
The second chapter presents the comparison of liposomes made from egg 
phosphatidylcholine, cholesterol and PEG conjugates (Mn 500 and Mn 2000) with 
polymersomes made from random copolymers having the same composition to that of 
the liposomes. The polymersomes were neutral in charge due to the absence of 
zwitterionic choline head groups as compared to liposomes. They were found to be 
smaller in size than liposomes when prepared by the reverse phase evaporation method. 
The comparison of polymersomes to liposomes revealed enhanced cellular uptake and 
good stability upon storage for the polymersome preparations. 
The third chapter of this research thesis focuses on the application of polymeric micelles 
for triggered drug delivery combined with real time monitoring of drug release using 
FRET. The micelles were prepared from amphiphilic random copolymers comprising of a 
decyl chain group and PEG (Mn 500) and encapsulated a FRET pair of bodipy and 
spiropyran compounds. The spiropyran moiety is capable of ring transformation to its 
merocyanine counterpart upon triggering by UV light. This transformation leads to the 
release of some of the micellar contents to the surrounding media while concomitantly 
displaying a molecular communication with the bodipy moiety remaining within the 
micelle. The in-vitro release of merocyanine and FRET efficiency between bodipy and 
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merocyanine in HeLa cells was confirmed. Validation of real time quantification of 
spiropyran conjugated API release through bodipy fluorescence was also demonstrated. 
Finally, the fourth chapter establishes the application of amphiphilic copolymer 
polymersomes for enhanced anticancer therapy. Three anticancer drugs namely, Dox, 5-
FU and Leucovorin calcium were encapsulated into polymersomes and observed for in-
vivo anti-tumour effects in pancreatic BxPC-3 ectopic xenograft mouse model after 
intratumoral and intravenous injections. Polymersomes encapsulated with the anticancer 
agents displayed an enhanced tumour reduction and less peripheral toxicity as compared 
to combination free drug solution at the same concentration. 
In conclusion, the work presented within this thesis highlights the important role of 
amphiphilic polymers within drug delivery. 
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1.1 Introduction to drug delivery 
Drug delivery systems (DDS) lie at the interface between chemistry and pharmacology and 
provide an effective way to deliver drugs to ensure maximum therapeutic effect and high 
patient compliance. Before 1950, all drugs were manufactured as pills and capsules which 
immediately released the drug upon contact with water1, 2. The first sustained release 
dosage form was manufactured by SmithKlein Beecham in 1952, which provided a 12-
hour release profile known as ‘Spansule technology’. During the next three decades 
various oral and transdermal dosage forms with controlled release profile were produced. 
These were based on different release mechanisms, such as dissolution and diffusion 
controlled systems utilizing a polymer pump or matrix, some of which are available in the 
market even today3. Oral drug delivery still remains the most attractive route of 
administration due to the cost of manufacture as well as the ease of dose regulation and 
patient compliance. Controlled release systems offer several advantages over immediate 
release, such as; maintaining therapeutic plasma levels, reduction of harmful side effects 
by allowing local administration and improvement of the half-life of drugs4. The second 
generation drug delivery systems developed after 1980 focused on different routes of 
drug delivery, such as; long term intramuscular or subcutaneous depot formulations and 
pulmonary delivery of insulin to overcome the various drawbacks of conventional oral 
dosage forms5, 6. Around 1990s, research involved the use of hydrogels and 
mucoadhesion techniques and the use of smart polymers responsive to temperature and 
pH7. In the late 1980’s and early 1990’s various controlled release oral formulations such 
as Procardia XL® and Ditropan XL®, based on osmotic push pull controlled delivery 
systems, were developed. The advent of biopharmaceuticals such as proteins, peptides 
and gene delivery further introduced the need for controlled delivery systems which can 
mimic the physiological pattern8. The last decade of the 20th century, saw a boost in 
research for cancer chemotherapy combined with surgery using nanoparticulate 
delivery9. In 1986, Maeda et al. observed that nanoparticles (NPs) accumulated better in 
tumour vasculature than normal blood vessels owing to enhanced permeation and 
retention (EPR) effects due to their nanometre size10, 11. This observation led to a shift in 
22 
 
focus on improving delivery vehicles for enhanced therapeutic effect rather than 
inventing new therapeutic molecules. 
 
1.2 Nanoparticulate drug delivery 
The industrial revolution sparked a dramatic interest in nanotechnology based systems 
with Richard Zsigmondy, a 1925 Nobel Laureate in chemistry, coining the term 
“nanometer” for the size of gold colloids that he measured under an ultramicroscope12. 
However, modern nanotechnology is credited to Richard Feyman, a Nobel Laureate in 
Physics, who, in 1965, presented a lecture at Caltech (the California Institute of 
Technology), at an APS (American Physical Society) meeting titled “There’s plenty of room 
at the bottom” where he introduced the notion of manipulating matter at atomic level. At 
around the same time in 1965, Bangham introduced lipid based bilayers for encapsulating 
small molecules and slightly later, in 1974, Nario Taniguchi, a Japanese scientist coined 
the term “Nanotechnology” for semiconductor processes at nanometer level. Towards 
the end of the 1980’s, Eric Drexler of MIT (Massachusetts Institute of Technology) 
published a book entitled “Engines of Creation: The Coming Era of Nanotechnology” in 
1986 utilizing the ideas from Richard Feynman and Taniguchi’s term of nanotechnology, 
generating further interest in the field 13, 14. Today, nanotechnology based drug delivery 
systems have become the driving force for advancements in the field of drug delivery. 
Nanotechnology has helped bridge the gap between conventional therapies and the need 
for novel targeted drug delivery systems for new age diseases such as cancer.  It has 
provided a tremendous boost in the field of drug delivery specifically in the delivery of 
new chemical entities, targeted drug delivery, co-delivery of multiple drugs, controlled 
release of drugs, tissue engineering, theranostics and also micro-/nanoelectromechanical 
device-based drug delivery systems15 utilizing both biodegradable and non- 
biodegradable materials for a variety of applications. A brief overview of different 
nanoparticulate systems is depicted in Table 1-1. 
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The use of nanotechnology has helped in the design of therapies of the future by lowering 
doses required for therapeutic efficacy as well as increasing the therapeutic index and 
improving safety profiles of new therapeutic molecules.  Current nanoparticulate DDS 
utilizing biodegradable materials being investigated include liposomes16, micelles17, 
nanospheres18, nanocapsules19, niosomes20 and polymersomes21, 22 among others. 
Nanotechnology based delivery systems are in the nanometre sized particles generally in 
the size range of 50 - 500nm containing encapsulated, conjugated, dispersed or adsorbed 
therapeutic or imaging agents. A schematic representation of the different types of NPs 
and their size range is illustrated in Figure 1-123.  
 
Figure 1-1 Illustration of the different types of NPs and their size range23. 
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Table 1-1 Different types of NPs in drug delivery 
Type Composition Size (nm) Applications in drug delivery Ref. 
Carbon 
nanotubes 
Seamless cylinders of one or more 
layers of graphene 
0.8 - 2 or 5 -
20 depending 
on number of 
layers 
Biosensors and medical devices, compatibility with 
DNA and proteins. Used for fluorescent and 
photoacoustic imaging, cell internalization for 
transport of anticancer drugs 
24 
Metallic NPs Colloids of gold and silver, iron oxide 
NPs, nanoshells and nanocages made 
of silica-gold shell 
1 - 100 Biomedical imaging such as Ultrasound, Magnetic 
resonance imaging (MRI), Computerized tomography 
(CT), optical imaging, Positron emission tomography 
(PET) and Surface enhanced raman spectroscopy 
(SERS). 
25 
Quantum 
Dots 
nanocrystal 
Semiconductor NPs made of CdS, CuBr, 
CdSe, PbS, ZnS, Zn3P2, Cd3P2 
synthesized in silicate glass and 
colloidal solutions 
10 - 100nm Bioimaging with/replacing organic fluorescent dyes 26, 27  
Liposome Bilayered nanovesicles made of natural 
and synthetic phospholipids 
Less than 500 Various areas of drug delivery especially anticancer 
therapy such as active and passive targeting, 
triggered delivery, controlled release, diagnostics etc. 
28 
Polymeric 
NPs 
Micelles, dendrimers, polymersomes 
made of amphiphilic copolymers 
Less than 500 Various areas of drug delivery 29 
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1.2.1 Need for nanoparticulate DDSs 
The discovery of new therapeutics to target specific diseases has led to many formulation 
challenges associated with the method of delivery. In particular, in cases where 
parenteral delivery is the inevitable mode of administration. The problems associated 
include poor retention of the pharmaceutical at the site of action, short circulation half-
life and infinite dilution of the therapeutic agent leading to injection of high 
concentrations or increased dosing frequencies. The administration of drugs with the help 
of delivery vehicles allows the therapeutic agent to be encapsulated within the DDS and 
subsequent release in a controlled fashion over a period of time, or on occasion the DDS 
can be adapted to ensure the local delivery of the drug at the site of action30. This 
nanometre size range allows them to be injected without obstructing needles and proves 
advantageous for certain disorders such as cancer and inflammation due to the 
pathophysiology of these conditions31.  
NP DDSs have provided a tremendous boost to enhance the parenteral delivery of 
therapeutic agents which typically have to be administered parenterally due to limited 
water solubility, low oral bioavailability and/or very short half-lives. For example, 
hydrophobic molecules such as anticancer drugs, hormones, anti-inflammatory drugs and 
drugs for pain relief such as morphine can be encapsulated into the hydrophobic interiors 
of the delivery vehicle and transported to the site of action to improve their efficacy30. 
Non-specific anticancer drugs such as Doxorubicin hydrochloride (Dox) are best 
encapsulated into a delivery vehicle to reduce its adverse side effects and help target the 
specific tumour sites. Many biopharmaceutical protein and peptide drugs, such as insulin 
and hormones, have a short shelf life due to limited structural stability on storage, benefit 
from encapsulation within a DDS to help improve their stability and efficacy 30.  
1.3 Liposomes- Reigning nanoparticulate systems for drug delivery  
The therapeutic use of siRNAs, proteins and enzymes has allowed for a revolution in 
healthcare regimes32. In order to reach its full potential, it is essential that such 
therapeutics can be delivered to their required site of action. The size and hydrophilic 
26 
 
nature of these compounds, combined with the fact they are often highly charged, 
presents a significant challenge from a formulation perspective. One successful method of 
delivering these types of compounds to their target cells is through the use of liposomes. 
Since the late nineteenth/early twentieth century scientists have appreciated that the 
cellular membrane consists of a lipid bilayer33 and as such, most nonpolar compounds can 
readily pass through this membrane to the interior of the cell. The translation of this 
mechanism for drug delivery purposes occurred in 1965 when Bangham34 coined the term 
‘liposomes’ with a description of self-forming lipid vehicles capable of encapsulating 
compounds for cellular transport. By mimicking the lipid bilayer, these vehicles, together 
with their content, could transcend the structurally similar cell membrane and enter the 
interior of the cell. Liposomes are composed of phospholipids with concentric lipid layers 
having an aqueous core. The presence of the hydrophobic bilayer allows the entrapment 
of hydrophobic drug molecules while hydrophilic molecules can be encapsulated into the 
aqueous core. This unique property allows them to deliver a large variety of drugs across 
the cell membrane35-38. Liposomes offer several advantages such as biocompatibility, 
ability of surface modification to enable active targeting and encapsulation of large 
amounts of payload 35-38.  
First generation liposomes had no surface modifications leading to limited performance in 
terms of circulation half-life and protection against serum proteins but could be adapted 
for desired sizes and rigidities39-42. These properties lead to the first commercialized 
liposomes loaded with Amphotericin B for the treatment of Leishmaniosis43, 44. The 
limitations of conventional liposomes lead to the development of various surface 
modification strategies such as, coating the liposome surface with polyethylene glycol 
(PEG) (1) which proved successful for liposome stabilization and increasing circulation 
times giving rise to second generation of surface modified liposomes also called as Stealth 
liposomes45-48.  
 
 
(1) 
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Several commercially available liposomes and those in clinical development consist of 
surface modification with PEG. Various first and second generation liposomes approved 
for clinical use and in different stages of clinical trials are depicted in Table 1-249, 50. 
Table 1-2 Various liposomal formulations in clinical use and different stages of clinical 
trials 49, 50 
Tradename® Drug encapsulated Indication Current status 
AmBisome Amphotericin B Fungal infections 
Leishmaniasis 
Approved 
Doxil/Caelyx Doxorubicin Kaposi's sarcoma, Breast 
cancer, Ovarian cancer 
Approved 
DaunoXome Daunorubicin Kaposi's sarcoma Approved 
Myocet Doxorubicin Breast cancer  
Amphotec, 
Abelcet 
Amphotericin B Aspergillosis Approved 
DepoDur Morphine sulfate Post-surgical pain Approved 
Diprivan Propofol Anesthesia Approved 
Lipo-Dox Doxorubicin Kaposi's sarcoma, Breast 
cancer, Ovarian cancer 
Approved 
SPI-077 Cisplatin Solid tumours Phase II 
CPX-351 Cytarabine:daunorubicin Acute myeloid leukemia Phase I 
CPX-1 Irinotecan HCI:floxuridine Colorectal cancer Phase II 
MM-302 ErbB2/ErbB3-targeted 
doxorubicin 
ErbB2-positive breast 
cancer 
Phase I 
MBP-436 Transferrin-targeted 
oxaliplatin 
Gastric and gastro-
esophageal junction cancer 
Phase II 
Lipoplatin cisplatin Non-small cell lung cancer Phase III 
ThermoDox Thermosensitive 
doxorubicin 
Primary hepatocellular 
carcinoma 
Phase III 
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Since their development liposomes have been utilized for numerous applications ranging 
from biomiaging to gene and vaccine delivery, treatments of infections and inflammation, 
lung diseases and most importantly anticancer therapy49. Liposomes have proved to be 
useful in reducing the side effects of encapsulated drugs and passively accumulate in 
areas of high vasculature when the particle size is below 200nm, an example of which is 
the clinically approved formulation with Dox. Dox has irreversible cardiotoxicity when 
injected as a free solution which is significantly reduced when encapsulated in liposomes 
and is commercially available as Doxil®51, 52. Active targeting strategies of liposomes have 
garnered a lot of attention recently. For example, Gabizon et al. and Yamada et al. found 
increased cellular uptake within tumour cells of folate conjugated to PEG linkers coated 
on the liposome surface53, 54. Another area of research for liposome development is the 
use of internal and external triggers for the controlled release of encapsulated drugs. 
Many intrinsic triggers such as enzyme triggered release, pH and redox triggered, and 
temperature sensitive liposomes55-57 as well as various remote triggers such as 
ultrasound, light and magnetic field58-61 have been developed recently. Even with the 
triggered drug release capabilities of liposomes and the problems of quick elimination by 
the RES in the first generation of liposomes being overcome by surface coating with PEG, 
they still possess several problems; such as physical and chemical instability due to their 
biological nature and drug leakage over time62, 63. They also lack control over the rate of 
drug release, have difficulty in overriding barriers such as the blood brain barrier, and 
insufficient loading of drugs64. These limitations have led to an exploration towards more 
synthetic polymer analogues of lipids, which possess similar properties of assembling into 
monolayer and bilayer NPs and can provide more stability than liposomes. 
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1.4 Polymeric systems for drug delivery 
During the latter part of the 20th century polymers had been utilized and marketed for a 
variety of functions. These included development of 1974 sustained release Pilocarpine 
by Alza Corp., Ocuserts® for the treatment of glaucoma65 as well as the 1976 FDA 
approved Progestasert®, an intrauterine device for sustained release of progesterone66 by 
the same company. In 1990, Wyeth-Ayerst Laboratories developed the contraceptive 
subcutaneous implants Norplant® for sustained release levonorgesterol67. Poly (ethylene-
co-vinyl acetate) (2) was commonly used drug release rate controlling polymer for the 
above mentioned devices68. With advancements in nanotechnology during this time, 
polymers have been increasingly used in various micro and nanoparticulate systems with 
various micro-sized systems based on zero order kinetics having more sustained release 
profiles69. Polymers used in drug delivery systems can be divided into two categories- 
Nonbiodegradable-mainly used as implants for diffusion controlled systems and 
Biodegradable-used for chemically controlled and triggered release systems as micro and 
NPs70. 
 
 
 
 
 
Various polymer based drug delivery systems can be summarized as follows; 
Implants: Implantable polymers can be biodegradable or nonbiodegradable depending on 
their application. Examples of such implants include those for ocular drug delivery such as 
non- biodegradable Vitasert® controlled release ganciclovir for the treatment of 
cytomegalovirus retinitis, Retisert® containing fluocinolone acetonide for non-infectious 
(2) 
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uveitis and biodegradable Ozurdex® intravitreal implant for sustained release 
dexamethasone for treatment of macular oedema71, 72. Polymers mostly used for non-
biodegradable implants include silicone, polyvinyl acetate (PVA) and ethylene vinyl 
acetate (EVA) whereas those used for biodegradable implants generally consist of natural 
polymers such as albumin, collagen and gelatin. The major disadvantage of implantable 
drug delivery systems is the need for surgery to introduce it into the body and the 
potential need for removing it from the body after use73.  
Hydrogel systems: Hydrogels are three-dimensional crosslinked polymer networks which 
swell rapidly in the presence of water. Hydrogels can be made of water soluble polymers 
which have the ability to absorb large amounts of water and can be formulated into 
various forms such as microparticles, NPs, films and coatings for a large range of 
applications74, 75. Despite various advantages, hydrogels have certain limitations such as 
rapid release of drugs due to fast swelling of polymer and fast degradation of polymer. 
Several strategies have been developed to overcome these drawbacks such as covalent 
bonding of the drug to the polymer, however their use is still limited in controlled drug 
delivery76. 
Microspheres: Microspheres can be defined as spherical particles in a size range of 10-
1000 microns. In these systems, the drug is either encapsulated inside the porous 
microspheres or dispersed into the polymer matrix. Polymer based microspheres have the 
potential to release their load either by the leaching of drug from polymer or by 
degradation of the polymer matrix. They can be manufactured by several methods such 
as emulsion-solvent evaporation, spray-drying, suspension polymerization, ultasonication 
and phase separation77. However their large size limits their application for cancer 
therapy. 
 
1.5 Amphiphilic copolymer vesicles- Next generation nanoparticulate drug delivery systems 
Supramolecular self-assembling DDS expanded from lipids to include both natural and 
synthetic polymers with the only prerequisite for successful formation being the presence 
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of both hydrophobic and hydrophilic units. The use of biopharmaceuticals has not 
replaced traditional small molecule drugs, when prescribed together they often display a 
synergistic benefit to the patient. The advances in such combination therapies has led to 
the requirement of drug delivery systems to expand so that both hydrophobic and 
hydrophilic drugs can be delivered in the same vehicle simultaneously78. This can present 
a significant challenge as the physicochemical properties of these two classes of 
compounds are quite literally ‘polar opposites’. The development of drug delivery 
systems formed from amphiphilic building blocks has obvious benefits when considering 
the delivery of compounds with distinctly different physical properties. These amphiphiles 
can self-assemble in solution to form entities with both hydrophilic and hydrophobic 
regions that are capable of delivering a wide range of both polar and nonpolar 
compounds79. Often these particles have diameters in the nanometre range and provide 
improved stability for their cargo, have good biocompatibility with tissues and cells and 
due to their subcellular size display a relatively high intracellular uptake80. It has been 
established that nanocarriers can become concentrated preferentially in tumours, 
inflammatory sites and at antigen sampling sites by virtue of the EPR effect of the 
vasculature. Once accumulated at the site, these NPs can act as a drug depot, providing a 
source of active pharmaceutical ingredient (API) to be released as and when required. 
This leads to enhanced bioavailability, a more sustained/controlled release and reduced 
toxicity that can be caused by a ‘burst release’ of the API. Central to the development of 
these delivery systems is the flexibility offered by using polymers as the building block. In 
particular, amphiphilic co-polymers81, formed from covalently linked polymer chains in 
blocks of two or more82, have demonstrated significant potential for the delivery of both 
large highly charged biological compounds as well as the more conventional small 
molecule and typically hydrophobic drug compounds. Several polymeric NPs, especially 
micelles, in various stages of clinical development for anticancer therapy are depicted in 
Table 1-383, 84. 
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Table 1-3 : Different polymeric NPs for cancer therapy in different stages of clinical 
development. 
Formulation Indication Clinical phase 
PEG–polyglutamate micelle loaded with 7-
ethyl, 10-hydroxy camptothecin 
Breast cancer Phase II 
PEG–polyaspartate micelles loaded with 
paclitaxel 
Advanced gastric cancer Phase II 
Pluronic® L61 and F127 micelles loaded with 
doxorubicin 
Adenocarcinoma of 
gastrointestinal tract 
Phase III 
PEG–poly(d,l-lactide) micelles loaded with 
paclitaxel 
Non small-cell lung, bladder, 
pancreatic, and ovarian cancer 
Phase II 
PEG–poly(γ-benzyl-l-glutamate) micelles 
loaded with cisplatin 
Solid tumours Phase I/II 
PEG–polyaspartate micelles loaded with 
doxorubicin 
Various types of cancers Phase II 
Cyclodextrin–PEG micelles loaded with 
camptothecin 
Lung & ovarian cancer Phase II 
PSMA targeted PEG-PLGA or PLA-PEG NPs with 
docetaxel 
Various types of cancers Phase II  
Polymeric micelles loaded with Paclitaxel Head and neck or breast cancer Phase II 
Poly amino acids with PEG conjugated with 
cisplatin as micellar systems 
Lungs, pancreatic, biliary or 
bladder advanced solid tumours 
Phase III 
Poly amino acid with PEG, conjugated with 
Oxaliplatin as micelles 
lymphomas and advanced solid 
tumours  
Phase I 
Silica-gold nano-shells coated with PEG for NIR 
light mediated thermal ablation 
Thermal ablation of lung and solid 
primary metastatic tumours 
N/A 
Silica NPs coated with PEG loaded with a NIR 
fluorophore and 124I radiolabeled cRGDY 
targeting peptide 
In-vivo imaging of melanoma and 
brain tumours 
N/A 
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1.6 Introduction to amphiphilic copolymers 
Amphiphilic systems capable of self-assembling provide unique opportunities in the 
design of advanced materials for applications in nanoparticulate drug delivery. The ability 
to self-assemble into ordered morphologies is mainly dependant on the thermodynamic 
incompatibility of the hydrophilic and hydrophobic blocks. This leads to their spatial 
organisation whereby blocks of similar nature align themselves in the nanoscale region. 
Furthermore, the reversible non-covalent interactions allow dynamic switching of the 
conformations into various other morphologies and functions in response to external 
stimuli, further providing a platform for designing smart amphiphilic supramolecules for 
nanobased drug delivery85. Amphiphilic polymers are capable of self-assembling into a 
wide variety of structures such as spherical micelles, cylindrical micelles, bilayered 
vesicles, nanofibers, nanotubes, lamellae and bi-continuous structures. These 
supramolecular moieties mimic the assembly of biological molecules such as proteins and 
lipids allowing them to integrate into the body and perform specific cellular functions. 
The recent advancements in polymerisation techniques has facilitated the facile synthesis 
of amphiphilic copolymers with defined compositions, molecular weights and elaborate 
structural design86. 
Many examples can be found in the literature where amphiphilic polymers have been 
used for drug delivery applications87. Such polymers have the ability to form a variety of 
assemblies depending on the nature of the two blocks hydrophilic and hydrophobic, the 
number of monomers used in the polymer synthesis and the particular polymerization 
process chosen for their assembly87, 88. The most common number of monomers used for 
the preparation of amphiphilic polymers is two, hence the term co-polymer88, three 
monomers polymerized are known as terpolymers89, while one amphiphilic monomer can 
also create an amphiphilic homopolymer90. The blocks can align themselves in the 
aqueous phase into various shapes depending on the hydrophilic lipophilic balance which 
affects their ability to form spherical structures.  Diblock copolymers with hydrophilic 
fractions (f value) less than 20% have a stronger tendency towards forming solid particles. 
Whereas increasing the f value between 20-40% generally form loose fluid-like bilayer 
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structures and f value above 40% generally leads to the formation of worm like and 
spherical micelles91.  Co-polymers can form conformations with alternating92, random93, 
graft94, star95 or brush96, 97 type structures (Figure 1-2), with the particular type created 
dependent upon the method of polymerization chosen. The simplest and most widely 
used of these structures is the random co-polymer, however these can be difficult to 
control in terms of reproducibility and so the brush copolymer and more recently the 
periodically grafted copolymers (PGCP)98, which are a nonionic version of the ionenes, 
have generated significant interest. Some new types of copolymers such as gradient and 
aperiodic copolymers have also emerged recently99. 
 
 
 
 
Figure 1-2 Types of amphiphilic copolymers 
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1.6.1 Block copolymers  
Block copolymers consist of two or more blocks of copolymers covalently attached to 
each other sequentially. Linear block copolymers consist of the copolymers attached in a 
linear fashion whereas star block copolymers are composed of three or more blocks 
attached at a common point although they can also be viewed at graft polymers91. Simple 
block copolymers composed of a single segment of A and B monomers are called A-B 
block polymers, whereas when monomer B is connected on both sides with monomer A, 
it is termed as ABA type block copolymer. In the third type, A and B segments are 
connected multiple times and are termed as multiblock copolymers100 as depicted in 
Figure 1-3. Block polymers consisting of two different monomer units have been terms as 
diblock polymers whereas those with three different monomer units have been termed as 
triblock polymers101. Novel synthetic strategies using ionic and radical polymerisation 
permit the synthesis of advanced tailor-made block copolymers capable of a multitude of 
functions. It is possible to combine the properties of incompatible materials, for example 
hydrophilic and hydrophobic monomers to generate amphiphilic block copolymers which 
are capable of demonstrating various interfacial properties in different solvents making 
them attractive for numerous applications. The synthesis of block copolymers has to be 
controlled precisely by sequential addition of monomers leading to effective control of 
molar mass distribution and thus the chemical heterogeneity which influence the final 
properties of the block copolymer102. Even though block copolymers exhibit excellent self-
assembling behaviour, their synthesis can be tedious and time consuming due to 
controlled synthesis and prolonged post polymerisation procedures such as grafting, 
hydrolysis, substitution and click chemistries. Amphiphilic block copolymers having 
different compositions and by various methods of preparation can produce different 
types of nanostructures such as micelles, core-shell NPs, nanospheres, nanocapsules and 
polymersomes.  
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Figure 1-3 Schematic representation of different arrangements of block and graft 
copolymers 
 
1.6.2 Random copolymers 
Also referred to as ‘statistical polymers’ random copolymers are a type of copolymer in 
which different monomers are arranged randomly and the likelihood of finding a 
monomer at any given point in the polymer is independent of the adjacent units. The 
synthesis of random copolymers is typically achieved by one step polymerisation of one 
or more monomers also called a “one pot” synthesis. The self-assembling properties of 
random copolymers is largely dependent on the hydrophilic/lipophilic balance of the 
monomers and affects the assembling morphologies of the copolymers. The assemblies 
can be easily tuned by controlling the ratio of the two monomer blocks. The resulting size 
of the polymer depends on the hydrophobic chains and the nature of the solvent used. 
Random copolymers have been employed for different applications not only due to their 
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advantage over block copolymers for ease of preparation but also their ability to form 
different types of nanostructures similar to block copolymers103. 
Yukari Oda et al. compared the structure activity relationship of block versus random 
copolymers as antibacterial and haemolytic agents104. They utilised random and block 
copolymers having poly (vinyl ether) based derivatives with both copolymers having a 
similar composition of monomers prepared by the living cationic polymerisation 
technique and demonstrated their activity against E Coli. They found that both 
copolymers had similar activity against E Coli however block copolymers had lesser 
haemolytic activity when compared to random copolymers. Thus, suggesting that 
copolymer assembly is not a determining factor for antimicrobial activity and the different 
single chain conformations of both the copolymers plays an important role104. In another 
example Matsumoto et al. created PEG and urea based random, block and graft 
copolymers having different monomer sequences, chain length, composition and 
functional groups by ruthenium-catalysed living radical polymerisation and observed their 
self-folding properties in water and chloroform105. They observed that PEGMA/BPUMA 
(PEG methyl ether methacrylate/urea-bearing methacrylate) based random copolymers 
having 30-40 % urea units efficiently assembled in water to form globular unimer micelles 
which were dynamic and reversible by the addition of methanol to the system and had 
good reproducibility. Thus, these polymers provide on demand controlling of assembly 
into micelles by temperature, solvents and presence of acidic compounds in the system, 
opening new applications in various areas of drug delivery105. Random copolymers have 
also been utilised as supramolecular assemblies which response to pH, temperature and 
light making them suitable for stimuli responsive drug delivery systems106-108 and those 
responsive to multiple stimuli109 . 
 
1.6.3 Graft copolymers 
Graft copolymers are segmented copolymers composing of a linear backbone with 
random branches of another homopolymer or copolymer attached, the branches of which 
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are structurally different from the main chain. These copolymers are capable of self-
assembling into unique nanostructures such as wormlike conformations possessing tight 
molecular dimensions and distinguished chain end arrangements as compared to linear 
block copolymers110. Graft copolymers can be formulated into a variety of shapes and 
conformations such as branched copolymers, cross linked polymers, comb like structures, 
star shaped configurations and dendritic systems (Figure 1-3) as well as many other 
recent complex topological systems. The growing attention to the synthetic strategies of 
well-defined polymers has led to the development of three different methods for 
synthesizing graft polymers which allow diversity, functionality and flexibility to these 
polymers and allow precise control over the micro environment, topology and 
composition to these graft polymers. These methods of polymerisation include: 
Grafting-onto method: based on attaching pre-formed side chains to a pre-synthesized 
backbone by coupling them together.  Both the polymer chains are synthesized separately 
allowing easy control on their pathways of synthesis and nature of the parent and 
attaching chains111.  
Grafting-from method: involves pre-synthesis of a polymer backbone which functions as 
micro-initiator for the growth of side chains onto its multifunctional sites. Living radical 
polymerization technique is commonly used for this type of synthesis.  Low concentration 
of free radical propagating species allows better control over the coupling and 
termination of the polymerization chain reaction and also limits the stearic hindrances 
which are unavoidable in the grafting-onto method forming polymers with narrow weight 
distribution and high grafting density. Tedious post processing and purification of the 
polymers can also be avoided by this method because of the absence of unreacted 
initiator after the completion of polymerization112.  
Grafting-through method: employs the use of surface attached self-assembled 
monolayer macromolecules having polymerizable groups. Thus the polymer generation is 
initiated in solution and the growing chains can be integrated into the surface bound 
polymer chains allowing its direct anchoring onto the monolayer polymer backbone, 
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however the chains can continue to grow allowing the integration of free or surface 
bound chains to the growing polymer chains. Thus the grafting through methodology is a 
combination of both grafting onto and grafting from methods 113.  
 Examples of graft copolymers are reported in literature emphasizing their use in different 
drug delivery applications. Hoskins et al. have presented a comprehensive review on 
Comb shaped graft copolymers highlighting the different homopolymer backbones used 
and various hydrophilic and hydrophobic side chains attached to the backbone114. Comb 
shaped copolymers have been used for various site- specific delivery applications, stimuli 
responsive NPs, anticancer drug delivery and have potential for oral delivery of proteins 
and peptides114. Fan et al. reviewed the formation of unimolecular micelles using various 
graft polymers such as amphiphilic dendrimers and dendritic polymers, hyperbranched 
polymers, star shaped polymers, cyclic and brush copolymers. They concluded that 
unimolecular micelles present various advantages over multimolecular micelles because 
of their non-reliance on self-assembly hence imparting better stability to environmental 
changes such as pH, temperature, dilution and ionic strength 115. 
 
1.6.4 Self-assembling polymers based on PEG  
Polyethylene Glycol (PEG) (1) is the most commonly used hydrophilic monomer for the 
synthesis of different types of amphiphilic copolymers. PEG is a non-ionic water-soluble 
polyether having good biocompatibility and poor immunogenicity. Additionally, it 
provides stealth properties to the NPs by reducing the adhesion of opsonins present in 
the blood serum thereby avoiding their recognition by the reticuloendothelial system 
(RES) and being invisible to the phagocytic cells allowing them longer circulation time in 
the blood. The most likely and acceptable mechanism for this property of PEG is the 
extendable conformations of PEG on the surface of the NPs which create stearic 
hindrances and repulsive forces for the opsonins thus effectively blocking interactions 
with the NPs. PEG, with a molecular weight less than 30kDa, are eliminated from the body 
by renal clearance. The circulation half-life and accumulation in tumour of PEG based NPs 
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is largely dependent on the molecular weight, chain density and molecular 
conformation116, 117. PEG has been derivatized and conjugated to a number of bioactive 
molecules. It not only offers the advantage of a hydrophilic polymer backbone having low 
molecular weight dispersity which is inert and soluble in most organic solvents but also 
provides reactive terminating end groups, generally an alcohol. These favourable reactive 
properties allow PEG to be employed as a building block in many areas of biomaterials 
synthesis and pharmaceutical preparations118.  
Polymer NPs self-assemble using PEG as the hydrophilic polymer and can be synthesized 
using a variety of hydrophobic polymers, for example, in micelles the hydrophobic part of 
the polymer chain is generally composed of poly (lactic acid) (PLA), poly (aspartic acid) 
(PAsp), poly (e-caprolactone) (PCL), poly (propylene oxide) (PPO), poly (lactic-co-glycolic 
acid) (PLGA) and poly (sebacic acid) (PSA). These block copolymer conjugates have been 
utilised for the encapsulation of a variety of drugs. The most common conjugates are 
PEG-b-PAAs (poly amino acids), PEG-b-Polyesters and PEG-b-PLGA. PEG based amphiphilic 
polymers are capable of forming micelles and polymersomes depending on the type of 
application. Self-assembling copolymers of PEG-b-PAA have shown promising results in 
anticancer drug delivery. The presence of poly amino acids provides good 
biocompatibility, are biodegradable and have significantly lower toxicity when compared 
to free drug solutions. Furthermore, PAAs have a wide range of highly reactive functional 
groups on their surface such as amino, hydroxyl, carboxyl and thiol groups which can be 
utilised to design site specific delivery vehicles with improved drug loading. The most 
common amino acids used to synthesize these block copolymers are PAsp and PGlu (Poly 
(Glutamic acid))116. PEG-b-Polyesters such as PEG-PCL are synthesized by the ring opening 
polymerisation of e-caprolactone with the help of stannous octoate as a catalyst and the 
reaction is initiated by PEG. These block copolymers have been widely used for the 
encapsulation of a number of anticancer drugs and conjugated with different targeting 
ligands119. These copolymers can exhibit a variety of shapes by simply adjusting the salt 
concentration of the micellar solutions. The different shapes can have varying degrees of 
cellular uptake and antitumour activity. The hydrophilic/hydrophobic ratios of the two 
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monomers affect the drug loading, size and trigger responsiveness of these self-
assembled NPs. Hence PEG-PCL copolymers can be easily tuned to a variety of desired 
functionalities. PEG-PLA are another widely investigated block copolymer for drug 
delivery and are synthesized in a manner similar to PEG-PCL. The self-assembling 
properties of PEG-PLA can be adjusted by varying the hydrophilic-hydrophobic ratio which 
also affects its size and drug loading capacity119. Other examples of amphiphilic 
copolymers having PEG as the amphiphilic block are depicted in Table 1-4. 
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Table 1-4 Recent examples of different types of amphiphilic copolymers with PEG as the hydrophilic block 
Type of 
Polymer 
Hydrophobic block 
Type of drug 
encapsulated 
Type of NP Disorders Ref. 
B
lo
ck
 c
o
p
o
ly
m
er
s 
PLGA-b-PEG-b-PLGA triblock 
Paclitaxel encapsulation 
with surface modification 
with protamine 
Not specified Liver cancer 120 
PEG–GATGE dendritic block copolymers, based 
on a gallic acid (GA) core and triethylene glycol 
(TG) butanoate arms 
SiRNA complexation 
Dendriplex 
NPs 
Nucleic acid 
delivery 
121 
PEG−polypeptide copolymers with pH 
responsive pendant amine chains 
Doxorubicin Nanovesicles Breast cancer 122 
R
an
d
o
m
 c
o
p
o
ly
m
er
s 
Poly (dodecyl methacrylate-co-polyethylene 
glycol methyl ether methacrylate), poly[DMAx-
co-mPEGy] 
(S)-(+)-camptothecin (CPT) Micelles 
Anticancer 
activity 
123 
Poly(lactide-co-glycolide)-d-a-tocopheryl 
polyethylene glycol 1000 succinate 
Docetaxel Not specified 
Cancer 
chemotherapy 
124 
Poly [(2-hydroxyethyl methacrylate-3,3'-
dithiodipropanoic acid)x-co-(poly(ethylene 
glycol) methyl ether methacrylate)y], 
poly[(HEMA-DTDPA)x-co-mPEGy], redox and pH 
Hydrophilic and 
hydrophobic dyes  
Polymersomes 
Cancer 
chemotherapy 
125 
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sensitive copolymers 
l-cys-graft-poly[GMA-co-mPEG300] 
 
Hydrophilic and 
hydrophobic dyes 
Polymersomes Drug delivery 
126 
Decyl chain 
Hydrophilic FITC-CM-
Dextran 
Polymersomes Drug delivery 127 
Decyl chain with Cholesterol Hydrophilic FITC-CM-
Dextran and Doxorubicin 
Polymersomes Drug Delivery 
128 
R
an
d
o
m
 
&
 B
lo
ck
 Oligo (ethylene glycol) and cholic acid pendant 
groups 
Paclitaxel Micelles Ovarian cancer 129 
St
ar
-s
h
ap
ed
 c
o
p
o
ly
m
er
s 
Poly (ethylene glycol) methyl ether 
methacrylate macromonomer (PEGMA), 2-
(dimethylamino)ethyl methacrylate 
(DMAEMA) and a disulfide dimethacrylate 
(cross-linker, SS) 
SiRNA complexation Not specified 
Nucleic acid 
delivery 
130 
Poly(PEG-b-L-lysine) arm poly(Lcystine) core 
stars with outer PEG coronas decorated with 
folic acid targeting moieties 
Tagged fluorescent dye Not specified 
Targeted drug 
delivery 
131 
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G
ra
ft
 c
o
p
o
ly
m
er
s 
Poly(dimethylsiloxane-g-ethyleneoxide) 
grafted copolymers (PDMS-g-PEO) 
Coated fibrinogen Microparticles 
Blood 
contacting 
132 
g 2-(ω-methoxy)PEGyl-1,3-dioxan-5-ylamine 
with poly(N-(acryloyloxy)succinimide-co-butyl 
methacrylate) by an acid-labile diamine cross-
linker bearing two symmetrical cyclic 
orthoesters 
Paclitaxel encapsulation 
Crosslinked 
micelles 
Cancer 
chemotherapy 
133 
Poly(D,L-lactide-co-2-methyl-2-
carboxytrimethylenecarbonate)-g-
poly(ethylene glycol) (P(LA-co-TMCC)-g-PEG) 
docetaxel Micelles 
Cancer 
chemotherapy 
134 
Poly(ethylene glycol) methacrylate with 
Methyl methacrylate P(PEGMA-co-MMA) 
Indomethacin Micelles 
Anti-
inflammatory 
therapy 
135 
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1.7 Self-assembling micelles of amphiphilic copolymers 
Amphiphilic molecules such as surfactants assemble at the boundary of two 
immiscible phases or in aqueous solutions they tend to orientate themselves such that 
the hydrophobic blocks get removed from contact with the aqueous surface to 
achieve minimum free energy. At a specific narrow concentration range called the 
critical micellar concentration (CMC) these molecules tend to self-assemble 
themselves into definite colloidal particles termed as micelles which have an inner 
hydrophobic core and an outer hydrophilic shell thus minimizing the interaction of the 
hydrophobic blocks with the aqueous phase. At concentrations higher than the CMC, 
the micelles are thermodynamically stable whereas at lower concentrations they tend 
to disassemble, thus effectively breaking the micellar structure. Micelles made of 
amphiphilic copolymers have a distinct advantage over conventional surfactants as 
they typically have lower CMCs and resist dissociation upon dilution due to the 
interactions among the polymer chains81. Polymeric micelles are generally made of 
amphiphilic AB type block copolymers however micelles made from other types of 
polymers have also been explored for drug delivery applications. They are typically in 
the size range of 10-100nm and can be used for various triggered drug delivery 
applications. Moreover, unique functional moieties can be added onto the block 
polymer backbone enabling them to be tuned for desired applications such as cell 
targeting136. Different parts of a micelle serve different purposes, for example the core 
of the micelle is responsible for encapsulating the drug and protecting it from 
degradation by the surrounding environment (Figure 1-4A).  The outer shell provides 
stealth properties to the micelles protecting them from phagocytosis by the RES 
leading to prolonged blood circulation thus enhancing drug efficiency. The corona also 
determines the hydrophilicity, surface functionality and charge of the micelles along 
with the stability, biocompatibility and pharmacokinetic behaviour of the 
encapsulated drugs137. The core of the micelles can be modified to obtain high 
encapsulation efficiency leading to good therapeutic drug levels. The miscibility of the 
polymer and drug along with hydrophobic interactions between the micelle core and 
the drug plays an important role. The length of the hydrophobic chain and types of 
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substituents also affect the encapsulation of certain drugs. Insoluble drugs can be 
encapsulated by physical encapsulation methods such as dialysis and emulsification138.  
1.7.1 Methods for the preparation of micelles 
There are various methods documented for the formulation of polymeric micelles, a 
number of which have been described below:   
Direct dissolution method:  Commonly used for preparing micelles of block 
copolymers with low molecular weights and short hydrophobic blocks, this method 
has the polymer directly dispersed in an appropriate solvent. When dispersed in the 
solvent, which should be a good solvent for one block but a non-solvent for the other 
block, the polymer forms micelles through association of insoluble segments. This 
association can be aided by stirring, heat and sonication leading to formation of 
uniform spherical micelles at optimum conditions.  Improper processing conditions 
can lead to aggregation and uncontrolled growth and attachment of structures which 
eventually aggregate139. 
Addition of a precipitating solvent: In this method, the polymer is first dissolved in a 
non-solvent to which a selective solvent for one of the blocks is added leading to the 
formation of micelles at the interface of the two phases. This non-solvent can also be 
a change in physical conditions such as temperature, pH and ionic compositions such 
as the addition of salts140. 
Dialysis method: Unsuitable for large scale production, the dialysis method involves 
solubilisation of the copolymer and drug in water-miscible organic solvent and 
dialyzing it against water. The slow replacement of organic solvent with water leads to 
the association of the block copolymer with the drug encapsulated into spherical 
micelles. The use of a semi permeable membrane allows separation of the micelles 
from the unencapsulated drug which gets dialyzed outside in the surrounding water. 
However, a drawback of this method is the incomplete removal of the free drug141.  
Oil-in-water emulsion method: In this method, the drug and block copolymer are 
dissolved in an organic solvent which is not miscible in water, such as chloroform, an 
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emulsion is formed in water by vigorous stirring. The organic solvent is then 
evaporated to instantly form micelles142. 
Solvent evaporation/Thin film hydration method: This method can be employed for 
encapsulation of both hydrophilic and hydrophobic drugs in which the former is 
dissolved in the aqueous medium. In this method, the drug and polymer are dissolved 
in an organic solvent such as chloroform and evaporated to form a thin film in a round 
bottom flask. This thin film is then hydrated with the aqueous phase by rotation for a 
specific period, or vigorous shaking or sonication to aid self-assembly into micelles. 
This method has the advantage of large scale production however can only be utilized 
for block polymers having a high hydrophilic lipophilic balance which aids in easy 
dispersion of the film in the aqueous medium143. 
Freeze-drying: This method involves the use of a freeze dryable solvent such as tert-
butanol in which the drug and polymer are dissolved and freeze dried. The freeze-
dried powder is later reconstituted in isotonic solution such as phosphate buffered 
saline. Even though this method is feasible for large scale production it has the 
limitation of limited solvents available for freeze drying142, 144.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1-4 Schematic representation of A. micelles and B. polymersomes 
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The functionality of micelles can be further enhanced by surface and core 
modifications such as shell crosslinked micelles, surface crosslinked micelles and 
surface functionalized micelles145. The addition of crosslinks reinforces the 
multimolecular micelle structure thus making micelles as a single molecule with 
crosslinked arms imparting better stability upon dilution and environmental changes 
along with maintaining their size and morphology. Unimolecular micelles consisting of 
a single polymer molecule have also been explored. They can be made with polymers 
having star-shaped or dendritic architecture. These are generally made up of graft 
copolymers and require controlled synthetic procedures as discussed in section 
1.6.3146. Micelles having different polymer compositions and architecture have been 
used recently for a variety of applications especially for cancer drug delivery. Micelles 
have been designed with built in drug interactive cores to enhance the encapsulation 
of drug and its delivery to the tumour sites and PEG-drug conjugates as dual function 
carriers for cancer drug delivery147. Various types of polymeric micelles for active and 
passive targeting including functional micelles which respond to various external 
triggers such a pH, temperature and light have also been designed148. The various 
applications of micelles will be reviewed in the next sections. 
1.8 Self-assembling polymersomes of amphiphilic polymers 
In addition to the unilayered micellar systems, amphiphilic block copolymers can also 
self-assemble into bilayered vesicles called polymersomes composed of a hydrophilic 
core and a hydrophobic bilayer (Figure 1-4B). They are analogous to liposomes which 
are made up of lipids however polymersomes are solely made up of amphiphilic 
copolymers. The mechanism of formation of these bilayered vesicles is similar to those 
of micelles such that the hydrophobic blocks of the copolymer associate with each 
other to minimize interactions with the outer aqueous environment whereas the 
hydrophilic blocks face the inner aqueous core and the outer aqueous environment. 
Polymersomes can prove advantageous over liposomes because of the better control 
over the bilayer composition which can be engineered to make much thicker than 
those of liposomes making them more stable on physical storage and better able to 
encapsulate hydrophobic drugs149. The ability of amphiphilic copolymers to self-
assemble into bilayered polymersomes largely depends on the 
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hydrophilic/hydrophobic balance. Discher et al. reported that block copolymers having 
a hydrophilic fraction (f) of 35% ± 10% by weight of the total polymers generally tend 
to self-assemble into polymersomes, whereas polymers with f > 45% tend to form 
micelles and those with f < 25% form inverted microstructures150 as shown in Figure 
1-5. Polymersomes are a distinct class of drug delivery vehicle as their molecular 
weight is often very large compared to lipid based vesicles and other small molecule 
surfactants. Asymmetric block copolymers are capable of assembling into various 
types of structures, the ability of which is dependent on the core-chain and inter-
coronal interactions and the interfacial energy in equilibrium with the surrounding 
media which depends on the composition of the various blocks. Block copolymers 
with long chain blocks have shown more stability due to a higher bending modulus 
when compared to short chain block copolymers. The reason for this is that the 
vesicular phase is more favoured than the lamellar phase, as the molecular weight of 
the polymer increases increasing the bending modulus. The hydrophobic bilayer of 
lipids generally lies between 3-5nm whereas that of polymersomes bilayers are bigger 
and can be designed from 3nm to up to 30nm by choosing the appropriate block 
compositions (Figure 1-5) 151, 152. Apart from the composition of the building blocks, 
several other factors affect the size and dispersity of the polymersomes such as the 
presence of ionizable groups on the polymer chain, hydrogen bonding, electrostatic 
interactions and also several processing factors such as solvent, temperature, 
additives and preparation method153.  
 
 
 
 
 
 
 
 
 
Figure 1-5 Role of f value and molecular weight in the formation of 
vesicles and thickness of bilayer 
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Polymersomes can be prepared using the same methods as that of liposomes and can 
be further fractionated and made uniform in size by extrusion, vortexing, sonication or 
freeze thawing methods similar to liposomes.  
1.8.1 Methods of preparation of polymersomes 
Several methods for preparation of polymersomes are reported, they can generally be 
divided into two major categories: solvent free techniques and solvent displacement 
techniques. 
Solvent free techniques: In these techniques, the polymer is directly brought into 
contact with the aqueous phase in a dry state, thus eliminating the use of organic 
solvent. Several methods use this technique such as154: 
Thin film hydration: In this method, the block copolymer is first dissolved in an 
organic solvent with or without the drug in a round bottom flask which is then 
evaporated under reduced pressure to form a thin film around the internal wall of the 
flask. This film is then rehydrated with aqueous medium to form vesicles155. 
Direct hydration: Some block copolymers are capable of self-assembling into 
polymersomes directly upon dissolving in the aqueous phase without the aid of other 
solvents156. 
Electroformation: This method is similar to thin film hydration method and is very 
suitable to produce homogeneous unilamellar polymersomes which are very large in 
size up to one micrometer. In the method, instead of preparing a film on a solid 
surface, it is spread out on a pair of electrodes such as indium-tin-oxide glass plates or 
gold or platinum wires. After the addition of buffer to the system, an electric current is 
applied which causes vesicles to form by reducing the membrane tension and 
electrostatic effects157. 
Solvent displacement techniques: These techniques involve dissolving the polymer in 
an organic solvent and then mixing it with the aqueous phase, the organic solvent is 
subsequently evaporated using various methods154. 
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Solvent displacement/Solvent injection: In this technique, the polymer is dissolved in 
an organic solvent and added dropwise to the aqueous phase with vigorous stirring. 
The organic solvent is then removed by dialysis. This method can be used for large 
scale production of polymers but it has certain drawbacks namely, the organic solvent 
is retained inside the polymersomes and in the surrounding aqueous phase which can 
lead to the collapse of the polymersome architecture and faster aggregation rates. 
The size and dispersity of polymersomes depends largely on the type of solvent, rate 
of injection and polymer concentration158. 
Solvent evaporation/reverse phase evaporation method: In this method, the 
amphiphilic polymer in the form of a film is redissolved in a water immiscible organic 
solvent or a solution of the polymer in the organic solvent is mixed with water to form 
a two-phase emulsion system. The organic solvent is then removed from the system 
by evaporation under vacuum. This is an easy and fast technique resulting in small 
unilamellar vesicles127. 
Double emulsion: This method involves the formation of water-oil-water (w/o/w) 
double emulsion and then evaporating the organic solvent to form polymersomes at 
the concentric interface of the double emulsion159.  
Different methods of preparation can yield different types of vesicles along with 
polymersomes such as micelles, nanovesicles or tubes. The presence of residual 
organic solvent can affect biological applications154, 160. 
 
1.9 Applications of self-assembling amphiphilic copolymers 
The ability to encapsulate a wide variety of drug including hydrophilic, hydrophobic 
and amphiphilic molecules renders polymersomes compatible with in-vivo 
applications with their thick outer membrane providing stability to these vesicles. 
Since most polymersome preparations have PEG as the amphiphilic block they have 
stealth properties and enhanced circulation times. These advantages of polymersomes 
have led to numerous applications in various areas of drug delivery such as anticancer 
therapy, quantum dots, gene and protein delivery and many more161. The combination 
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of polymersomes with triggered drug delivery has led to several applications especially 
in cancer therapy. This has been achieved by designing polymers responsive to various 
stimuli such as temperature, pH and light or the incorporation of dynamic molecules 
into the core or the hydrophobic bilayers of polymersomes162. Furthermore, 
crosslinking these polymersomes can make them structurally “locked” which provides 
better stability to these nanovesicles and allows controlled release of encapsulated 
cargo for the desired period of time90. The ability to tune surface properties of 
polymersomes has provided unique opportunities for bioconjugation of various 
protein, lipids and antibodies allowing more functional diversity to these vesicles 
being fully derived from synthetic materials163. 
Some recent applications of amphiphilic polymers are described in the following 
sections. 
1.9.1 Drug solubilizing agents 
More than 70% of new chemical entities (NCEs) are poorly water soluble with 
approximately 40% of oral immediate drug release formulations on the market 
considered practically water insoluble leading to various issues. Low solubility affects 
drug dissolution leading to low bioavailability and hence necessitating increase in 
therapeutic dose causing additional side effects. This further causes decreased patient 
compliance and increased manufacturing costs164. The utilization of micelles made of 
amphiphilic block copolymers has been researched extensively for anticancer drugs 
which have poor aqueous solubility. The solubilisation ability of micelles largely 
depends on the nature of the hydrophobic core of the amphiphilic block copolymer. 
Kim et al. describe an increase in the solubility of paclitaxel, a poorly water soluble 
anticancer drug (5.6mg/L), to up to 38.9mg/ml by the use of N, N-diethylnicotinamide 
and N-picolylnicotinamide which proved to be good hydrotropic agents for 
Paclitaxel165. Another study utilizing PEG-DSPE/TPGS micelles enhanced the 
solubilization of Paclitaxel from 0.3μg/ml to 5mg/ml increasing the solubility up to 
5000 times166. Additionally, the solubility of tamoxifen, another poorly soluble 
anticancer drug, increased from 0.24ug/ml to 0.12mg/ml indicating a 500-fold 
increase. This was achieved by encapsulating tamoxifen into amphiphilic copolymer 
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micelles made of PEG 2000 and Palmitic acid with polyaspartylhydrazide (PAHy) graft 
copolymers167-169. Camptothecin, a topoisomerase I enzyme inhibitor is utilized for 
treatment of several cancers, with an aqueous solubility of approximately 1.3 μg/ml 
when loaded into micelles composed of PEG-Pluronic copolymers conjugated with 
poly (acrylic acid) a 3-4 fold enhancement in solubility in aqueous medium was 
recorded170, 171. 
1.9.2 Stability improvement 
The presence of PEG in amphiphilic copolymers allows the encapsulated drug to be 
shielded from interactions with opsonins and phagocytosis leading to better 
circulation times and stability of the drug molecule by inhibiting drug degradation in-
vivo. The encapsulation of Camptothecin in N-phthaloylchitosan-grafted PEG methyl 
ether (PLC-g-MPEG) micelles increased the in-vivo circulation time by up to 96 hours 
and also protected the lactone block of the molecule from being hydrolyzed which is 
crucial for its activity and prevent systemic toxicity as compared to unencapsulated 
Camptothecin172. Nagano et al. demonstrated that the encapsulation of Dox in PEG-
poly(beta-benzyl-L-aspartate) (PEG-PBLA) amphiphilic block copolymer micelles 
caused 77.5% of drug to be cleared from circulation as compared to free Dox which 
was 100% cleared, leading to better concentration in tumour site and reducing 
unwanted side effects173. These stabilization and protection properties apply not only 
to micelles but also polymersomes made of amphiphilic copolymers. Lee et al. 
demonstrated the stability of proteins encapsulated into polymersomes of PEG diblock 
copolymers. They found that polymersomes readily entrapped these large proteins 
and also protected them from plasma degradation. The polymersomes were inert to 
white blood cells and were thermally stable156. Furthermore, Photos et al. have shown 
the effect of varying molecular weight on the circulation half-life of amphiphilic block 
copolymers. They state that it is difficult to incorporate high molecular weight PEG 
into lipids because of the preference to form micelles by very large molecular weight 
PEG however, polymersomes are mainly composed of PEG-based copolymers which 
provide additional advantages towards stability and stealth properties. They found 
that the in-vivo circulation time of PEG based polymersomes was up to two fold longer 
(20h-30h) than that of PEGylated liposomes. The blood clearance of these PEGylated 
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polymersomes was by opsonization by plasma protein and elimination through liver 
and spleen 174. 
1.9.3 Sustained release 
The release of entrapped drug molecules from polymersomes is directly dependent on 
the thickness of the polymersomes membrane175. By reducing interactions with 
plasma proteins, however it improves the uptake by cells and release of drugs by 
proteases present in the cellular environment. This uptake is favoured by the 
functionalization of the outer corona with negative charge and addition of more site-
specific moieties87. Controlled release of drugs plays a very important role when 
designing scaffolds for tissue engineering. In a recent study by Saito et al., the 
incorporation of recombinant human bone morphogenetic protein-2 (rhBMP-2) which 
is an osteroinductive growth factor, into PEG-PLA micelles, supported better ectopic 
bone formation when implanted in dorsal muscles of mice than micelles with just PLA 
homopolymers. This effect is attributed to the sustained release of the growth factor 
rather than a burst release at the site of action and is attributed to the lower 
degradation rate of micelles 176.  
1.9.4 Triggered release 
Stimuli sensitive amphiphilic copolymers form a special class of polymers which 
undergo structural changes in response to various internal or external stimuli leading 
to the disintegration, isomerization, destabilization or polymerization of the self-
assembled nanostructures. Tumour microenvironment can have various intrinsic 
properties such as elevated temperature, redox potential, lowered pH and 
overexpressed enzymes. External stimuli constitute temperature, light, magnetic 
fields, ultrasound or their combinations. Various external and internal stimuli have 
been exploited to trigger the stabilization of polymeric micelles or vesicles to release 
their content in specific microenvironments to reduce side effects in other parts of the 
body177. Amphiphilic copolymers composed of an ionic block are mainly pH sensitive 
which enables their destabilization at the low pH of the tumour microenvironment. 
Most commonly used pH sensitive ionic blocks are poly (acrylic acid) (3) and poly 
(methacrylic acid) (4) which have acid labile carboxylic groups which are unionised at 
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lower pH leading to disruption of the vesicular structure. Cationic polymers having 
tertiary amino group such as poly (vinyl pyridine) (5) and poly (histidine) (6) are non-
ionic at physiological pH but become protonated at low pH are other examples of pH 
sensitive polymers178.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The elevated levels of glutathione present in cancer cells has been exploited to trigger 
release of drugs in the intra-tumoral environment. Amphiphilic copolymers having a 
sulfide bond are stable at room temperature but the disulfide bond is reduced in the 
presence of glutathione tripeptide (GSH) and instantly release the encapsulated drug 
at the target site179. Disulfide crosslinks (-S-S- linkages) are generally introduced at the 
interface of the hydrophilic and hydrophobic blocks. Fan et al. synthesized micelles 
having amphiphilic copolymers using thioctic acid (7) based disulfide linkages and 
loaded them with paclitaxel. Resultant micelles demonstrated ~3-5 fold greater 
plasma concentration than non-crosslinked amphiphilic copolymer micelles and 
improved kinetic and thermodynamic stability with instant release of drug in high GSH 
tumour environment180.  
(3) 
(4) 
(5) (6) 
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Temperature responsive polymers rely on the thermo-responsive properties of the 
amphiphilic block copolymers which are completely soluble below a certain 
temperature but at slightly elevated temperatures undergo a sharp change in their 
solubility due to breakage of hydrogen bonds, leading to destabilization of the 
nanostructures, thus releasing the drug in the surrounding environment.  
 
 
 
 
 
 
 
A common example of a thermo-responsive polymer is poly (N-isopropyl acrylamide) 
(8) which is a hydrophilic coil-like structure at room temperature but above 32°C 
undergoes a phase change leading to a hydrophobic globule state which precipitates 
out of solution triggering drug release181.  
Apart from the above intrinsic triggers, many external stimuli such as light, magnetic 
field and ultrasound can be employed to enable the release of drugs from within the 
nanosphere environment. Light has been used extensively as a trigger because of its 
ease of use and the ability to control drug release with spatial and temporal 
accuracy182, 183. Light can work in two ways as a stimulus, first by photoinduced 
structural changes such as reversible isomerization, crosslinking and/or changes in 
hydrophilicity/lipophilicity. Secondly, light can induce degradation or cleavage of the 
polymer at specific junctions leading to breakage of the nanoassembly. Most widely 
used photoresponsive materials are azobenzenes (9), spiropyrans (10), O-nitrobenzyls 
(11), 2-diazo-1,2-naphthoquinones and coumarin derivatives. For example, 
spiropyrans (10) undergo reversible photoisomerization in UV light from the closed 
(7) 
(8) 
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ring hydrophobic spiropyran to a hydrophilic open ring merocyanine and reverses in 
the presence of visible light. Liu et al. reported the synthesis of PEG-b-PSPA block 
copolymer with spiropyran using carbamate linkages and formed polymersomes with 
a reversible bilayer permeability alternating UV and visible light184. In another 
example, O-Nitrobenzyl (ONB) (11) has been utilized as a photocleavable 
photochromic moiety which can be integrated in copolymer blocks during synthesis. 
As reported by Meier et al., amphiphilic block copolymers having ONB linkers were 
synthesized and loaded with low molecular weight dyes into the vesicles. Upon 
exposure to UV radiation, the vesicles disintegrated into smaller micellar structures 
releasing the payload in the process which was controllable by varying intensity of UV 
light 185, 186.  
 
 
 
 
 
 
 
Furthermore, a magnetic field has been employed as an external stimulus by 
encapsulating ferromagnetic molecules, such as ferric oxide, along with the drug 
inside the nanovesicles. The application of an extracorporeal magnetic field at the 
biological site causes high accumulation of the nanocarrier at the target site leading to 
increased drug concentration and thus better efficacy187. Ultrasound is another 
external stimulus which employs the use of ultrasound waves to trigger destabilization 
by cavitational phenomenon188 of micelles, polymersomes, liposomes and 
microbubbles. Examples of ultrasound mediated delivery include PEG-PCL 
nanobubbles loaded with perfluorocarbon and curcumin, mPEG-PLGA micelles loaded 
(9) 
(10) 
(11) 
NO2 
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with Dox and perfluorocarbon and paclitaxel loaded mPEG-poly (D, L-lactide) micelles 
to achieve high accumulation in prostate cancer cells189-191. 
1.9.5 Imaging applications 
In-vivo imaging can play a major role in determining the kinetics of drug molecules 
further influencing its therapeutic efficiency. Non-invasive techniques to study 
biodistribution of amphiphilic molecules can help greatly in the development of 
delivery vehicles without the need to sacrifice animals. Infrared and near-infrared light 
are more commonly used for deep tissue imaging than visible light because of their 
better penetration ability. Hence dyes which fluoresce/luminesce in the presence of 
near infrared light can be encapsulated or conjugated to a polymer and monitored in-
vivo to observe the effects of the amphiphilic copolymers in real time22, 192. 
Amphiphilic copolymer micelles have been extensively used for different areas of 
purely diagnostic imaging or imaging with drug delivery for visual control of kinetics193. 
Encapsulation of contrasting agents for imaging into NPs provides many advantages, 
such as longer circulation time and targeting of delivery vehicle to the desired site of 
imaging to reduce signal to noise ratio. In addition, multiple molecules of the contrast 
agent can be encapsulated into a single NP along with cancer targeting ligands 
allowing better contrast specificity and tuneable biodistribution194. Paramagnetic 
materials such as iron oxide, gadolinium (Gd), Manganese (Mn) are a few examples of 
contrast agents commonly used for bioimaging. Apart from contrast agents, many 
fluorescence based dyes that excite in the near infrared region are also utilized for 
bioimaging. These dyes have advantages of minimal interference from biological 
fluids, good tissue penetration and reduced light scattering. NIR dyes commonly used 
for biological applications are cyanines such as indocyanines (12), porphyrins such as 
photoporphyrins (14) and BODIPY (13) analogs195 . 
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1.9.6 Multifunctional nanocarriers  
Recent challenges in the development of advanced drug delivery systems have led to 
the development of multifunctional carriers which combine the therapeutic purpose 
of the nanovehicles with a diagnostic/imaging property to provide unique theranostic 
systems. Multiple modes of treatment such as triggered release, tumour targeting 
using ligands, photodynamic therapy, chemotherapy etc. can be combined with 
imaging techniques such as MRI, fluorescent dyes as markers for imaging or FRET, 
nuclear imaging methods such as CTs, PETs to facilitate real time or retrospective 
imaging of the drug delivery system which can provide insights into the 
pharmacokinetics, pathways and efficacy of the delivery system196, 197. Schematic 
representation of different attachments to obtain multifunctional nanonacarriers is 
depicted in Figure 1-6. 
(13) 
(14) 
(12) 
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In a recent example by Gong et al., they developed pH responsive amphiphilic 
copolymer vesicles using heterofunctional triblock polymers loaded with 
superparamagnetic iron oxide NPs (SPIONs) into the inner core and Dox conjugated to 
the PGlu segment of the polymer via hydrazine linkages. This dual property of the NPs 
allowed excellent stability with pH controlled release of Dox and MRI contrast imaging 
of the NPs at the tumour site198. Furthermore, multifunctional NPs can be used to 
combine different targeting strategies into one nanocarrier to achieve selectivity or 
enhanced therapeutic efficacy of the delivery system. For example, Huang et al. 
synthesized complex NPs into which SPIONs were loaded in the inner core and 
cisplatin was coordinated in the hydrophilic shell. These NPs showed increased 
anticancer activity with the combined effects of cisplatin and SPION induced 
hyperthermia199. Kataoka et al. developed cancer specific folate bound ligands on the 
micelle surface and Dox linked to the hydrophilic block via acid cleavable bonds, the 
folate leads the micelles to the tumour tissue and were endocytosed via receptor 
mediated endocytosis200. The folate bound micelles displayed significant cell growth 
inhibition and higher cellular uptake when analysed by MTT and flow cytometry 
respectively. 
Figure 1-6 Schematic representation of multifunctional nanocarriers 
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1.9.7 Passive targeting 
NPs can passively retain in tumours for longer duration of time due to the enhanced 
EPR effect even if there are no targeting ligands present on the delivery vehicle 201. 
Generally, solid tumours possess high vasculature, incomplete vascular profile, 
increased extravasation due to presence of vascular permeability factors and 
immature lymphatic network (Figure 1-7). These properties make them vulnerable to 
macromolecules which are not easily drained due to improper lymphatic drainage 
leading to retention of these molecules in tumours for prolonged periods of time46, 202. 
To achieve good passive targeting by the EPR effect, many obstacles such as 
glomerular excretion, elimination by the RES, interaction by plasma proteins and 
phagocytosis have to be overcome. The addition of PEG to the amphiphilic copolymer 
provides stealth properties which help overcome some of the above mentioned 
problems. Particle size is also a key factor in passive targeting since a lot physiological 
elimination processes such as hepatic filtration, renal excretion, tissue diffusion and 
extravasation are dependent on particle size203. The optimum particle size to avoid 
phagocytosis and hepatic clearance is less than 200nm204 and upto 40kDa mass to 
avoid renal filtration. The leaky vasculature of tumour blood vessels means they 
contain intercellular gaps which do not require energy dependent material movement. 
Jain et al. determined that liposomes up to 400nm in diameter were permeable into 
tumour tissue suggesting tumour penetration cut off size of 400-600nm205.  The shape 
of NPs is also favoured to achieve good passive diffusion. Inert worm-shaped micelles 
have shown to have longer circulation times than spherical micelles with short worm-
like micelles more preferred than longer worms206, 207. Although passive diffusion 
helps to concentrate NPs, various factors such as tumour heterogeneity, types and 
location of tumour limit this approach of drug delivery208. 
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1.9.8 Active targeting 
Diseases such as cancer and inflammation have overexpressed epitopes and receptors 
which can be used as targets to enhance accumulation of NPs at the desired tumour 
site. Ligands coupled to the NP surface which bind specifically to the target receptors 
can be used for active targeting of therapeutics for enhanced activity209, 210 (Figure 
1-7). Ligands can be coupled to the surface of the amphiphilic copolymer by various 
methods such as covalent and noncovalent binding. Common binding methods include 
disulfide bonds, crosslinking, acid base reactions and aldehyde-amine reactions. 
However, these methods can be rigorous and destructive for the binding ligand. Non-
covalent bindings also have associated problems such as weak binding, low 
concentrations and poor control of binding reactions211. Active targeting by binding 
ligands to polymer NPs has several advantages, such as a high encapsulation ability, 
avoidance of drug modification by binding ligand to drugs leading to efficient 
therapeutic activity of drug, possibility of large number of ligands attachment at 
various sites on the surface of the polymer and small size of the ligand-polymer 
conjugate leads to higher extravasation into the tumour site without affecting any 
Figure 1-7 Mechanism of passive and active targeting in tumour tissues 
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binding sites on healthy tissues31. Various targeting receptors that are overexpressed 
in tumours are: carbohydrate based targeting, mAb based targeting, folate based 
targeting, protein/peptide based targeting and aptamer based targeting137. Another 
active targeting approach is to take advantage of locally applied signals such as 
ultrasound and magnetic field to mediate the transport of the nanocarriers to the site 
of action 137.  
 
1.9.9 Simultaneous drug delivery 
The advances in combination therapies has led to the requirement of drug delivery 
systems to expand so that both hydrophobic and hydrophilic drugs can be delivered in 
the same vehicle simultaneously78. Several examples of amphiphilic copolymer 
micelles for simultaneous delivery of both hydrophobic and hydrophilic drugs are 
reported179. The most common approach is where the nonpolar core is used to 
encapsulate the hydrophobic drug while a charged outer corona (usually positively 
charged) is used to electrostatically interact with the biological component. Both Qian 
et al. and Bian et al. have successfully encapsulated Dox in the core of the micelle and 
conjugated micro-RNA and green fluorescence labeled DNA212, 213 to the corona. Qian 
et al. used amphiphilic star branched copolymers using polylactic acid (PLA) and 
polydimethylaminoethyl methacrylate (PDMAEMA) while Bian et al. used poly 
(ethylethylene phosphate)-blockpoly(e-caprolactone)-block-poly[2-(dimethylamino) 
ethyl methacrylate (PEEP-b-PCL-b-PDMAEMA). The PLA and PCL chains formed the 
hydrophobic core whereas the PDMAEMA forms the positively charged outer corona 
to which the RNA/DNA was attached by electrostatic interactions. There are a few 
examples where these same drugs have been combined within a polymersome214. 
Iatrou et al. 215 have investigated two different polymersomes for the independent 
delivery of Dox and PTX, comparing a tri block co-polymer with a terpolymer. They 
concluded that both forms of polymer were capable of encapsulating both drugs, but 
did not allude to whether the possibility of simultaneous delivery was to be 
investigated in the future but did anticipate the incorporation of genes with either of 
the anticancer drugs. 
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1.10 Aims and Objectives 
The main aim of the work carried out in this thesis was to evaluate different 
amphiphilic copolymers for their ability to self-assemble into micelles and 
polymersomes and to evaluate their efficiency for encapsulating different types of 
dyes and anticancer drug in-vitro and in-vivo. Although the primary focus of this 
research work is the preparation and evaluation of polymersomes (Chapters 2 &4), 
chapter 3 evaluates the preparation of micelles using amphiphilic copolymers and a 
novel application approach. The specific aims of each chapter are as follows, 
1.10.1  Chapter 2: Design of self-assembling random copolymer based polymersomes and 
their comparison to pegylated liposomes 
The aim of this research work was to prepare amphiphilic random copolymers using 
free radical polymerization having structural similarities to liposomes. Accordingly 
amphiphilic random copolymers having composition consisting of an octadecyl chain 
and oleic acid, cholesterol and two chain lengths of PEG (P500 and P2000) were 
synthesized and confirmed using Mass spectroscopy and 1H NMR spectroscopy.  These 
polymers were evaluated for their ability to form bilayer polymersomes using dynamic 
light scattering and zeta potential. They were then compared to liposomes for cell 
toxicity, cellular uptake and stability over time. 
1.10.2 Chapter 3: The integration of triggered drug delivery with real time quantification 
using FRET; creating   a super ‘smart’ drug delivery system.  
The aim of the work undertaken in this chapter involves the encapsulation of 
photodynamic spiropyran (32) within micelles of an amphiphilic copolymer. The 
application of UV light allowed hydrophobic spiropyran to convert to hydrophilic 
merocyanine allowing it to transcend across the micelle into the surrounding 
environment. This release affected the FRET relationship between a bodipy compound 
(31) and merocyanine, allowing real time quantification of merocyanine release from 
the micelles. 
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1.10.3 Chapter 4: Multi drug loaded polymersomes for increased efficacy of cancer therapy 
This chapter involves the simultaneous encapsulation of multiple anticancer drugs into 
polymersomes and evaluation of their encapsulation efficiency and particle size. The 
polymersomes were evaluated for their pharmacokinetics in-vivo by imaging with 
Indocyanine green (ICG) loaded polymersomes. The tumour reduction ability of 
Doxorubicin hydrochloride (Dox), 5-Fluorouracil (5-FU) and Leucovorin calcium (LV) 
loaded polymersomes was observed after intratumoral and intravenous injection in 
mice and measurement of tumour volume over time. 
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2 Chapter 2 
Design of self-assembling random copolymer based 
polymersomes and their comparison to pegylated liposomes  
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2.1 Introduction to bilayer drug delivery systems 
Single layer drug delivery systems such as polymeric micelles made of amphiphilic 
copolymers have shown success as drug delivery vehicles for hydrophobic drugs 
having poor solubility and low bioavailability216. Micelles have been employed as drug 
delivery systems not only for cancer chemotherapy217-220 but also for other areas of 
therapeutic drug delivery such as Herpes Simplex Virus HSV infection221, gene 
delivery222 and inflammation223. Polymeric micelles are single layer supramolecular 
assemblies which have a hydrophobic core to accommodate hydrophobic drugs and 
hydrophilic shell which makes them easily water dispersible, thus allowing the delivery 
of these drugs224. However the presence of a single layer means that they can deliver 
only hydrophobic drugs making them less advantageous than bilayer systems such as 
liposomes and polymersomes. Liposomes are nanovesicular structures that are 
typically made of lipids whereas polymersomes are fully synthetic polymeric 
analogues of liposomes225. These bilayer structures are biphasic and consist of a 
hydrophilic core for encapsulation of hydrophilic drug and a hydrophobic bilayer 
which can accommodate hydrophobic drugs. They have a hydrophilic outer corona 
which allows them to disperse in aqueous medium226, 227. Due to the amphiphilic 
nature of the lipids and polymer blocks, these molecules can spontaneously assemble 
into bilayer nanovesicles determined by the hydrophilic lipophilic balance. Based on 
the type of lipid and polymers, these systems can be tailored according to the nature 
of application228.  Liposomes and polymersomes based bilayer systems offer several 
advantages such as the ability to encapsulate a larger variety of drugs and better multi 
functionalisation than single layer micellar systems. Further, these systems can be 
utilized to co-encapsulate both hydrophilic and hydrophobic drugs simultaneously, 
further increasing their advantages over the single layer systems229. Liposome and 
polymersome based systems have been employed for a wide range of drug delivery 
systems such as theranostics involving both therapeutic and diagnostic delivery230, 231, 
large molecules such as proteins and gene delivery232, 233 and stimuli responsive drug 
delivery234. 
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2.2 Composition of liposomes 
Phosphatidylcholines extracted from egg or soybean are commonly used lipids for 
making liposomes because they are a major component of the cell membrane235. 
Phosphatidylcholine (15) typically consists of a choline head group with a saturated 
fatty acid such as palmitic or hexadecanoic acid and an unsaturated fatty acid such as 
oleic acid (15)236. Liposomes also consist of cholesterol (16) which helps achieve 
rigidity of the bilayer membrane and a PEG (1) outer layer which gives stealth 
properties to liposomes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Nguyen et al. encapsulated paclitaxel in soy phosphatidylcholine and cholesterol 
liposomes and observed their in-vitro properties. They found that the liposomes were 
less than 200nm in size and demonstrated more than 90% encapsulation of 
paclitaxel237. Tao Yang et al. demonstrated increased solubility of paclitaxel 
encapsulated in egg phosphatidylcholine and cholesterol liposomes (molar ratio 
90:10) and compared their cytotoxicity in MDA-MB-231 human breast cancer cell line 
against marketed formulation Taxol238.  
Physical properties of liposomes depend on lipid composition, size, surface charge and 
method of preparation. For example phospholipids exhibit more permeable and 
unstable bilayers. Cationic surface charge on liposomes leads to rapid clearance from 
(15) 
(16) 
69 
 
the body but demonstrates better cell internalisation239.  Even though liposomes are 
identical to biomembranes, they are still foreign objects to the body and are rapidly 
cleared by the mononuclear phagocytic system (MPS) on contact with plasma 
proteins. This problem is solved by coating liposomes with polyethylene glycol (PEG). 
PEG reduces uptake by macrophages and prolongs circulation time240. Surface 
modification of liposomes using PEG improves their circulation time thus providing 
better uptake into target cells and avoids elimination via RES241, 242.  Many liposomal 
formulations are currently in the market and many more are in different phases of 
clinical trials50, 243 for treatment of various cancers however they are still considered to 
be disadvantageous because of their low stability and membrane leakage244. 
 
2.3 Polymersomes synthesized with amphiphilic random copolymers 
Polymersomes as nanoparticulate drug delivery systems have gained a lot of attention 
recently for having several advantages over liposomes such as higher stability, better 
control over membrane properties and ability to encapsulate large variety of drugs245. 
Polymersomes are next generation nanovesicles facilitating to overcome the 
shortcomings of liposomes and provide advanced therapeutic care especially for 
cancer therapy. An insight into recent research demonstrates the ability of 
polymersomes used for targeted delivery, stimuli responsive drug delivery such as 
redox responsive125, pH sensitive126, 246, temperature sensitive247, hypoxia 
responsive248, delivery of genes249 and combined anticancer therapy250. Polymersomes 
have a vesicular structure similar to liposomes with a hydrophilic core and a 
hydrophobic bilayer allowing encapsulation of both hydrophilic and hydrophobic drugs 
with a hydrophilic corona. Polymersomes are mainly made of block polymers capable 
of self-assembling into nanoscale vesicles with PEG as the hydrophilic block251. These 
high molecular weight polymers possess similar amphiphilic properties as lipids but 
are comprised of polymer chains covalently linked as successions of two or more 
blocks offering a membrane which is more compact providing rigidity and better 
stability to these vesicles252. It is important for polymersomes to be biodegradable or 
to be at least biocompatible, most block polymers used for making polymersomes 
typically have PEG as the hydrophilic block attached to a hydrophobic block such as 
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poly-Ɛ-caprolactone (PCL), poly(lactide), poly-(N-(2-hydroxypropyl) methacrylamide) 
(pHPMA), poly(ethylene-imine) (PEI),   poly(vinylpyrrolidone) (PVP)245, 253  The main 
disadvantage of using block copolymers is their method of preparation. Synthesis of 
block copolymers requires controlled polymerisation and post processing such as 
substitution, hydrolysis and click chemistries making the process multi step and time 
consuming requiring specific equipment and additional resources254, 255. Hence 
random copolymers have been explored for their ability to self-assemble and their 
ease of preparation and adaptability. Synthesis of random copolymers is an easy one-
step process also referred to as ‘one pot synthesis’ proving attractive to synthetic 
chemists for use as self-assembling amphiphilic polymers103. Recent research 
investigations using random copolymers have demonstrated self-assembly into 
different shapes such as nanovesicles, spheres and honeycomb films depending on the 
hydrophilic/lipophilic balance256. Dey et al. demonstrated the ability of amphiphilic 
random copolymer scaffolds to form vesicles and induce myotube formation from 
C2C12 cells which had the ability of differentiate in the presence of growth media 
allowing them to be used for muscle cell regeneration257. Hirai et al. demonstrated the 
ability of amphiphilic random copolymers to be able to form nanovesicles in an 
aqueous environment. These polymers were composed of PEG as the hydrophilic 
component and hydrophobic dodecyl chains which were polymerised using both 
metal catalysed living radical polymerisation and conventional free radical 
polymerisation. The tendency of those polymers to self-assemble into intramolecular 
and intermolecular nanovesicles could be controlled by increasing or decreasing the 
hydrophobic moiety and degree of polymerisation which also affected size of the 
particles258. 
 
2.4 Aims of Chapter  
The overall aim of this chapter was to create a polymersomal system to mimic a 
liposomal system closely then compare the two NP’s in terms of stability, 
encapsulation and release as well as size and surface charge. The individual 
components of the liposomes and polymersomes were compared allowing the 
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creation of NP’s of similar composition. Figure 2-1 displays the components with each 
DDS.   
In this research chapter we investigate the ability of long chain polymers having 
octadecyl side chains with cholesterol and high molecular weight PEG to form 
polymersomes encapsulating both hydrophilic and hydrophobic dyes and compare 
their cellular uptake to liposomes having a similar composition. The hydrophilic dyes 
used were negatively charged FITC-CM-Dextran (FCD), positive charged FITC-DEAE-
Dextran (FDD) and neutral FITC-Dextran(F-D) having average MW 4000 Da freely 
soluble in water and PBS. FITC-Carboxymethyl-Dextran has an anionic charge due to 
the presence of negatively charged carboxyl groups. FITC-Diethylaminoethyl-Dextran 
have a net positive charge due to the presence of tertiary amino groups. F-D is neutral 
due to the low level of substitution leading to minimal charges on the dextran moiety. 
The hydrophobic dye employed was anthracene, a polycyclic aromatic hydrocarbon 
which gives a blue fluorescence and is soluble in chloroform, alcohols and hexane. 
Figure 2-1 : Schematic representation of comparison and design of chemical 
structure of polymers to lipid 
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The aim of this research work was to prepare amphiphilic random copolymers using 
free radical polymerisation having composition analogous to liposomes, Figure 2-1. 
The specific aims of the chapter were, 
1. Synthesis of amphiphilic copolymers composed of an octadecyl chain and oleic 
acid, cholesterol and two chain lengths of PEG (P500 and P2000).  
2. Preparation of polymersomes and liposomes by three methods of preparation-thin 
film hydration (TFH), emulsion evaporation (EMEV), reverse phase evaporation 
(RPE). Evaluation of size, PDI, zeta potential and % encapsulation efficiency of FCD, 
FDD, F-D and anthracene in liposomes and polymersomes. 
3. Observation of cellular uptake of FCD and anthracene encapsulated polymersomes 
and liposomes in HeLa cells. 
4. Observation of cellular uptake pathways of polymersomes and liposomes loaded 
with FCD by chemical inhibition of endocytosis using chlorpromazine in HeLa cells. 
5. Fluorescence observation of cellular uptake of FCD and anthracene loaded 
liposomes and polymersomes. 
6. Evaluation of cell cytotoxicity of polymersomes compared to liposomes having PEG 
2000 in three cell lines-HeLa cells, BxPC-3 cells and CHO cells. 
7. In-vitro release studies of liposomes and Polymersomes of PEG 2000 for both 
hydrophilic and hydrophobic dyes. 
8. Physical stability studies of PEG 2000 liposomes and polymersomes loaded with 
hydrophilic and hydrophobic dyes under refrigerated conditions and 25°C for 
observation of changes in size and encapsulation efficiency. 
 
 
2.5 Results and discussion 
2.5.1 Synthesis of monomers and polymers 
Three monomers namely cholesteryl methacrylate, octadecyl methacrylate and oleic 
methacrylate were synthesized as discussed in below sections, 
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2.5.1.1 Synthesis of cholesteryl methacrylate (21) 
Synthesis of 21 was a two-step process with an intermediate of cholesteryl ethylene 
diamine (19). The reaction scheme for synthesis of 21 is depicted in Scheme 2-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The compound 19 was synthesized according to the procedure described by Martin et 
al.128 discussed in detail in section 6.3.1. and confirmed by mass spectroscopy. Figure 
2-2 displays the LC/MS (ESI) m/z: [M + H]+  positive mode for 19 with the expected 
parent ion of 474.7 confirming the conjugation of ethylene diamine (18) with 
cholesteryl chloroformate (17). 
Figure 2-2 Mass spectrum of cholesteryl ethylene diamine conjugate (19) 
(17) 
(18) 
(19) 
(20) 
(21) 
Scheme 2-1 Synthesis of cholesteryl methacrylate (21) 
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The second step involved in the synthesis of 21 as depicted in reaction Scheme 2-1 
and involves the formation of an amide bond. Successful synthesis of 21 was 
confirmed by Mass and 1H NMR spectroscopy. The LC/MS (ESI) m/z: [M + H]+ 
calculated for 21 was found at 541.0 accounting for the +1 peak (Figure 2-3).  
 
Synthesis of 21 was further confirmed by 1H NMR spectroscopy (Figure 2-4). The 
spectral shifts were assigned to their corresponding protons as illustrated in the 
structure insert. 
Figure 2-4 1H NMR spectrum of cholesteryl methacrylate (21) 
Figure 2-3 Mass spectrum of cholesteryl methacrylate (21) 
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2.5.1.2 Synthesis of oleic methacrylate (24) 
Synthesis of 24 was a two-step process with the formation of the intermediate oleic-
ethylene diamine (23). The reaction scheme for the synthesis of 24 is illustrated in 
Scheme 2-2. The detailed procedure for synthesis is discussed in section 6.3.2. 
 
The first step involved the synthesis of 23 which was confirmed by Mass spectroscopy. 
LC/MS (ESI) m/z: [M + H]+ calculated for 23 was, 324.54; and found to be 325.2 as seen 
in Figure 2-5 confirming successful synthesis. 
Figure 2-5 Mass spectrum of oleic ethylene diamine conjugate (23) 
(22) 
(20) 
(18) 
(23) (24) 
Scheme 2-2 Synthesis of oleic methacrylate (24) 
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The second step involved the coupling of the methacrylic acid (20) to the primary 
amine of 23 to form 24. LC/MS (ESI) m/z: [M + H]+ calculated for 24 C24H44N2O2, 
392.3402; was found, 393.3 (Figure 2-6), confirming successful outcome. 
 
Synthesis of 24 was further confirmed by 1H NMR spectroscopy (Figure 2-7). The 
spectral shifts were assigned to their corresponding protons as illustrated in the structure 
insert. 
Figure 2-7 1H NMR spectrum of oleic methacrylate (24) 
Figure 2-6 Mass spectrum of oleic methacrylate (24) 
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2.5.1.3 Synthesis of octadecyl methacrylate (26) 
The synthesis of 26 was a one step process with the direct coupling of the carboxylic 
acid of the methacrylate moiety to the alcohol group of 1-octadecanol to create a new 
ether bond. The schematic diagram of the synthesis step is represented in Scheme 2-3 
with the procedure detailed in section 6.3.3. 
 
 
 
 
 
 
 
 
 
 
 
The successful synthesis of 26 was confirmed by Mass and 1H NMR spectroscopy. The 
LC/MS (ESI) m/z: [M + H]+ calculated for 26 C22H42O2, was 338.3 and found to be, 
339.4, displayed in Figure 2-8, confirming successful synthesis. 
 
(25) 
(26) 
(20) 
Scheme 2-3 Synthesis of octadecyl methacrylate (26) 
Figure 2-8 Mass spectrum of octadecyl methacrylate (26) 
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The 1H NMR spectrum of 26 is shown in Figure 2-9. The addition of a new peak at 1.95 
ppm, interpreting for three protons is indicative of the methyl group of the 
methacrylate. The two ethylene protons can be seen at 5.5 and 6.0 ppm, each 
interpreting for one proton. 
 
2.5.1.4 Synthesis of Polymers 
The polymers were designed to mimic the composition of liposomes. Scheme 2-4 
displays the different monomers used for the polymerisation reaction. An octadecyl 
side chain in the designed polymer was used in place of palmitic chain in liposomes, 
whereas oleic acid was incorporated as the unsaturated side chain. Cholesterol and 
PEG were added to the polymer to complete the final composition and ensure 
similarity to liposomes. The main difference between the polymersome and liposome 
is that of surface charge.  The choline head group in liposomes imparts the typical 
zwitterionic charge to them whereas the synthetic polymers are neutral in charge. 
After the successful synthesis of monomers, they were combined together for the 
synthesis of polymers in specific molar ratios (detailed in Table 2-1) by Freeze-thaw 
method discussed in detail in section 6.3.4. Two different polymers were created by 
varying the size of the PEG moiety. PEG-methacrylate (Mn 500) and PEG-methyl ether 
methacrylate (Mn 2000) were purchased and added to final polymer to create one 
Figure 2-9 1H NMR spectrum of octadecyl methacrylate (26) 
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polymer with low molecular weight PEG and the other with high molecular weight 
PEG. The reaction scheme for synthesis of polymers is represented in Scheme 2-4. 
 
Table 2-1 Ratios of different monomers for synthesis of polymer (28) 
 Moles Mass (g) Molecular weight 
(21) 0.001 0.54 540.81 
(26) 0.001 0.33 338.57 
(24) 0.001 0.39 392.34 
(27)  
MW 500/2000 
0.001/ 
0.00025 
0.5/ 
0.5 
500/ 
2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
7
7
n
(21) 
(24) 
(26) 
(27) 
(28) 
Scheme 2-4 Synthesis of polymers (28) 
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f = Hp/Hp+Hn 
Monomers were polymerised with either PEG 500 methacrylate or PEG 2000 
methacrylate in the desired ratio using free radical polymerisation and AICN as the 
initiator. Monomers join together at the methacrylate end to form random 
copolymers P500 or P2000 depending on PEG chain length in a Michael addition 
reaction. 
Polymers 28 were confirmed by 1H NMR spectroscopy as seen in the stacked 1H NMR 
(Figure 2-10) which shows the disappearance of the methacrylate proton peaks.  
 
 
 
The hydrophilic block fraction also called as the f value is the amount of hydrophilic 
volume with respect to overall polymer especially in PEG based polymers. According 
to Guan et al. and Christian et al., it is calculated by the formula 
where Hp is the volume of PEG and Hn is the overall volume of polymer fraction. The f 
value should be 25 % <f< 40 % to obtain spherical uni-lamellar vesicles82, 259. The f 
value of P500 was 25% (1:4 molar ratio) and P2000 was 30% (1:3.25 molar ratio) 
indicating that both the polymers are capable of forming bi-layered spherical 
polymersomes.  
 
Figure 2-10 Stacked 1H NMR spectra of polymers (28) P500 and P2000 
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2.5.1.5 Synthesis of cholesteryl-mPEG 2000 and cholesteryl-mPEG 550 for 
pegylated liposomes 
Methoxy PEGs (29) Mn 550 and 2000 were attached to cholesteryl chloroformate (17) 
to form cholesteryl-mPEG conjugates (CH-mPEG) (30). These conjugates were used for 
the preparation of pegylated liposomes to obtain chemical composition similar to 
polymersomes. The reaction scheme for the synthesis of 30 is depicted in Scheme 2-5 
and the detailed synthesis procedure is discussed in section 6.3.5. 
 
 
 
 
 
 
 
 
 
 
 
The successful synthesis of 30 was confirmed by 1H NMR spectroscopy (Figure 2-11). 
The 1H NMR shifts of both conjugates confirmed synthesis with the PEG protons in CH-
mPEG 2000 integrating for significantly more than CH-mPEG 550. 
 
 
(17) 
(29) 
(30) 
n
Scheme 2-5 Synthesis of cholesteryl-mPEG conjugates (30) 
Figure 2-11 Stacked 1H NMR spectra of (30) cholesteryl-mPEG 550 and 2000 
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2.5.1.6 Calculation of fixed aqueous layer thickness 
Hydrophilic layer of PEG called the fixed aqueous layer surrounding NPs prevents their 
interaction with serum protein. Fixed aqueous layer thickness (FALT) can be measured 
by evaluating zeta potential of the nanoparticles in different concentrations of NaCl 
and gives an idea of the extent of PEG layer surrounding the NPs260. FALT of liposomes 
and polymersomes with PEG 500 (L500 and P500 respectively) and PEG 2000 (L2000 
and P2000 respectively) are specified in Table 2-2 and proves that the extent of 
surrounding PEG layer of both polymersomes was comparable to that of liposomes.  
 
Table 2-2 Fixed Aqueous Layer Thickness (nm) of different PEG chain lengths. N=3, 
represented as average±SD. 
L500 P500 L2000 P2000 
0.78±0.12 0.63±0.46 1.40±0.46 1.71±0.20 
 
2.5.2 Preparation and characterisation of liposomes and polymersomes 
Polymersomes were prepared using the polymers created above, with PEG 500, 
creating polymersome 500 (P500) or PEG 2000, creating polymersome 2000 (P2000). 
Liposomes were made using 15 from egg yolk and 30 with either PEG 550 (L500) or 
PEG 2000 (L2000) as discussed in detail in section 6.3.7. There are a number of 
different methods available within the literature regarding the preparation of such 
NPs. The two most commonly used methods for preparation of liposomes are thin film 
hydration and reverse phase evaporation method. Thin film hydration method 
involves hydration of the thin polymer/lipid film formed after vacuum evaporation in a 
round bottom flask using an aqueous medium such as PBS28. The emulsion 
evaporation method which is also referred to as the reverse phase evaporation 
method is less conventional and involves formation of an emulsion of the organic 
phase such as chloroform dissolving the lipid/polymer and the aqueous phase261, 262. In 
this method, the liposomes/polymersomes are formed by evaporation of the organic 
phase from the emulsion under reduced pressure. The reverse phase evaporation 
method is a combination of both thin film hydration and emulsion evaporation 
method and involves formation of a lipid/polymer film followed by evaporation of a 
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drug layer on top of the film to ensure close contact between the lipid/polymer and 
drug. This is followed by emulsification of the drug and lipid/polymer layer and further 
evaporation of the organic layer which forms the NPs263.  
As seen in Table 2-3, FCD loaded liposomes L500 and L2000 had a particle size of 
approximately 250nm and increased to 300nm for anthracene loaded liposomes. It is a 
general consideration that liposomes increase in size when encapsulating hydrophobic 
drugs because of the intercalation between the bilayers. However, polymersomes had 
a particle size of approx. 160 nm and managed to retain their low particle size even 
after loading anthracene with P500 having size of 180 nm and P2000 at upto 260nm. 
Even though polymers are considered to have a higher molecular weight than lipids, 
the polymersomes were significantly smaller in size than liposomes as seen in Table 
2-3. Thus proving that the rigid dense membrane of polymersomes can help retain 
molecules without significantly affecting the particle size. The particle size of both 
liposomes and polymersomes was lowest for reverse phase evaporation method. The 
observation of bigger particle size of thin film evaporation method as compared to 
emulsion evaporation method (Table 2-3) can be attributed to the emulsion formation 
step in the latter method which aids in easier formation of particles whereas thin film 
hydration method requires hydration of film over a long period of time and may 
require an additional step of probe sonication to convert multilamellar particles to 
unilamellar and help reduce size. 
L500 and L2000 had a PDI of 0.5-0.6 but P500 had very high PDI of approx. 0.7-0.9 
whereas P2000 had PDI of less than 0.5. Similar to observations of size, reverse phase 
evaporation method had lowest PDI for liposomes and polymersomes with PEG 2000 
when compared to other methods of preparation. Evaluation of zeta potential 
indicated that P500 and P2000 loaded FCD and anthracene were almost neutral 
having charge up to 1-4mV than liposomes which had a net negative charge from 3-
16mV. L2000 and P2000 were more positively charged than L500 and P500 
respectively owing to the dense PEG chain on them.  Anthracene loaded liposomes 
and polymersomes were slightly more positive than FCD NPs. The method of 
preparation did not have any effect on the zeta potentials of the both types of NPs. 
Hence, from the observations of size and PDI, it can be concluded that the reverse 
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phase evaporation method provides smaller sized homogenous NPs as compared to 
the other two methods of preparation. 
Table 2-3 Characterisation of liposomes (L500/2000) and polymersomes (P500/2000) 
loaded with FCD and anthracene prepared by three methods-Thin film hydration 
(TFH), Emulsion Evaporation (EMEV) & Reverse phase evaporation (RPE). N=3 
represented as average±SD. 
FCD  L500 P500 L2000 P2000 
Size (nm) TFH 394.3±74.7 160.3±47.5 444.3±75.1 188.1±66.7 
 EMEV 305.9±14.6 174.2±45.4 318.5±84.6 223.4±50.3 
 RPE 266.1±31.2 163.4±66.8 239.2±55.4 162.9±20.1 
      
PDI TFH 0.5±0.1 1±0 0.3±0.01 0.3±0.05 
 EMEV 0.5±0.1 0.8±0.1 0.4±0.07 0.4±0.1 
 RPE 0.5±0.09 0.7±0.2 0.4±0.1 0.3±0.05 
      
Zeta (mV) TFH -16.4±2.9 0.9±2.1 -11.3±4.3 2.2±1.4 
  EMEV -10.2±4.09 1.8±1.2 -10.05±1.8 2.2±1.6 
 RPE -8.1±2.1 1.6±1.7 -10.8±1.8 0.9±1.5 
      
Anthracene  L500 P500 L2000 P2000 
Size (nm) TFH 660±53.7 404.7±46.1 493.1±80.4 294.9±22.4 
 EMEV 174.6±5.6 316.2±76.0 442.9±48.1 419.4±69.7 
 RPE 348.2±18.5 184.8±23.5 300.2±71.0 261.9±82.6 
      
PDI TFH 0.3±0.1 0.9±0.1 0.7±0.1 0.4±0.06 
 EMEV 0.3±0.09 1±0 0.4±0.03 0.4±0.03 
 RPE 0.4±0.05 0.9±0.1 0.4±0.09 0.5±0.1 
      
Zeta (mV) TFH -6.5±0.3 3.7±0.1 -4.3±0.8 4.3±0.9 
 EMEV -11.9±0.7 3.5±1.0 -2.6±1.3 4.8±0.1 
 RPE -9.8±1.8 3.1±0.3 -3.6±0.7 4.5±0.2 
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Table 2-4 represents the characterisation of L500, L2000 and P500, P2000 loaded with 
FCD and anthracene prepared by three methods for percentage encapsulation 
efficiency. There was almost no variation in encapsulation efficiency of FCD liposomes 
and polymersomes with PEG 500 and 2000 for all three methods of preparation. 
Reverse phase evaporation method indicated that the encapsulation efficiency of FCD 
in both liposomes and polymersomes was quiet high (up to approximately 75%). This 
relates to the findings of Sardan et al. who have shown that up to 75% encapsulation 
efficiency of a hydrophilic drug such as Dox in liposomes can be achieved when 
prepared by reverse phase evaporation method264. In other cases there has been up 
to 40% encapsulation of highly water soluble proteins such as Drosophilia AChE and 
hydrophilic potassium chromate in liposomes prepared by thin film hydration 
method265, 266. A slightly less encapsulation efficiency of FCD (upto 60%) was observed 
in liposomes L500 having smaller PEG chain length but there was good encapsulation 
efficiency in polymersomes for both P500 and P2000. Hence polymersomes having 
both smaller and larger PEG chain lengths can be used to achieve high encapsulation 
efficiency. Similarly there was high encapsulation of hydrophobic anthracene in both 
L2000 and P2000 and slightly less in L500 and P500 considering the more dense nature 
of PEG 2000 chain allows better entrapment of molecules.   
Table 2-4 Comparison of liposomes and polymersomes loaded with FITC-CM-Dextran 
(FCD) and anthracene for % Encapsulation efficiency by three methods of 
preparation. N=3 represented as average±SD. 
FCD L500 P500 L2000 P2000 
TFH 72.5±1.6 72.6±2.9 71.9±1.8 77.4±1.5 
 EMEV 65.4±5.8 72.8±5.3 71.2±5.9 76.7±0.9 
RPE 58.3±10.6 75.9±4.4 75.1±6.9 75.9±1.9 
     
Anthracene L500 P500 L2000 P2000 
TFH 78.6±7.3 82.7±10.0 78.5±9.0 88.5±9.3 
 EMEV 77.7±10.4 57.9±0.2 72.3±3.9 89.7±6.3 
RPE 72.2±7.5 71.6±1.8 77.0±11.3 80.0±1.4 
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To study the effect of charged molecules on the polymersomes, L2000 and P2000 
encapsulating FDD (positive charge) and F-D (Neutral) were prepared by reverse phase 
evaporation method and evaluated for particle characteristics ( 
 
Table 2-5). There was higher encapsulation of negatively charged FDD than neutral F-D. 
The particle size and PDI of L2000 and P2000 was not affected by charge of 
encapsulating moiety. There was no significant difference in zeta potential of 
polymersomes because of the presence of charged compounds. P2000 were 
significantly smaller in size and had a slightly higher encapsulation efficiency than 
L2000. Both L2000 and P2000 had PDI less than 0.5 and P2000 were more positive 
charged than L2000, thus leading to the conclusion that charge did not have any effect 
on the encapsulation and size of liposomes and polymersomes, this can again be 
attributed to the dense PEG layer coating the surface of liposomes and polymersomes. 
 
Table 2-5 Characterisation of L2000 and P2000 loaded with FITC-DEAE-Dextran (FDD) 
(Positive) and FITC-Dextran (F-D) (Neutral) prepared by reverse phase evaporation 
method to enable evaluation of effect of charge. N=3 represented as average±SD. 
 
FDD (FDD) L2000 P2000 
EE (%) 80.8±1.7 86.5±2.0 
Size (nm) 285.6±21.8 154.3±14.1 
PDI 0.4±0.07 0.2±0.01 
Zeta (mV) -0.9±1.9 4.0±0.8 
F-D (F-D) L2000 P2000 
EE (%) 68.1±2.0 72.4±18.9 
Size (nm) 241.9±39.7 147.±45.8 
PDI 0.3±0.05 0.3±0.09 
Zeta (mV) -7.1±1.1 2. 1±1.3 
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Representative size distribution curve of polymersomes is shown in Figure 2-12a.  
Scanning Electron microscopic images Figure 2-12b of P2000 shows spherical particles 
which are uniform in size.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.3 Cellular uptake of FCD and anthracene loaded polymersomes and liposomes 
In an attempt to establish the cellular uptake of the 4 NP’s, each DDS was loaded with 
a hydrophilic dye (FCD) or a hydrophobic dye (anthracene) and both were incubated 
with HeLa cells for 4 hours at 37°C at concentrations of 250µg mL-1 FCD and 50µg mL-
1 anthracene.   
(a) 
(b) 
Figure 2-12 (a) Representative size distribution graph of polymersomes showing 
formation of bilayer polymersomes of size approx. 150nm and a small number of 
micelles formed in the process. (b) SEM image of P2000 polymersomes. 
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As seen in Figure 2-13, P500 had an average higher uptake of FCD up to 0.9±0.3µg/mg 
protein as compared to P2000 (0.6±0.08) and L500 (0.5±0.1) and L2000 (0.4±0.09). The 
uptake of anthracene in polymersomes P500 and P2000 at 1.01±0.2 and 0.5±0.002 
was significantly higher than liposomes. Due to the negative charge character of the 
plasma membrane, small sized positively charged and neutral particles are better 
absorbed and endocytosed than negatively charged particles especially through 
clathrin mediated endocytosis267, 268. Due to their smaller size and neutral charge, 
polymersomes can prove advantageous for rapid uptake into cells. Hence it can be 
concluded that polymersomes have shown to have better uptake for both FCD and 
anthracene than liposomes. Random copolymers having cholesterol with PEG 500 and 
decyl side chains have been reported to have high uptake of FCD in polymersomes as 
compared to free FCD solution in HeLa cells128. Even though there was a significant 
reduction of cellular uptake of L500, there was no significant change in the uptake of 
liposomes with L2000.  
 
2.5.4 Fluorescence microscopy 
Following the demonstration that our synthesized polymersomes have better cellular 
uptake than liposomes, especially for hydrophobic dyes, we visualised them in cells to 
see their effect on live cells by fluorescence microscopy. Evaluation of cellular uptake 
Figure 2-13 Cellular uptake of FCD and anthracene in liposomes and 
polymersomes. N=3, represented as average±SEM, * indicates p value <0.1.  
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enabled us to see the uptake of hydrophobic and hydrophilic compounds separately, 
however to go one step further, FCD and anthracene were encapsulated 
simultaneously in liposomes and polymersomes and incubated with Hela cells. Cells 
were then observed under microscope for simultaneous uptake of both dyes. Figure 
2-14, showing merged images of P500 and P2000 demonstrate good overlap indicating 
clear uptake of both dyes. However merged images of liposomes did not show blue 
fluorescence of anthracene associated with green fluorescence of FCD indicating that 
anthracene was outside the cell rather than on the inside thus proving the lesser 
cellular uptake of anthracene. Hence P500 and P2000 have a better ability for 
simultaneous encapsulation and uptake of both FCD and anthracene which can prove 
advantageous in multiple drug delivery. 
Anthracene FCD Merged 
P500 
P2000 
L500 
L2000 
Figure 2-14 Fluorescence microscopic observation of FCD and anthracene loaded liposomes 
and polymersomes. 
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2.5.5 Mechanism of uptake by chemical inhibition of endocytosis 
The mechanism of cellular uptake was evaluated by chemical inhibition of endocytosis 
using chlorpromazine HCl. Chlorpromazine inhibits clathrin coated pit formation by 
reversible displacement of clathrin and its adapter proteins from cell membrane to 
intracellular vesicles thereby inhibiting endocytosis by this pathway269, 270. The results 
of which are displayed in Figure 2-15.  
 
Cellular uptake of P500 and P2000 decreased significantly by 37.6±19.7% and 
46.3±21.0% respectively on inhibition of endocytosis thus indicating that uptake of 
polymersomes is predominantly by clathrin- mediated endocytosis as seen in Figure 
2-15. Longer PEG chain lengths such as MW 2000 and 5000 have been associated with 
increased circulation time in blood when compared to liposomes modified with 
shorter PEG chain lengths such as PEG 500 and 750, even though smaller molecular 
weight PEG has shown to have higher cellular uptake in both liposomes and polymer 
NPs271-274. Miller et al. have shown that sterically stabilised liposomes with PEG 2000 
undergo significantly less endocytosis than conventional non pegylated liposomes and 
it is possible that they are taken up by other mechanisms. Thus proving our 
Figure 2-15 Effect of inhibition of endocytosis using chlorpromazine HCl incubation 
of 30 minutes before treatment of cells with FCD loaded liposomes and 
polymersomes. N=3, represented as average±SEM, * indicates p value <0.1. 
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Figure 2-16 Cytotoxicity of blank P2000 and L2000 at 0.25mg/ml in 3 cell lines 
after overnight incubation. N=3, represented as average±SEM, * indicates p 
value <0.1. 
observation of liposomes with PEG 2000 have only 10.2±22.5% change in cellular 
uptake indicating cellular uptake via other pathways whereas liposomes with PEG 500 
demonstrated 47.5±16.3% decrease in uptake275.  
2.5.6 Cell viability using MTT assay 
Following the research described in section 2.5.3, it was established that 
polymersomes with PEG 500 have better cellular uptake of both FCD and anthracene. 
However, when this information was considered alongside the high PDI values they 
were not taken for further evaluation. Liposomes made with PEG 2000 have been 
extensively used in research for anticancer therapy for their stealth properties and 
providing effective masking from serum proteins276-278. Therefore only the two NP’s 
using the higher weight PEG were analysed further within this study. Cell toxicity 
studies of blank liposomes and polymersomes at different concentrations in three cell 
lines after overnight incubation were observed using MTT assay. Figure 2-16 shows 
the percent cell viability of polymersomes and liposomes at 0.25mg ml-1 in HeLa cells, 
CHO cells and BxPC-3 cells. There was no statistically significant difference in the cell 
toxicities of blank liposomes and polymersomes in Hela and BxPC-3 cells with 
viabilities of 85.5±4.6% and 87.2±9.4% for liposomes in HeLa and BxPC-3 cells and 
73.0±3.9% and 86.8±6.2% for polymersomes in HeLa and BxPC-3 cells respectively. 
Polymersomes were statistically slightly more toxic to CHO cells at 0.25mg/ml 
demonstrating cell viability of 77.3±2.6% viability as compared to liposomes having 
88.0±1.4% viability.  
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When compared to cell toxicity at 0.5mg/ml concentration (Figure 2-17), it was found 
that polymersomes were significantly more toxic to cells at higher concentration. 
There was 55.4±1.7% cell viability of HeLa cells when treated with polymersomes and 
71.5±2.5% cells were viable in CHO cells whereas 83.6±8.2% cells were viable in BxPC-
3 cell line as compared to liposomes having 81.7±4.4, 91.0±0.8 and 98.5±5.9% viability 
in HeLa, CHO and BxPC-3 cells respectively.  
 
Nevertheless 0.5mg/ml concentration is quiet high to work with and hence it is safe to 
conclude that our polymers are safe to use at concentrations up to 0.25mg/ml. On the 
contrary, toxicity of these polymers at higher concentrations can prove advantageous 
in cancer treatment where when combined with anticancer drugs can have the 
possibility of synergistic effect thus providing effective cell cytotoxicity at lower 
anticancer drug concentrations and reduce other unwanted side effects.  
 
2.5.7 In-vitro release studies 
Figure 2-18 shows the in-vitro release profile of P2000 and L2000 for FCD and 
anthracene conducted over a period of 24 hours. The results indicated that 
polymersomes were slightly faster at releasing their cargo than liposomes. There was 
a gradual release of FCD and 86.0±2.9 and 94.3±2.8% was released by 24 hours from 
Figure 2-17 Cytotoxicity of blank P2000 and L2000 at 0.5mg/ml in 3 cell lines. N=3, 
represented as average±SEM, ** indicates p value <0.01, *** indicates p value <0.001. 
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liposomes and polymersomes respectively. P2000 and L2000 with anthracene were 
slower in release with 44.3±4.4% releasing after 24 hours from liposomes and P2000 
showing slightly greater release of 60.0±9.2% than liposomes but there was no 
statistically significant difference between the two release profiles.  
 
Polymersomes have been reported to be slower in release than liposomes which is 
considered as disadvantageous, however considering the above results we can say 
that our polymersomes have a release profile similar to liposomes279, 280.  
Release studies of L2000 and P2000 loaded with FDD (Figure 2-19) have shown release 
of 34.2±0.7% and 38.3±2.9% after 24 hours for L2000 and P2000, respectively but 
liposomes L2000 with FITC dextran were faster in releasing the dye at 87.0±7.9% after 
24 hours than polymersomes which released only 54.8±6.4% of the dye after the same 
period leading to the conclusion that polymersomes are slower in releasing cationic 
and neutral molecules.  
 
 
 
Figure 2-18 In-vitro release of L2000 and P2000 loaded with FCD and anthracene 
in PBS and Ethanol:PBS 1:1 respectively at 37°C for 24 hours. N=3, represented as 
average±SEM. 
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2.5.8 Physical stability studies 
Physical stability of liposomes has always been a matter of concern especially for 
practical purposes of storage and handling. Thompson et al. have extensively studied 
the stability of liposomes made with soya phospholipids at various conditions such as 
pH, temperature and storage time266. They have found that there was substantial 
increase in particle size of liposomes after 10 days of storage at 20-30°C. In another 
study, liposomes loaded with vancomycin have shown an increase in particle size and 
reduction in encapsulation efficiency after 2 months storage at 25°C with fungal 
growth considering the biological nature of lipids281. We compared the stability studies 
of P2000 to L2000 loaded with FCD and anthracene under refrigerated conditions and 
25°C for 8 weeks and evaluated them for size and encapsulation efficiency. As seen in 
Figure 2-20, encapsulation efficiency of L2000 and P2000 of FCD and anthracene was 
not significantly affected at refrigerated conditions, however as the encapsulation 
efficiency decreased slightly at 25°C for FCD in liposomes and polymersomes, there 
was drastic decrease in encapsulation efficiency of anthracene liposomes.  
 
Figure 2-19 In-vitro release studies in PBS at 37°C of L2000 and P2000 loaded 
with FDD and F-D to evaluate effect of charged compounds on release. N=3, 
represented as average±SEM. 
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This decrease in encapsulation is reflected in the increase in size of liposomes after 8 
weeks (Figure 2-21). Encapsulation of anthracene in P2000 was not affected as much 
as L2000 and also size of P2000 was more stable after 8 weeks at 25°C than L2000 for 
both FCD and anthracene. There was a slight increase in size of polymersomes with 
FCD after 8 weeks at 5°C. Size of anthracene liposomes were not affected at 5°C. 
Hence our studies conclude that liposomes are more stable under refrigerated 
condition but they can be unstable when stored at room temperature which proves 
previous observations in literature, whereas the size and encapsulation efficiency of 
P2000 of both FCD and anthracene was stable at 25°C hence concluding that 
polymersomes were more stable than liposomes giving them an advantage over 
liposomes.  
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Figure 2-20 Effect of storage time and temperature on encapsulation efficiency of 
L2000 and P2000 loaded with FCD and anthracene. N=2, represented as 
average±SEM, * indicates p value <0.1, ** indicates p value <0.01.  
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Figure 2-21 Effect of storage time and temperature on size of L2000 and P2000 loaded 
with FCD and anthracene. N=2, represented as average±SEM, * indicates p value <0.1. 
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Similarly the stability studies of L2000 and P2000 loaded with FDD and F-D were also 
conducted to study the effect of charge on stability however it was found that there 
was no significant difference in the encapsulation efficiency and size of polymersomes 
and liposomes over time Figure 2-22.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6 Conclusion 
Polymersomes are multipurpose polymeric nanoparticle carriers which can be 
adapted for numerous applications in nanomedicine. Polymersomes made with 
random copolymers can prove advantageous over block copolymers because of their 
ease of preparation. In this study we have synthesized random copolymers using 
octadecanol, oleic acid, cholesterol and PEG 500 (P500) or PEG2000 (P2000) to obtain 
a chemical composition similar to liposomes (L500 and L2000). These polymers were 
capable of self-assembling to form bilayer polymersomes when prepared by reverse 
phase evaporation method and compared to liposomes. The polymersomes had good 
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Figure 2-22 Physical stability studies of L2000 and P2000 loaded with FDD and F-D at 
refrigerated and 25°C for 8 weeks. (a) Effect of storage time and temperature on 
encapsulation efficiency (b) Effect of storage time and temperature on size. N=2, 
represented as average±SEM, * indicates p value <0.1, ** indicates p value <0.01.   
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encapsulation efficiency of both hydrophilic (FCD) and hydrophobic anthracene dyes. 
The hydrodynamic radius of the polymersomes was smaller than their liposome 
counterpart and had better cellular uptake of FCD and anthracene than liposomes. 
Polymers were non-toxic to cells at 0.25mg/ml concentration and had a fast release of 
their cargo with 100% releasing within 24 hours. Physical stability of polymersomes 
was better than liposomes when stored at 25°C for 8 weeks. Thus, we have 
successfully synthesized biomimetic, versatile, biocompatible and stable 
polymersomes imitating liposomes encapsulating different types of compounds and 
having good cellular uptake. Polymersomes are versatile and capable of encapsulating 
different types of drugs. Even though liposomes are considered as good 
nanoparticulate delivery systems especially for cancer therapy, polymersomes have 
shown great promise and it will be interesting to see their use as multifunctional 
therapy systems in future. 
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3. Chapter 3 
The integration of triggered drug delivery with real time 
quantification using FRET; creating a super ‘smart’ drug 
delivery system.  
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3.1 Introduction 
In the past few decades, smart drug delivery systems (DDS) have evolved to deliver an 
appropriate dose to meet the individual patients’ needs282. Delivering the drug at a 
controlled rate, triggered drug release and targeted drug delivery are some methods 
that have been extensively investigated. Some examples of such systems include the 
development of biopharmaceutical systems capable of interacting with intracellular 
components that respond as a direct result to environmental stimuli283 and NPs that 
specifically bind to tumour cells using receptor targeted systems284, 285. Among these, 
triggered release plays a substantial role in controlling timing and location of drug 
release, since it can be induced by several external stimuli acting on the intracellular 
vehicles response286. Examples of stimuli used to facilitate drug release are 
temperature287, pH288, magnetic field289, electric field290, ultrasound291, enzymatic 
activity292 and light293.  
With increasing focus towards nanotechnology based drug delivery, many complex 
drug delivery systems such as liposomes, micelles polymersomes, nanofibers, 
dendrimers have been developed to treat a variety of disease. However, no 
compendial or regulatory standards exist for release testing from NPs294. There is an 
urgent need for a sensitive, robust, reliable and reproducible method for analysis of 
drug release from a nanoparticulate system. Forster Resonance Energy Transfer (FRET) 
is one such method which has been explored recently to allow real time observation 
drug release. 
The ability to quantitatively monitor the amount of drug release, from a DDS in real 
time using a simple but effective approach is an essential companion in the advance 
towards second-generation health care. To this end, there have been a number of 
examples where mesoporous silica NPs (MSN) have been used as a cage for drug 
delivery with the drug co-incorporated alongside a photochromic compound295, an 
oligonucleotide containing a recognition element296 or a redox active FRET pair297 so 
that the system operates like a molecular valve. In each case, the drug was prevented 
from exiting the pores of the NP due to the large bulky groups surrounding the MSN. 
On application of external stimuli, the outer layer (valve) was disrupted and the inner 
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cargo released from the MSN. In addition to the triggered release, a FRET mechanism 
was utilized to enable real time monitoring of drug release.  
3.1.1 Fluorescence resonance energy transfer (FRET) 
FRET is non-radiative energy transference phenomenon in which quantum energy is 
carried from an excited fluorophore donor molecule to an acceptor molecule placed 
within close proximity to each other. The process does not consist of emission and 
reabsorption of photons, but involves energy transfer by inter-molecular dipole-dipole 
coupling, hence it is called “resonance energy transfer’’ (Figure 3-1). The principle of 
FRET is that a donor molecule absorbs light at a definite frequency that temporarily 
places it into a higher energy state. Before it decays down to its ground state, the 
close presence of another molecule results in non-radiative transfer of energy by 
dipole-induced dipole interaction298. The emission wavelength of the donor molecule 
must coincide with the absorption wavelength of the acceptor molecule, which is not 
necessarily fluorescent299.  
 
  
 
 
 
 
 
 
 
 
For FRET to successfully occur between two molecules there are two essential criteria 
that must be met: The acceptor and donor moieties should have favourable dipole 
alignment and the emission spectrum of the donor molecule should overlap with the 
Figure 3-1 Illustration of FRET energy transfer between a donor 
and acceptor FRET pair. 
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excitation spectrum of the acceptor molecule. If there is no sufficient overlap in the 
spectra, then the dipole coupling between the donor and acceptor molecules will not 
occur and hence FRET will not take place between them300. FRET is sensitive to 
distance between the donor and acceptor as the two molecules should be separated 
by a distance typically 20–60 Å and the transfer efficiency falls inversely as the 
separation distance between the two molecules increases. 
Due to its extreme sensitivity to molecular distances, FRET phenomenon can be 
utilized as an indicator for close proximity between the molecules as well as a 
communicator for very small fluctuations in proximity leading to FRET being referred 
as a ‘‘spectroscopic ruler’’. Hence FRET is suitable for biomedical applications as the 
range at which FRET occurs matches with the dimensions of many biological 
molecules, such as proteins, cell membranes and polymeric NPs such as micelles. 
When encapsulated within a micellar system the FRET pair are in close proximity 
within the nanoscale region which favours efficient FRET between the molecules.  The 
limited intra-micellar space can be exploited by the FRET mechanism allowing micellar 
delivery systems to incorporate FRET within the design producing self-communicating 
delivery systems.  Another advantage of FRET is that it can be applied under 
physiological conditions in biological systems particularly in real time299.  
3.1.2 Photochromic compounds 
Light responsive drug release is an attractive mechanism because of its ease of 
production, non-invasiveness, controllable intensity and the ability to control the 
spatial and temporal triggering of the release process301. Triggered release using light 
has been used in many applications for smart targeted drug delivery systems. The 
response to light of substrates can be irreversible or reversible depending on their 
nature of the substrates for example; photocleavable polymers have an irreversible 
response to light leading to cleavage of unstable bonds to polar stable states with the 
help of photons, whereas photochromic materials have a reversible reactions to light 
such as photo-oxidation, double bond rotation, and cleavage which undergo 
reformation or reisomerization after removing the light source. Furthermore, different 
types of light can be used like ultraviolet light with (100−400nm), visible light 
(400−750nm), and near-infrared (750−2000nm)302. Numerous examples of 
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photochromic materials capable of transforming under the influence of activating 
radiation have been explored over recent years303. However, the photo activating 
ability of spiropyran compounds was recognised as early as the 1920’s304. 
Spiropyran is a dynamic molecule consisting of a chromene and indolene moiety 
bound together via a spiro junction and oriented perpendicular to each other. When 
exposed to UV light (λ= 365nm), spiropyran can undergo a reversible response to light 
and chemical stimulations. The closed ring stable state of spiropyran (10a) can be 
converted to its open form, merocyanine (10b), when irradiated with UV light, which 
is converted back into its original state when irradiated with visible light (Figure 3-2).  
 
The property that makes spiropyrans unique is that both its isomers have very 
different properties. The spiropyran form, is a hydrophobic four-ring system and 
preferentially favours a non-polar environment whereas its open ring zwitterionic 
merocyanine counterpart prefers a more hydrophilic environment. In this chapter, we 
exploit differences in the hydrophobic/hydrophilic balance between the two isomers 
to mediate drug release from a micellar based delivery system. This simple 
photochromic transformation has found many applications ranging from molecular 
sensors305 to DNA-based logic operations306 and bioimaging93.   
3.1.3 The FRET pair 
Boron-dipyrromethene (BODIPY) (13) belongs to the class of fluorescent dyes which 
have proved ideal as fluorescent probes for FRET analysis due to their high fluorescent 
UV 
irradiation 
Vis 
irradiation 
10(a) 10(b) 
Figure 3-2 Illustration of the phototranformation of spiropyran to 
merocyanine and transformation back under visible irradiation 
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quantum yield, low molecular weight and small stokes shift307. The bodipy derivative 
31 having an aliphatic decyl chain was synthesized in the laboratory and its structure 
was confirmed by 1H NMR and mass spectroscopy and used without further 
modification.  
 
 
 
 
 
 
 
The emission spectrum of bodipy overlaps with the absorption wavelength of 
merocyanine which renders it as a suitable donor chromophore in the FRET 
relationship. The phototransformation of spiropyran to merocyanine acts as 
photochromic switch to the fluorescence emission of bodipy.  The presence of 
merocyanine in the system allows the transfer of excitation energy from bodipy to 
merocyanine resulting in quenching of bodipy fluorescence.  Whereas the removal of 
light source, allows the reversion of merocyanine back to spiropyran causing increase 
of bodipy fluorescence. This process is termed as photochromic FRET and utilizes a 
dynamic photochromic compound to switch ON and OFF the fluorescence of the 
donor compound and can be repeated until fatigue resistance of the donor compound 
occurs308.  
Hydrophobic spiropyran (32) was synthesized in the laboratory by attaching a decyl 
chain to it which enables sufficient hydrophobicity to spiropyran whereas its light 
induced isomer merocyanine is more hydrophilic which allows its transport across the 
micellar membrane. Its successful synthesis and structure were further confirmed by 
1H NMR and Mass spectroscopy.  
(31) 
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The attachment of a decyl chain to the spiropyran molecule enabled it to achieve 
sufficient hydrophobicity to reside in the hydrophobic depths of the micellar core 
along with bodipy without affecting its photochromic isomerization properties. Thus 
allowing it to convert to merocyanine on irradiation with UV light. 
 
3.1.4 Chapter overview 
In this chapter, a micellar system capable of delivering hydrophobic drugs was 
combined with both a triggered drug release mechanism and FRET communication to 
allow for the real time quantitative analysis through molecular communication as well 
as triggered drug release of lipophilic compounds. This was achieved using a FRET 
mechanism whereby a hydrophobic FRET pair were contained within the interior of a 
self-forming amphiphilic micelle.  Upon application of an external UV light trigger, one 
of the FRET pair, a spiropyran moiety, underwent the photo transformation described 
in Figure 3-3, to the more hydrophilic merocyanine isomer and subsequently 
transcended the micellar membrane into the aqueous external environment. The 
other half of the FRET pair, a hydrophobic bodipy fluorochrome, remained within the 
non-polar environment of the micelle. Thus, release of the merocyanine isomer from 
the micelle modulates the donor-acceptor energy transfer process enabling the 
release process to be followed by fluorescence spectroscopy, illustrated in Figure 3-3.   
 
(32) 
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The scope of this approach was further extended by conjugating an Active 
Pharmaceutical Ingredient (API) onto the spiropyran isomer enabling its release to be 
controlled and monitored in real time. To illustrate this, we have also attached 
ibuprofen to spiropyran using an ester linkage and determined its release from the 
micelle upon UV light irradiation and compare these results with unmodified 
spiropyran.   
 
3.1.5 Aims of chapter 
The creation of a micellar drug delivery system capable of triggered drug delivery and 
subsequent communication using a FRET mechanism to establish real time drug 
release from the micelle.  
 
 
Figure 3-3 Schematic representation of the UV triggered release caused by the photoisomerism of 
spiropyran to the zwitterionic merocyanine transcending the amphiphilic micelle and concomitant 
quantification using FRET with a bodipy donor moiety. 
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Specific aims: 
1. Preparation of and characterization of micelles with the capacity to encapsulate 
FRET communicating compounds. Characterization will be achieved using particle 
size and PDI, zeta potential and encapsulation efficiency. 
2. Establishment of the physical parameters required for the photo-transformation of 
spiropyran to merocyanine. In particular, the time required for complete conversion 
of spiropyran to merocyanine in both DMF and in aqueous medium (encapsulated 
within a micelle) will be determined. 
3. Optimization of bodipy and merocyanine FRET relationship, by establishing the 
optimal molar ratio of bodipy to spiropyran at which optimal FRET efficiency occurs. 
4. In-vitro triggered release of merocyanine from micelles using Franz diffusion cells. 
5. Observation of FRET through changes in bodipy fluorescence in Hela cells following 
merocyanine release 
6. Application of the delivery system demonstration release of encapsulated cargo 
attached to an API indirectly communicated by bodipy fluorescence following UV 
light trigger in visible and dark conditions. 
7. Observation of real time release of spiropyran-ibuprofen complex and its correlation 
to quenching of bodipy fluorescence. 
 
3.2 Results and Discussion 
3.2.1 Preparation and characterization of micelles 
Micelles made of amphiphilic polymers have been used extensively in recent years. 
Micelles made with polyethylene glycol have the ability to easily form micelles which 
are supramolecular structures having a hydrophobic core and a hydrophilic exterior. 
The amphiphilic polymer (34) used for the preparation of micelles was composed of a 
Decanyl chain (33) polymerized with PEG Mn 500 (27) in 3:5 ratio by free radical 
polymerization using AICN as the free radical initiator as seen in Scheme 3-1 
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Micelles are able to carry hydrophobic compounds in their interior whereas the 
hydrophilic exterior allows them to be suspended in aqueous medium. The 
encapsulation of a FRET pair inside the micelles offers several advantages which 
enhance their potential as self-communicating drug delivery systems. Firstly, bodipy 
and spiropyran are hydrophobic in nature which allows them to reside in the 
hydrophobic core of the micelles thus increasing their solubility in aqueous medium. 
The decyl chain attached to bodipy and ibuprofen moiety attached to spiropyran 
ensures that both compounds reside in the hydrophobic core of the micelles. 
Secondly, the presence of the FRET pair within the close proximity of a micelle core in 
the nanoscale region enhances their FRET relationship. 
Micelles were prepared using the thin film evaporation method according to the 
procedure described in section 6.4.1. Micelles encapsulating compounds 31 and 32 or 
35 were prepared by hydrating polymer film with specified quantities of compounds 
after forming a film of mixture of polymer and compounds solution in chloroform in a 
round bottom flask and evaporating it to dryness.  DLS measurements of micelles 
loaded with 31 and 32 indicate an average particle size of 27.5 ±0.98 nm with PDI 
0.416 ±  0.009 and surface charge of -1.67 ± 0.73 as determined by zeta potential 
(33) 
(27) 
(34) 
Scheme 3-1 Synthesis of amphiphilic copolymer 34 
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measurements (Table 3-1). These observations were in agreement with those 
observed previously by Yildiz et al. using the same polymeric micelle with 
encapsulated cargo93. However, when 32 was replaced by 35, the micelle size 
increased to 45.93 ± 2.72nm and PDI was 0.346 ± 0.04 with -2.05 ± 0.61 zeta potential. 
This slight increase in micelle size may be attributed to the greater rigidity of 35 
causing a larger hydrophobic internal core within the micelle. There was no major 
change in the PDI and zeta potential values for micelles following encapsulation with 
regards to content indicating successful incorporation of 35 inside the micelle. As 
indicated in table 3.1, the encapsulation efficiency of compound 32 in micelles was 
found to be 82.4±3.7% whereas the encapsulation efficiency of compound 35 was 
94±3.1%. Figure 3-4A shows a representative particle size distribution graph for 
micelles loaded with 31 and 32, while a scanning electron microscopic image of 
micelles loaded with 31 and 35 (Figure 3-4B) shows well-formed particles with 
spherical morphology. 
Table 3-1 Characterization of micelles. N=3 represented as average±SD. 
 % EE of 32 & 35 Size (nm) PDI Zeta Potential (mV) 
Micelles loaded 
with 31 & 32 
82.4±3.7 27.5±0.9 0.4±0.009 -1.6±0.7 
Micelles loaded 
with 31 & 35 
94.0±3.1 45.9±2.7 0.3±0.04 -2.05±0.6 
 
Figure 3-4 A. Dynamic light scattering displaying the hydrodynamic radius of 
micelles. B. SEM image of micelles 
109 
 
3.2.2 Quantification of photo physical transformation of 32a to 32b 
For efficient FRET to occur between a donor-acceptor pair, two main criteria must be 
met. First, the donor and acceptor molecules must be in close proximity to each other 
and secondly, the emission spectrum of the donor must overlap effectively with the 
absorption spectrum of the acceptor. In the context of the micellar delivery system 
described above, as both the donor and acceptor are originally confined within the 
central hydrophobic core of the micelle, a nanoscale distance between the two 
molecules can be guaranteed299.  In terms of spectral overlap, the absorbance 
spectrum of 32a encapsulated within the micelle was determined to have a maximum 
absorbance centred at 360nm (Figure 3-5). Upon activation by UV light, 32a undergoes 
a ring opening of the spiro carbon to its corresponding merocyanine, 32b (Figure 3-2). 
The merocyanine is zwitterionic, and therefore more hydrophilic. It has also an 
extended area of conjugation and therefore induces a significant bathochromic shift to 
a new absorbance maximum at 550nm.  The absorbance spectrum of merocyanine 
coincides with the emission wavelength of 31 (Figure 3-5) therefore providing an 
excellent spectral overlap from the donor moiety (31) to the acceptor moiety (32b). 
No such FRET relationship occurs between compound 31 and the spiropyran version of 
32 (32a).  
Figure 3-5 Absorbance spectra of 32a and following photoconversion to 32b with the 
emission spectra of 31 with Ex 525 nm. 
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This spectral cohesion of absorbance and emission of 32b and 31 is imperative for 
energy transfer from 31 (the fluorescent donor) and 32b (the photochromic acceptor). 
Nevertheless, the time required for conversion of 32a to 32b can significantly affect 
the energy transfer from 31 to 32b. 
In an attempt to understand the photoconversion of 32a to 32b, compound 32 was 
exposed to varying time intervals of UV light and the absorbance spectra collected at 
each point. As the compound was hydrophobic, this analysis was first carried out in 
DMF with the results shown in Figure 3-6.  
 
 
 
 
 
 
 
 
 
 
It can be seen from Figure 3-6, that complete conversion of 32a to 32b was achieved 
after 12 minutes exposure to UV light. A similar experiment was then conducted in the 
aqueous solution using the micelle drug delivery system to ensure solubility of the 
compounds. Figure 3-7 displays the results achieved from this experiment. 
Figure 3-6 Absorbance spectra of 32b in DMF after photo-conversion of 32a by UV 
exposure at 365nm for specific time intervals at increments of 2 minutes 
111 
 
From Figure 3-7 it can be seen that it required 5 minutes irradiation for complete 
conversion from 32a to 32b loaded within a micelle. When considering the aqueous 
environment in the photoconversion, after 5 minutes, the absorption reached a 
plateau beyond which there was no increase in the absorption intensity. However 
complete conversion of 32a to 32b took 12 minutes in DMF medium (Figure 3-6).  This 
can be explained by the increased polar nature of 32b when compared to its 32a 
counterpart, therefore favouring a faster conversion to the zwitterionic 32b in the 
more polar aqueous medium. The polar nature of 32b is fundamental to encourage its 
release from within the micelle to the surrounding polar aqueous environment, 
enabling a triggered release of micellar content.  
 
3.2.3 FRET efficiency between 31 and 32b 
In order to identify the optimal ratio of 31 to 32b which allows linearity between 
energy transfer and concentration between the fluorophore and photochrome, the 
two compounds were encapsulated into the micelles at different molar ratios and the 
decrease in fluorescence emission of 31 was recorded. From Figure 3-7, we deduced 
that 5 minutes irradiation with UV light was sufficient in aqueous media to facilitate 
complete conversion of 32a to 32b. Figure 3-8 shows the emission profile of 31 at 
Figure 3-7 Absorbance spectra of 32b at λmax 550nm increasing with increasing exposure to UV 
light of 365nm encapsulated in micelles in PBS. Spectra displayed following exposure to 0, 0.5, 
1.0, 1.5,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 and 6.5 mins UV light at 465 nm from a fixed distance. 
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varying ratios of 32b. As expected, the emission of 31 was highest when there was no 
32b present in the micelle (spectrum a). As the concentration of 32a in the micelles 
increased, more 32a was converted to 32b upon irradiation with UV light and 
quenched the emission of 31 at 540nm proportionately (spectra b-h). In addition, 
emission from 32b (merocyanine emission at 637nm) was observed as a broad 
bathochromic shifted peak upon increasing the concentration of compound 32 
indicating an excess of 32b. The plot of percentage depletion in fluorescence emission 
of 31 (Figure 3-9) shows that the relationship between 31 and 32b is only linear until a 
certain concentration when a plateau was reached after a ratio 1:6 of 31:32. In order 
for this system to be capable of self-quantifying it is essential that a linear relationship 
exists between donor and acceptor moieties. A molar ratio above that of 1:6 of 31:32 
suggests a saturation concentration was reached with no more 31 available for energy 
transfer. Therefore it can be concluded that the optimal FRET molar ratio between 
donor and acceptor to allow for quantitative analysis is 1:6. This is reflective of the 
difference in extinction coefficient between our donor and acceptor moieties. This 
was the ratio chosen for all subsequent studies. 
 
 
 
 
 
Figure 3-8 Fluorescence emission of 31 following exposure to varying molar ratios 
of 32 after photoconversion to 32b. a: no UV exposure and b-h: solutions were 
exposed to 5 mins UV light at 365 nm from a fixed distance and molar ratios of 
compounds bodipy 31 : merocyanine 32b  b-1:0.5; c-1:1, d-1:2, e-1:4, f-1:6, g-1:8 
and h-1:10 consecutively. 
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3.2.4 In-vitro triggered release  
The ability of the micellar system to encapsulate the hydrophobic guests (31 and 32) 
was established by the encapsulation efficiency (results displayed in Table 3-1). 
Perhaps of more importance, is the ability of these delivery systems to release cargo 
under particular conditions. UV light acts as a trigger for the photoinduced 
transformation of 32a, which is hydrophobic with a closed ring system, to an open ring 
32b which is polar in nature with higher solubility in aqueous medium. The dynamic 
property of micelles would suggest that 32b can easily come out of the micellar 
system permitting release of encapsulated cargo. In an attempt to establish this 
relationship, we subjected the micelles containing compound 32 to continuous 
photoactivation and using a Franz diffusion cell loaded with a semi permeable 
membrane monitored the amount of 32b released to the outside of the micellar 
environment through the semipermeable membrane into the wider aqueous 
environment. The results, displayed in Figure 3-10, show the release of 32b from 
within the micelle with and without photoactivation using UV light.  It can be seen that 
with UV activation the amount of 32b released into the surrounding environment 
within 12 minutes was 24% which was significantly higher than the 5% release in the 
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Figure 3-9 FRET efficiency of 31 and 32b following exposure to 5 mins UV light 
at 365 nm from a fixed distance. Concentration of 31 remains constant at 3.64 
µM. Percentage efficiency was determined by the relation depletion in the 
emission of 31 at 545 nm. 
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absence of photoactivation. In order to ensure that no 32a was being released from 
the DDS, all samples were subjected to further UV light just prior to the analysis of 
merocyanine.  
 
 
 
 
 
 
 
 
 
 
This design of a triggered fast release system is essential for successful release of 
drugs attached to 32 for therapeutic applications. The results displayed above, suggest 
that the photoconversion of compound 32, is indeed both fast enough with a 
sufficient change in polarity to drive the triggered release from the hydrophobic 
micellar environment.  
3.2.5 Observation of FRET in HeLa cells 
Encapsulation of cargo within micelles enables them to be transported across the cell 
membrane leading to better cellular uptake owing to their biocompatibility and size. 
In order to determine the feasibility of communication and triggered release from 
within the micelles, we incubated HeLa cells with micelles loaded with 31 and 32a and 
enabled the photoconversion of 32a to 32b present within the cells to confirm FRET 
communication between 31 and 32b. As seen in Figure 3-11, fluorescence emission of 
31 fluctuated drastically according to status of 32b present within the cells, as a direct 
result of molecular communication between them. The ability of 32b to switch back to 
Figure 3-10 In-vitro triggered release of 32b from micelles after continuous 
activation with UV light for 12 minutes and no UV activation. N=3, 
represented as average±SEM, ** indicates p<0.005. 
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32a in the presence of visible light broke the communication between 31 and 32b 
allowing the emission of 31 to be observed. These results in HeLa cells support our 
previous observations in-vitro conditions in section 3.2.6. It can be seen that 
immediately following 5 minutes UV irradiation there is an 82.5% quench in the 
fluorescence emission of 31, attributed to the energy transfer to the acceptor moiety, 
32b. Upon subsequent photoactivation cycles of 32b there was significantly less 
quenching of the emission from our donor compound 31 (75.3% and 64.2% 
respectively).  This can be attributed to the more polar 32b form leaving the micelle 
DDS (24.7% and 35.8 % released after 10 and 15 minutes irradiation). 
 
Figure 3-11 Bar chart: Fluorescence emission of 31 in HeLa cells incubated overnight 
with micelles loaded with 31 and 32a and following cycles of UV exposure (365 nm, 5 
mins) leading to conversion of 32a to 32b and subsequent resting time in visible light 
conditions permitting reversion of 32b back to 32a. Line graph: control using micelles 
containing 31 only. Insert: % quenching of 31 following UV irradiation. N=3 
represented as average±SEM, ** indicates p<0.01, * indicates p<0.05. 
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As expected the emission of 31 lapsed back faster in visible light conditions compared 
with dark conditions (Figure 3-12), further confirming that the photoconversion of 32b 
to 32a is faster in the presence of visible light and is indirectly communicated in the 
form of higher emission of 31. Additionally, the quenching effect after subsequent UV 
irradiation cycles in the dark was similar to that seen in light conditions. Similarly, 
observations of cells by confocal microscopy indicated significant reduction in 
fluorescence emission of 31 on photoactivation of 32b confirming its presence within 
cells (Figure 3-13). 
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Figure 3-12 Fluorescence emission of 31 in HeLa cells incubated overnight with 
micelles loaded with 31 and 32a and following cycles of UV exposure (365 nm, 
5 mins) leading to conversion of 32a to 32b and subsequent resting time in 
dark conditions permitting reversion of 32b back to 32a. N=3 represented as 
average±SEM. 
Figure 3-13 Confocal microscopic images of HeLa cells incubated with micelles 
loaded with 31 and 32a showing (a) Clear field (b) Fluorescence emission of 31 (Ex 
514nm, Em 520-590nm) before UV exposure (c) Fluorescence emission of 31 after 
UV exposure (365nm, 5 mins). 
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3.2.6 Application of the delivery system 
Having established the FRET relationship between the bodipy (31) and spiropyran (32) 
moieties, the ability to extend upon these particular compounds, by the generation of 
conjugates was a paramount importance for the translation of this novel DDS into a 
more general delivery system. To this end, ibuprofen conjugated spiropyran 
(Compound 35), was synthesized in the laboratory by an esterification reaction 
between spiropyran and ibuprofen. Compound 35 can be considered as a novel 
prodrug of ibuprofen conjugated via an ester bond to spiropyran. The spiropyran 
section of the compound is still capable of isomerization in the presence of UV and 
therefore would be expected to change the polarity of compound 35 sufficiently to 
allow the compound to transcend the micelle environment thus demonstrating the 
ease with which this triggered DDS can be applied to regular therapeutic drugs. 
Compound 35 was created as a prodrug, to contain an API (Ibuprofen) covalently 
linked to the photochromic spiropyran moiety. 
 
 
 
 
 
 
 
Once released from the internal core of the micelle after phototransformation by a UV 
trigger, it is anticipated that compound 35 would be subjected to hydrolysis via 
esterase’s enzymes and hence release the API. The micelles containing both 
compounds 31 and 35 were subjected to various cycles of UV exposure both in light 
and dark conditions. Figure 3-14 shows the in-vitro fluorescence emission of 31 in the 
presence of 35, the subsequent photochromic switching between the spiropyran form 
(35a) to its merocyanine counterpart (35b) is visualized by the quenching of emission 
(35) 
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from 31. The UV exposure cycle was repeated three times with the results displayed in 
Figure 3-14 indicating the reproducibility of the system.  
 
When there was no 35b present in the system (in the absence of UV light), there was a 
significantly high emission of 31.  This emission was quenched upon photoactivation of 
35a to 35b as the absorption signature of 35b overlaps with emission signature of 31. 
As 35b slowly reverted back to 35a owing to its reversibility in heat and visible light 
conditions, the emission of 31 slowly increased. The hydrophilic nature of 35b 
encourages it to transcend the hydrophobic internal core of the micellar system into 
the wider aqueous environment. Although the system was kept in the dark, there 
were three cycles of 5 minutes irradiation, allowing for significant movement outside 
the micelle. This movement was observed as a decrease in the quenching efficiency of 
31 upon subsequent photoactivation cycles (Figure 3-14 insert) as less 35b was 
Figure 3-14 Bar chart: Fluorescence emission of 31 within micelles loaded with 35a 
following cycles of UV exposure (365 nm, 5 mins) leading to conversion of 35a to 35b 
and subsequent resting time in dark conditions permitting reversion of 35b back to 
35a. Line graph: control with micelles containing only 31. Insert: % quenching of 31 
following UV irradiation. N=3 represented as average±SEM. * indicates p<0.05,** 
indicates p<0.005. 
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present within nanoscale distance for FRET to successfully take place between the two 
molecules in each subsequent excitation. This decrease in the quenching of emission 
of 31 is of similar magnitude to the % release of internalized compound 32, observed 
in Figure 3-10, with 19% release after 10 minutes of 35 when compared to the 15 % 
release of 32 after 10 minutes displayed in Figure 3-10. The increase in release is 
attributed to the time lapse between UV stimulation and subsequent photoconversion 
allowing for more hydrophobic 35b to leave the micelle.  
It is seen from Figure 3-14 inset that a further fluorescence quenching of 74.4 % is 
recorded after 15 mins UV irradiation and would suggest that 25.6 % of 35 has been 
released. A similar effect was seen in light conditions, but the % of quenching of 31 
was slightly less, due to the faster photoconversion back to the original more 
hydrophobic spiropyran moiety (35a), ensuring that less compound was released and 
hence more available for the subsequent energy transfer to the donor (Figure 3-15). 
Micelles loaded with only 31 did not show any changes in fluorescence emission after 
photoactivation and after subsequent resting periods, in addition there was limited 
photobleaching of 31 after UV irradiation. 
Figure 3-15 Bar chart: Fluorescence emission of 31 within micelles loaded with 35a following 
cycles of UV exposure (365 nm, 5 mins) leading to conversion of 35a to 35b and subsequent 
resting time in light conditions permitting reversion of 35b back to 35a. Line graph: control 
with micelles containing only 31. Insert: % quenching of 31 following UV irradiation. N=3 
represented as average±SEM. * indicates p<0.05. 
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3.2.7 Real time quantification of encapsulated cargo 
The photoswitchable nature of 35 and its molecular communication with 31 can prove 
beneficial in real time quantification of release of encapsulated materials from within 
the micellar environment. To quantify this occurrence, micelles loaded with 31 and 35 
were loaded on to dialysis membranes in Franz diffusion cells and photoactivated for 5 
minutes to allow conversion of 35a to 35b resulting in its release from the micellar 
environment recorded over 20 minutes of resting time in both dark and visible light 
conditions. Two parameters were measured simultaneously at various time points in 
an attempt to correlate the communication seen through 31 with release of 35.  This 
was achieved by monitoring the amount of 35a present within the micelles by 
absorbance at 345 nm. Following removal of the sample for analysis a set period of 20 
minutes was observed with the sample subjected to visible irradiation, to ensure that 
all 35 was in the spiropyran form, 35a.  The results of the depletion in 35a absorbance 
can be seen in Figure 3-16a. The simultaneous measurement of bodipy emission (31) 
was collected, following the original 5 minutes UV irradiation, each sample removed 
for analysis was subjected to 20 minutes visible light before the emission of 31 was 
recorded, and the decrease in quenching is plotted in Figure 3-16b.  
From Figure 3-16, a good correlation is seen between both the fluorescence increase 
from 31 and the absorbance of 35a. The largest magnitude of change is observed from 
the UV stimulation in dark conditions, this is expected as 35b would favour the more 
polar environment.  Specifically, an 8.4% decrease in 35a absorbance is observed after 
10 minutes, indicating a transfer of 35 across the dialysis membrane. This is indirectly 
communicated through a 7.0 % increase in the fluorescence emission of 31 (Figure 
3-16b). Similarly, a 17.4 % decrease in absorbance of 35a is seen at 20 minutes 
compared to 11.6 % increase in fluorescence emission of 31 at the same time point. 
Visible light conditions led to conversion of 35b back to 35a leading to lesser release of 
only about 7% from micelles which was reflected as approximately 4% increase in 
fluorescence emission of 31. However, there was negligible release in the absence of a 
UV trigger and is suitably revealed as insignificant increase in fluorescence emission of 
31. This close correlation between the FRET communication when compared to the 
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direct measurement of remaining spiropyran would suggest that there is indeed 
potential to further develop these smarter DDSs.  
 
3.3 Conclusion 
The ability to control drug release at a specific physiological target enables the 
possibility of an enhanced therapeutic effect with reduced off-target toxic side effects. 
The discipline of controlled drug release has grown to include most areas of medicine 
with examples in the literature of targeted drug delivery to the majority of organs 
within the human body. In addition, a variety of external stimuli used to meditate the 
drug release process have also been investigated. The number of smart DDSs capable 
of real time communication with concomitant stimulated drug release is increasing in 
response to the nanotechnology revolution302. The need for variation between the 
mechanism of stimulus, as well as the parameters involved in communication is 
paramount to the success of these advanced materials so to allow these nano-
platforms to reach the full echelon of their potential. Recent examples illustrating this 
diversity can be seen by Huang et al.309 whereby they have incorporated the 
anticancer agent Dox into a supramolecular nanoparticle and also double up its use as 
Figure 3-16 (a) In-vitro release of 35a from micelles with and without UV trigger and 
subsequent resting time in dark and visible light conditions measured by decrease in UV 
absorbance at 345 nm. (b) Observation of % increase in fluorescence emission of 31 at 
Ex 503 Em 514 nm measured concomitantly with release of 35a. N=3 represented as 
average±SEM, ** indicates p<0.005, *** indicates p<0.0005. 
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the FRET acceptor to allow self-communicating. Another interesting example is seen 
by Du et al.310 and their incorporation of five stimuli responsive moieties on to their 
NP. Nonetheless, the concurrent real time monitoring of drug release has not been 
widely studied. 
The work presented in this chapter describes a novel micellar drug delivery system 
that is not only capable of releasing its cargo when stimulated by light but also 
provides a real time analysis of the amount of cargo remaining. We have designed a 
photo-activated DDS capable of real time communication using the photochromic 
properties of spiropyrans and exploiting the differences in physiochemical properties. 
Controlled drug release from the delivery system was mediated by physicochemical 
changes of a spiropyran-merocyanine photochromic dyad, while drug quantification 
was enabled using a Förster Resonance Energy Transfer (FRET) relationship between 
the photochrome and a co-encapsulated BODIPY fluorophore. The percentage of drug 
released from the delivery system was significantly greater (24%) when exposed to 
light irradiation compared to an analogous control maintained in the dark (5%). 
Furthermore, the fluorescence read-out capability also enabled the drug-release 
process to be followed in living cells with a significantly reduced fluorescence emission 
observed for those cells incubated with the delivery system and exposed to light 
irradiation compared to control cells maintained in the dark. By adopting a prodrug 
approach, we have developed an ibuprofen-spiropyran analogue, which has displayed 
significant stimulated release from within a micelle environment. In addition, with the 
incorporation of a hydrophobic bodipy compound within the micelle hydrophobic 
core, the FRET communication between the two species present within the micelle 
has shown significant potential for real time analysis of content. Thus, this smart DDS 
has the potential to be adapted for a number of different API, by simply linking the API 
with the spiropyran through an ester or potentially an amide bond, thus increasing 
application for such nanoplatforms to include a large number of drugs with the only 
prerequisite being that they contain a suitable reactive functional groups. Combined, 
these results highlight the utility of this approach to theranostic drug delivery with the 
potential of light-triggered released together with a fluorescence read-out to enable 
quantification of the drug release process.  
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4 Chapter 4 
Multi drug loaded polymersomes for increased efficacy of 
cancer therapy   
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4.1 Introduction to cancer chemotherapy  
Cancer is one of the leading causes of death and was responsible for nearly 8.8 million 
deaths in 2015 globally which accounts for 1 in 6 people dying of cancer311. Cancer is 
characterised by the uncontrolled proliferation of malfunctioning cells involved in 
complex interactions with the environment, surrounding healthy tissue and the 
immune system312. There are various ways of treating cancer including surgical 
removal of the tumour mass, chemotherapy, radiotherapy, hormonal therapy and 
biological therapy depending on the type of cancer, its size and extent of metastasis 
and general health of patient313. Chemotherapy with one or more drugs is generally 
the first line of treatment for patients diagnosed in advanced stages of local and 
metastatic cancers. The main challenge of chemotherapy is to administer drugs at 
doses of maximum therapeutic efficiency and reduced toxicity314. As well as advances 
in the chemotherapeutic agents used in chemotherapy, early detection and treatment 
have benefited cancer patients leading to an increase in the number of cancer 
survivors315. The mechanism of action of many of these anticancer agents such as 
anthracyclines, antimetabolites, alkylating agents and microtubule disruptors is to 
destroy any rapidly proliferating cells, although cancer cells are indeed rapidly 
proliferating, a leading drawback of this type of treatment is due to non-selectivity 316-
318. These anticancer agents can target healthy cells that divide rapidly such as bone 
marrow, hair follicles, digestive tract and macrophages causing immunosuppression, 
rapid hair fall and anaemia. Furthermore these chemotherapeutic agents generally 
have low solubility and get washed out rapidly from blood circulation. They achieve 
lesser accumulation in tumour due to multidrug resistance because of the 
overexpression of P-Glycoprotein, a multidrug resistant protein on the surface of 
cancerous cells leading to failure of treatment319, 320.  Multidrug resistance (MDR) is a 
major problem in cancer chemotherapy and can occur via various mechanisms. MDR 
plays a major role in tumour metastasis and relapse accounting for 90% of 
chemotherapy failures in metastatic cancers321.Tumours are generally a mixed 
population of malignant cells of which some are drug sensitive and others are drug 
resistant. Chemotherapeutic drugs kill the sensitive cells but leave behind a good 
proportion of resistant cells causing the chemotherapy to fail because of the presence 
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of a large number of drug-resistant cells322. Other mechanisms of action include 
increased DNA repair capacity, overexpression of MDR related transporter proteins 
leading to high drug efflux, reduced drug uptake, activation of detoxification and 
evasion of apoptosis314, 321 leading to gradual decrease in sensitivity to the therapeutic 
agent and eventual development of MDR. Thus, MDR is multifactorial and can involve 
various cellular pathways simultaneously in clinical drug resistance. However, 
knowledge of the particular mechanism of drug resistance can help devise new 
strategies of cancer treatment323.  
 
4.2 Different classes of anticancer agents 
Cancer patients are generally treated with either one or a combination of surgery, 
radiation and chemotherapy regimens. Surgery is often the main line of treatment for 
early stages whereas chemotherapy with singular or combination drugs is used in later 
stages of cancer324. Chemotherapy drugs can be classified by their chemical structure, 
their mechanism of action and their relation to other drugs. The choice of 
chemotherapy drug depends on the type of cancer, its size, location, age and health of 
patient 325.  
 
4.2.1 Anthracycline based antitumour antibiotics 
 Anthracylines have shown good efficiency against cancer and are routinely used in the 
treatment of several types of cancer such as ovarian, breast, lung, thyroid, multiple 
myelomas, Hodgkin’s and non-Hodgkin’s lymphomas and soft tissue sarcomas326. They 
are highly conjugated rigid structures all containing four six membered rings fused 
together linearly. They all contain a sugar moiety and are highly oxygenated and 
contain a net positive charge at physiological pH, Dox (36) is a common example of 
these compounds.   
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Many mechanisms of action are suggested for the cytotoxic activity of these 
compounds. Firstly they act by inhibiting the enzyme, topoisomerase II, which is 
responsible for DNA replication327. Anthracyclines have also the ability to intercalate 
between DNA due to the planar lipophilic nature of the cyclic structure and form an 
adduct independent of topoisomerase II activity leading to further cell death. Finally, it 
has been shown that anthracyclines can cause oxidative stress and ceramide over 
production leading to further cytotoxic effects316. As these mechanisms of action are 
not competitive then can act synergistically and it is hypothesised that all these 
actions make them very effective cytotoxic agents, however, it also increases their 
non-selectivity and cytotoxicity against healthy cells. Dox was one of the first 
anthracycline compounds to be described and has a very high cardiotoxicity leading to 
cardiomyopathy and congestive heart failure which is attributed to the oxidative 
stress produced due to myocardial production of reactive oxygen and susceptibility of 
the heart to anthracyclines328. Other anthracycline compounds include Daunorubicin, 
Epirubicin and Idarubicin. 
 
4.2.2 Antimetabolites 
Antimetabolites such as 5-Fluorouracil (5-FU) (37) is an analogue of Uracil with 
Fluorine at the C-5 position. Fluoropyrimidines were developed in the 1950’s after the 
observation that uracil, which forms one of the four bases of RNA, was taken up by rat 
(36) 
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hepatoma more rapidly than healthy tissues indicating its usefulness for 
antimetabolite chemotherapy329.  
 
 
 
 
 
 
 
 
 
 
It is frequently used alone or in combination with LV and other anticancer agents for 
the treatment of a wide range of cancers such as breast cancer, stomach and digestive 
tract and oesophageal cancers330-332. Antimetabolites act by inhibiting a compound or 
enzyme essential for the normal growth of a cell.  The cytotoxicity of 5-FU is due to its 
ability to inhibit the enzyme thymidylate synthase which is the source of synthesis of 
thymidylate necessary for the replication and repair of DNA. The 5-FU metabolite 
FdUMP (Fluoro-deoxyuridine monophosphate) binds to thymidylate synthase thereby 
preventing its binding to the normal metabolite dUMP and thus inhibiting its ability to 
form thymidylate. Another metabolite of 5-FU, FUTP (fluorouridine triphosphate) 
incorporates itself into RNA thus disrupting normal RNA functioning and repair and 
post transcriptional conversion of uridine to pseudouridine thus inducing cell 
toxicity317, 333, 334. All antimetabolite drugs act at a specific stage of cell cycle and 
disrupt normal DNA and RNA function. Other antimetabolite agents include 
methotrexate and gemcitabine. 
 
4.2.3 Alkylating agents 
Alkylating agents act by forming covalent bonds with biological molecules such as 
DNA, RNA and proteins. To induce chemotherapeutic action, they bond with nitrogen 
at the 7th positon of guanine in DNA and also form bonds with other carboxyl, sulfydryl 
(37) 
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and phosphate groups and are effective at any stage of the cell cycle335. Different 
types of alkylating agents include nitrogen mustards such as cyclophosphamide and 
melphalan, nitrosoureas such as carmustin and streptozosin, aziridines such as 
mitomycin and platinum derivatives such as cisplatin (38), carboplatin and 
oxaliplatin336, 337. 
 
 
 
 
 
4.2.4 Microtubule disruptors 
Microtubule disruptors exhibit anticancer activity by disrupting normal polymerisation 
of microtubules, affecting mitosis leading to inhibition of cell proliferation and thus 
inducing apoptosis338. Vinca alkaloids and taxane derivatives such as paclitaxel (39) are 
microtubule inhibitors. Vinca alkaloids prevent the formation of microtubules whereas 
paclitaxel prevent microtubule disassembly by polymerisation thereby affecting 
normal cell cycle318.  
 
 
 
 
 
 
 
 
 
(39) 
(38) 
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4.2.5 Nontoxic compounds included within chemotherapeutic regimens  
In addition to the cancer reducing compounds included within chemotherapeutic 
regimes, there are a small amount of other compounds included to either reduce the 
side effects, such as peripheral neuropathy, hair loss and anaemia, for example the 
use of multivitamins as neuroprotective agents for taxane induced neuropathy339, 340 
or enhance the efficacy of the cancer killing drugs, for example leucovorin calcium (LV) 
(40) combined with 5 Fluorouracil.  
 
 
 
 
 
 
 
 
 
 
 
LV is also known as Folinic acid and is a 5-formyl derivative of tetrahydrofolic acid and 
converts to folic acid derivatives such as tetrahydrofolate having vitamin activity 
similar to folic acid. It generally occurs as calcium salt and is used for counteracting the 
toxic effects of methotrexate and enhance the activity of 5 fluorouracil. LV enhance 
the inhibition of thymidylase synthetase which is the key mechanism of action of 5-FU 
metabolite FdUMP. Clinical studies have suggested that LV can significantly enhance 
the therapeutic efficacy of 5-FU341-344.  
 
 
 
 
 
(40) 
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4.3 Multidrug combinations for anticancer therapy 
The first combination chemotherapy was introduced towards the end of 1960s with 
the clinical success of VAMP (Vincristine, amethopterin, 6-mercaptopurine, and 
prednisone) following the discovery of activity of Vinca Alkaloids by Elle Lily Company 
in 1963 for the treatment of acute lymphocytic leukemia (L1210) in children345, 346. 
Since then, many chemotherapeutic drugs showing synergistic action have been used 
in combination to enhance cytotoxic effects347. Furthermore, combination 
chemotherapy using multiple anticancer agents injected either simultaneously or 
sequentially have also proved effective against MDR cancers employing drugs having 
different molecular pathways or drugs having similar molecular pathways leading to a 
synergistic or additive action348, 349. For example, Lilenbaum et al. compared the 
efficacy of injecting Paclitaxel alone or in combination with carboplatin in 561 patients 
with advanced non-small cell lung cancer. The response rate was 17% in patients 
receiving paclitaxel alone with 2.5 months failure free survival, whereas patients 
receiving Paclitaxel with Carboplatin had a 30% response rate with 4.6 months failure 
free survival350. Carrick et al. compared single agent vs multiple agent treatment for 
metastatic breast cancer in 9742 women involving 43 clinical trials. They found that 
combination therapy showed statistically significant advantage in survival rate, 
response rates and time to progression than single agent therapy however the women 
with combination therapy experienced increased toxic effects in terms of alopecia, 
nausea, vomiting and white cell count. Thus indicating the possibility of sequential 
treatment with single agents than simultaneous combination therapy351.  Many 
combination therapy regimens are used clinically are shown in Table 4-1352. 
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Table 4-1 Clinically used combination drug regimens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Nanoparticulate drug delivery for cancer therapy 
Nanotechnology provides an alternative delivery mechanism to conventional 
chemotherapy and offers several approaches to overcome its limitations. Specifically, 
NPs offer the fundamental advantage of tumour targeting by enhanced accumulation 
in tumour cells via the EPR effect. This in turn enhances their efficacy and reduces 
unwanted side effects353, 354. Furthermore, the ability to design NP carrier systems as 
per their application and their multi-functionality makes them ideal for cancer therapy 
as active targeting through selective molecular recognition can be achieved. The 
Abbreviation Composition Type of cancer 
BEAM Carmustine, Etoposide, Cytarabine, 
Melphalan 
Hodgkin’s and non-
Hodgkin’s lymphoma 
BEP Bleomycin, Etoposide, Cisplatin Testicular cancer 
CMF Cyclophosphamide, methotrexate, 
5-fluorouracil 
Breast cancer 
CTD cyclophosphamide, thalidomide, 
dexamethasone,  
Myeloma 
CAV Cyclophosphamide, Doxorubicin, 
Vincristine 
Small cell lung cancer 
ECF Epirubicin, Cisplatin, 5-Fluorouracil Oesophagus and stomach 
cancer 
FOLFIRINOX Folinic acid, 5-FU, Irinotecan, 
Oxaliplatin 
Pancreatic cancer 
FOLFIRI Folinic acid, 5-FU, Irinotecan Bowel cancer 
FOLFOX Folinic acid, 5-FU,Oxaliplatin Bowel cancer 
GemCap Gemcitabine, Capecitabine. Pancreatic cancer 
TAC Docetaxel, doxorubicin, 
cyclophosphamide 
Breast cancer 
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surface modifications of NPs can allow them longer circulation times by minimizing 
uptake from the RES improving their efficacy355, 356 and the ability to attached high 
affinity targeting ligands. NPs can not only carry large therapeutic payloads but can 
also accommodate multiple drugs with different solubility profiles357.  A variety of NPs, 
made of different materials, such as chitosan245, polycaprolactone124, poly (lactic-co-
glycolic acid)358, liposomes359, 360, micelles361, 362 and dendrimers363, 364 are currently 
being investigated. These NPs involve different mechanisms of action such as active 
and passive targeting and triggered release. 
4.5 Liposomes in multi-drug anticancer therapy 
There has been a dramatic rise in the past decade in novel therapies for delivery of 
therapeutic agents for cancer therapy. The commercialization of Dox liposomes 
(Doxil®) in 1996 has led to exploration in various areas of cancer chemotherapy 
involving encapsulation of anticancer drugs in liposomes365, 366. Liposomes have been 
used as drug delivery vehicles for many anticancer agents such as anthracyclines54, 367, 
368, platinum compounds369, antimetabolites370 and Vinca alkaloids371-373 aiming to 
reduce their side effects without affecting their efficacy. Liposomes take advantage of 
the Enhanced Permeability and Retention (EPR) effects of the tumour vasculature as 
described in chapter 1184, 374. Co-encapsulation of multiple drugs in liposomes has 
shown to provide synergistic action increasing their efficacy. For example, Jie Meng et 
al. co-encapsulated resveratrol and paclitaxel in phosphatidylcholine and DSPE-
PEG2000 liposomes for MDR reversal in breast cancer cells375. Walls et al. co-
encapsulated Dox with Listeriolysin O to achieve synergistic effect against ovarian 
cancer cell line A2780 and Dox resistant ovarian cancer cell line376. Camacho et al. 
encapsulated Dox and 5-FU in zwitterionic and cationic liposomes and evaluated their 
therapeutic efficacy. They found that the synergistic ratios of the drugs caused up to 
90% tumour reduction as compared to free drug solution in 4t1 mammary carcinomas 
and required doses far below the maximum tolerable doses of individual drugs377. 
Although there has been much evidence to suggest that liposomes have a great 
impact in improvement of existing chemotherapeutic treatments for cancer, they still 
have some problems such as low stability and shelf life and diffusion of drug across 
the liposomal membrane with time378. 
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4.6 Polymersomes in multidrug anticancer therapy 
The limitations of liposomal delivery systems have led to a shift in focus towards more 
synthetic alternatives. Discher et al. demonstrated in the late 1990s, the ability of 
diblock copolymers to assemble into bilayer vesicles termed polymersomes87, 379. 
Polymersomes provide a unique advantage to cancer drug delivery combining the 
advantages of bilayer forming liposomes and providing more stability to the 
formulations because of their synthetic nature380, 381. They can be designed to be 
biodegradable and biocompatible along with the addition of any other desirable 
properties simply by modifying the core polymer blocks175, 382.  The large molecular 
weights of polymers used for these structures and their versatility in incorporating 
different functional groups into the polymer backbone gives them attributes which 
can significantly improve their membrane properties such as permeability, thickness 
and robustness383. Similar to liposomes, polymersomes have the ability to encapsulate 
both hydrophilic and hydrophobic compounds, however owing to the larger size of the 
hydrophilic cores384 and thicker hydrophobic bilayer (3-5 nm in liposomes and 3-30 nm 
in polymersomes)152, the amount of drug that can be incorporated is greater. 
Polymersomes encapsulating multiple anticancer drugs have been explored recently 
because of the advantages of multi drug therapy compared to single drug385, 386. 
Combination anticancer therapy using 5-FU and Dox loaded in NPs such as dendritic 
nanomicelles387, polymer drug conjugated NPs388 and nanocomplexes389 have revealed 
their synergistic action against different types of cancer. 
Ahmed et al. simultaneously encapsulated Dox and paclitaxel in PEG-PLA and PEG-PBD 
diblock copolymers based polymersomes and observed up to 50% reduction in tumour 
volume and higher maximum tolerated dose in polymersomes treated groups as 
compared to free drug solution in human breast xenograft mouse model214. Colley et 
al. also coencapsulated Dox and Paclitaxel, however here they included a pH sensitive 
PMPC-PDPA polymersomes for enhanced anticancer activity against head and neck 
squamous cancer cells250. Kim et al. coencapsulated siRNA with Dox in mPEG-b-PLA 
block copolymer polymersomes for combination chemotherapy in human gastric 
cancer cell lines and observed better cytotoxic effects at lower doses390. Thus, 
polymersomes can prove to be valuable tools for the co-delivery of multi drugs which 
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is not only effective in treating resistant and recurrent tumours but also improves 
patient compliance and tolerance. Future designs of multi-modal polymersomes can 
help extend their applicability to a large variety of drug delivery and imaging 
applications22. 
 
4.7 Aims of Chapter 
In this research work, we report the simultaneous encapsulation of three anticancer 
agents into random copolymer based polymersomes for enhanced activity against 
pancreatic cancer. We aim to encapsulate Dox, 5-FU and LV simultaneously in the 
same polymersome. The presence of three drugs in the same polymersomes has 
potential for synergistic therapeutic action with enhanced retention in the tumour 
tissue. The polymersomes will be observed for their anticancer effect in ectopic 
pancreatic BxPC-3 tumours in mice after intratumoral and intravenous injection. The 
schematic representation of the drug loaded polymersomes and intended in-vivo 
studies is depicted in Figure 4-1. 
 
 
Dox, 5-FU, LV 
Decyl, 
Cholesteryl, 
PEG 500 
Polymersomes 
Intratumour or 
intravenous injection 
NOD-SCID xenograft mouse 
model with ectopic pancreatic 
BxPC-3 tumours  
Figure 4-1 Schematic representation of multi drug loaded polymersomes and in-vivo mouse 
model 
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Thus, the encapsulation of multiple polymersomes and observation of their activity in-
vivo forms the overall aim of the chapter. The specific objectives are, 
1. Preparation of polymersomes loaded with Dox, 5-FU and LV within the same 
polymersomes and analysing their encapsulation efficiency, particle size, PDI, Zeta 
potential and in-vitro drug release. 
2. Cytotoxicity of BxPC-3 cells treated with individual and combination drug solution and 
their comparison with combination drug loaded and blank polymersomes.  
3. Observation of in-vivo pharmacokinetics of fluorescently labelled polymersomes in 
NOD-SCID mice for 24 hours using an In-vivo Imaging Systems (IVIS). 
4. Observation of anti-tumour activity of combination drugs loaded polymersomes after 
intra-tumoral injection in mice and comparison with combination free drug solutions 
and blank polymersomes for a specified time period 
5. Observation of anti-tumour activity of combination drugs loaded polymersomes after 
intravenous injection in mice and comparison with combination free drug solutions for 
a specified time period. 
 
4.8 Results and Discussion 
4.8.1 Preparation and characterisation of polymersomes 
The amphiphilic random copolymer used for the preparation of polymersomes was 
composed of three components, two hydrophobic components comprising of a decyl 
(C10) chain, and cholesterol as well as a hydrophilic component, poly (ethylene) glycol 
(PEG) with an average molecular weight of 500Da. The polymerisation was achieved 
by free radical polymerisation using AICN as the initiator. The molar ratios of each 
component are detailed in Table 4-2 and the schematic illustration of the amphiphilic 
copolymer is represented in Figure 4-2. As the polymer formed is a random co-
polymer the exact positioning of each monomer relative to each other is not 
guaranteed, however on formation of the polymersome, due to the amphiphilic 
nature of the components the PEG 500 forms the hydrophilic inner core and outer 
corona of the polymersome whereas the cholesterol and decyl chain form the 
hydrophobic bilayer of the polymersomes.  
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Table 4-2 Ratios of monomers used for the synthesis of amphiphilic copolymer 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple drug loaded polymersomes were prepared by reverse phase evaporation 
method as discussed in section 6.5.1 with all the three drugs being encapsulated into 
the aqueous core because of their water-soluble properties. Dox is a red, crystalline 
solid generally available as a hydrochloride salt which is soluble in water and aqueous 
alcohols391. Dox is administered intravenously at 60-75mg/m2 single or divided doses 
on 2-3 consecutive days every 3 weeks or at 30-60mg/ m2 for combination therapy392. 
5-FU occurs as a white crystalline powder which is soluble in water393. For pancreatic 
cancer, 5-FU is administered in combination with LV as a 400mg/m2 bolus dose by IV 
Monomer MW 
(Da) 
Molar Ratio % 
(mol) 
PEG methacrylate 
(27) 
500 5 75 
Cholesteryl 
methacrylate (21) 
540 0.75 9 
Decyl methacrylate 
(33) 
226 2.25 0.11 
AICN 244 0.3 4.5 
Figure 4-2 Schematic diagram of amphiphilic copolymer 41 
(41) 
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injection followed by 2400mg/m2 continuous IV infusion over 46 hours at 2 weeks 
intervals394. LV occurs as a yellow coloured powder which is soluble in water395. It is 
available in tablet and injection form given as 200mg/m2 slow IV injection followed by 
5-FU for colorectal cancer396.  
 
Table 4-3 Concentration of compound for in-vitro and in-vivo studies 
Compound Amount added for in-vitro 
and cell cytotoxicity  studies 
Amount added for in-
vivo studies 
Dox (36) 0.1-0.2mM 5mg/kg 
5-FU (37) 4mM 20mg/kg 
LV (40) 0.25mM 2.5mg/kg 
Polymer (41) 2.5mg/mL 50mg/kg 
 
 
Table 4-3 displays the concentrations of drugs loaded in polymersomes for in-vitro 
studies and cell toxicity studies. These concentrations were then further optimised for 
in-vivo studies to match the therapeutic concentrations of the drugs. The 
polymersomes were observed to have similar particle size and PDI across both the 
concentration ranges.  The hydrodynamic size measurement of the combination drugs 
loaded polymersomes was 132.9±35.5nm with a PDI of 0.4±0.1 indicating particles 
uniform particles of small size and having zeta potential of 2.7±1.2mV. This small zeta 
potential is attributed to the neutral charge of the polymer. 5-FU intravenous 
injections are formulated as alkaline solutions using Sodium Hydroxide, but Dox 
degrades in alkaline solutions because of its acidic nature. Owing to these physical 
incompatibilities, 5-FU and Dox solutions are not mixed together397. The simultaneous 
encapsulation of 5-FU, Dox and LV eliminates their solution incompatibilities and 
allows their simultaneous administration with enhanced therapeutic effect. The ability 
to encapsulate multiple drugs into a single nanovehicle highlights the benefit of this 
platform for drug delivery. The large aqueous core of the polymersomes allows the 
simultaneous encapsulation of the three drugs with good encapsulation efficiency 
while still maintaining the small vesicle size and PDI398. The encapsulation efficiency of 
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the drugs was determined by the centrifugal filtration of polymersomes and analysing 
the filtrate, as described in detail in section 6.2.9. The encapsulation efficiency of the 
drugs Dox was 81.5±5.5%, 5-FU was 74.5±20.1 and LV was found to be 72.1±0.7% in 
agreement with those reported in literature. Kalra et al. evaluated the simultaneous 
encapsulation of Dox and 5-FU in pegylated cationic liposomes prepared by thin film 
evaporation method and found that there was more than 90% encapsulation of both 
drugs and particle size of approximately 200-240nm in the liposomes at various 
(3,5,10 & 20) molar % drug loaded preparations399. In another example, Chao et al. 
prepared mPEG-b-PCL polymersomes with Dox using thin film hydration method and 
observed encapsulation efficiency of up to 65% with very small particle sizes of up to 
60nm400 giving further evidence of the comparability of this method of encapsulation 
within the polymersome. In-vitro release studies were conducted by placing 
polymersomes in semipermeable dialysis membrane in PBS and stirring at 37°C for 
fixed intervals of time, the results of which are displayed in Figure 4-3. 
 
It was found that polymersomes demonstrated a burst effect and had a fast release of 
drugs with more than 84.7±4.8% of 5-FU released within 8 hours, whereas 51.8±7.4% 
Dox and 43.6±0.2% LV was released after 8 hours of initiation of study. Almost all of 5-
FU 92.4±7.2% was released after 24 hours however, release of Dox and LV remained 
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Figure 4-3 In-vitro release profiles of Dox, 5-FU and LV in multi drug loaded polymersomes 
at 37°C in PBS. N=3 represented as average±SEM. 
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constant at 51.0±7.0 and 44.2±1.2% respectively after 24 hours indicating no further 
release. Hence, even though the release of Dox and LV was fast initially, it remained 
steady to roughly around 50% over 24 hours. Thus, the amphiphilic copolymer 
polymersomes were small in size with good encapsulation of multiple drugs and 
capable of immediate release of encapsulated cargo into the surrounding 
environment. 
 
4.8.2 Cell viability studies  
To evaluate the synergistic action of the combination drugs, free solutions of 5-FU, LV 
and Dox were compared to their combination free solution and combination drugs 
loaded in polymersomes at concentrations 5-FU (4mM), LV (0.25mM) and Dox 
(0.1mM) loaded onto BxPC-3 cells as described in section 6.5.2. As seen in Figure 4-4, 
the viability of individual drug solution treated cells were 91.7±11.0 for Dox, 
91.3±8.6% for 5-FU and 107.7±7.0% for LV indicating only limited toxicity at the above 
mentioned concentrations. When the same cells were subjected to the combination 
solution toxicity was higher with 74.9±6.6% viable cells, showing a synergistic action 
with approx. 25% cytotoxicity. The toxicity was greatly enhanced when the same 
concentrations were combined within polymersomes, they displayed ~65% cell 
toxicity with only 36.5±3.6% live cells. The observation of toxicity of blank 
polymersomes shows that they were biocompatible with 83.50% viable cells after 
treatment so could not have accounted for this dramatic increase in cytotoxicity. Thus 
further proving the better uptake and cell death of polymersomes loaded drugs.  
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In an attempt to further increase the cytotoxicity, the concentration of Dox was 
doubled to 0.2mM while keeping the other drug and polymersome concentrations the 
same, the results of which are displayed in Figure 4-5. At this concentration, no 
synergistic effect was observed for the combined solutions as the free solution of Dox 
at 0.2mM had similar cell viability to that of the combination solution of Dox with 5-FU 
and LV. As would be expected the toxicity of both the free Dox and the combination 
solution was higher with the increased concentration of Dox. The toxicity of 
combination drug loaded polymersomes with increased Dox (0.2mM) was also 
enhanced with only 17.0± 1.0% viable cells showing approx. 83% cytotoxicity after 24 
hours which is significantly higher than combination free drug solution at the same 
concentration.  
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Figure 4-4 Viability of BxPC-3 cells after treatment for 22 hours with 5-FU (4mM), 
LV (0.25mM), Dox (0.1mM) individual and combination solutions and combination 
polymersomes at same concentration showing synergistic action. N=3 represented 
as average±SEM. ** indicates p<0.01. 
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4.8.3 In-vivo pharmacokinetics of polymersomes  
In order to ascertain the behaviour of these polymersomes in-vivo we employed 
polymersomes loaded with Indocyanine green (ICG) (12). ICG is a near infrared dye, 
commonly used for in-vivo imaging because of its water solubility, easy loading into 
NPs, good tissue penetration and reduced light scattering401, 402. Although the method 
is semi quantitative, it provides the advantage of real time kinetics of polymersomes 
pathway in the body. Polymersomes loaded with 12 (0.2mg/mL) were injected into 
the tail vein of mice previously implanted with ectopic BxPC-3 tumour to observe the 
in-vivo kinetics of the polymersomes in real time. As seen from Figure 4-6, the 
fluorescence after initial injection shows that polymersomes containing the 
fluorophore 12 were immediately accumulated in the tumour in high amounts. This 
high accumulation is shown by the bright fluorescence in the tumour area, however 
some polymersomes also distributed to other parts of the body. The polymersomes in 
peripheral circulation slowly started to dissipate with a significant amount of 
polymersomes were retained in the tumour tissue and were seen ever after 22 hours 
of administration.  
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Figure 4-5 Cell viability after treatment with 5-FU (4mM), LV (0.25mM), Dox 
(0.2mM) combination free solution and polymersomes loaded drugs and 
individual Dox solution (0.2mM) showing enhanced cytotoxicity. N=3 
represented as average±SEM. *** indicates p<0.001 
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Figure 4-6 In-vivo kinetics of ICG loaded polymersomes at various time 
intervals showing preferential accumulation in tumour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The plot of tumour fluorescence expressed as a ratio with respect to the fluorescence 
of peripheral tissues indicates a 6-fold accumulation of polymersomes in the tumour 
after 8 hours as compared to systemic circulation which only decreased slightly after 
22 hours (Figure 4-7).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Plot of tumour fluorescence with respect to peripheral 
tissue fluorescence, N=2 represented as average±SEM. 
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This leads to the conclusion that the elimination of polymersomes from the body is 
slower than the free dye, most likely due to the presence of PEG in the polymer which 
allows longer circulation times and thus can increase the efficacy of the encapsulated 
drugs.  In order to further confirm the accumulation of polymersomes in tumour and 
determine their tissue distribution, the mouse was dissected and individual organs 
were collected for fluorescence observation. Figure 4-8 shows the individual excised 
organs with the fluorescence emission from each quantified and compared to a blank. 
It was seen that there was large accumulation of polymersomes in the tumour, 
however a significant amount was also seen in the liver. This would indicate that 
polymersomes are mainly accumulated in the liver and tumour. Elimination is mainly 
through the liver with a small amount being eliminated by the kidneys however no 
fluorescence was observed in the bladder indicating the possibility of a slow excretion 
by the kidney. However, Figure 4-9 displays the fluorescence emission seen from the 
faeces of the mouse before and after injection with polymersome containing 12, 
further confirming excretion through the liver.  
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Figure 4-8 Observation of fluorescence in organs obtained from 
sacrificing the mice after 22 hours pharmacokinetic study. N=2 
represented as average±SEM. 
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This is in agreement with previous studies carried out by Photos et al. and Fei Lu et al. 
They demonstrated that PEG based polymersomes were mainly eliminated by the liver 
followed by the spleen with a small amount being eliminated by the kidneys174, 403. 
This observation of tumour accumulation properties of polymersomes provided an 
insight into their preferential uptake into tumours and formed the basis of further in-
vivo therapeutic study. In addition, the lack of accumulation in the heart was an 
encouraging indication for the potential use of NPs with cardio toxic compounds such 
as Dox.  
 
4.8.4 In-vivo toxicity after Intratumoral injection 
In the first efficacy study, the formulation was injected by intratumoral injection to 
eliminate any additional effects of tissue distribution. Intratumoral injection has been 
shown to improve tumour concentrations and tumour-organ ratios of injected 
drugs404. NOD-SCID mice were implanted with BxPC-3 tumours and allowed to reach 
an average volume 200-250mm3. Mice were intratumorally injected on Day 0 and Day 
5 with combination drug loaded polymersomes, combination solution and compared 
to mice injected with blank polymersomes and those that received no treatment. 
Tumour volume was measured every day until the end of treatment at Day 13. Figure 
4-10 shows the percent reduction in tumour growth of all the groups. The group 
treated with blank polymersomes had no effect on the tumour toxicity showing 
160.2±21.6% increase in tumour volume from initial and having the same trend as the 
untreated group whose tumour volume increased by 173.5±42.0% after 13 days.  
Figure 4-9 Faeces of mouse with fluorescence emission pre injection 
and 22 hours following injection with polymersome containing 12. 
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It was expected that the free drug solutions will provide good reduction in tumour 
volume since the concentrations of Dox, 5-FU and LV were at therapeutic doses. 
Indeed, the group treated with combination solution had a significant reduction in 
tumour growth with an increase of only 59.6±32.8% tumour volume from the start of 
the experiment. However the group treated with combination drug loaded 
polymersomes had a maximum cytotoxic effect on the tumour showing a decrease of 
2.3±20.4% in the tumour volume after 13 days which is significantly higher than the 
percent increase of free solution and untreated group.  
 
 
 
 
 
 
 
 
 
 
 
 
It was interesting to note that there was a false increase in tumour volume for 2 days 
after intratumoral injections on Days 0 and 5 owing to retention in the tumour which 
slowly dissipated over 2 days as seen by the tumour volumes on Days 1 and 2 and 
consecutively on Days 6 and 7 of all the treated groups corresponding to treatment 
days. The false increase in tumour volume for free solution treated group was 30-40% 
whereas those treated with polymersomes was only 5-10%. This lesser increase in 
tumour volume can be indicative of better tumour distribution properties of 
polymersomes due to their nanoparticle size demonstrating EPR effect. The 
particulate nature of NPs allows them to diffuse through the interstitial space and 
lymphatic vessels of the tumour leading to homogeneous distribution throughout the 
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Figure 4-10 Graph of percentage increase in tumour growth after 
intratumoral injection of combination drugs loaded polymersomes and 
combination free drugs. N=3 represented as average±SEM, * indicates p<0.1, 
*** indicates p<0.001 
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tumour tissue. Whereas intratumoural injection of free unencapsulated drug solution 
gets absorbed directly into the blood supply of the tumour resulting in non-
homogeneous distribution405.  
Throughout the duration of the study the body weights of the mice were regularly 
recorded and found to remain steady at 90±10% throughout the experiment (Figure 
4-11) indicating the mice were normal and the injected solutions were solely 
concentrated in the tumour region without any other systemic toxicity. 
 
 
 
 
 
 
 
 
 
 
After the completion of the study, mice were euthanized, their tumours were 
collected and weighed. Figure 4-12 displays a photo of each group containing both the 
mouse and the excised tumour. It can be clearly seen that the smallest tumour was 
excised following polymersomal treatment with the combination drugs, the next most 
effective treatment was from the free solutions with both the control and the blank 
polymersomes displaying the largest tumours after 13 days.  
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Figure 4-11 Graph showing percentage body weight change after intratumoral 
injection for each of the four groups over the 13 days duration of experiment. 
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The percentage increase in tumour weight was calculated for each mouse with the 
results of each group displayed in Figure 4-13A. The control and blank polymersomes 
group show the largest increase in tumour weight of 173.6±42.0 and 160.2±21.6% 
increase in tumour weight after 13 days respectively, the combination solution group 
had 82.3±29.3% increase from the initiation of treatment with the polymersome 
containing the three drugs showing a 2.37±20.4% decrease in tumour weight, 
illustrating that not only did the combination solution prevent tumour growth, it also 
showed a slight decrease in tumour size. The calculation of tumour doubling times 
shows that it took 10.3±1.20 days for the tumour volumes of the control group and 
10.0±1.4 days and 6±2.8 days for blank polymersomes and combination solution 
treated group respectively to increase to double their size from the initial day of 
treatment (Figure 4-13B), however the rate of tumour growth for the polymersomes 
group was quite slow and it would take average 67.0±22.0 days for the tumour 
volume to double in size. 
 
 
Figure 4-12 Photograph of one mouse from each group before 
tumour excision with the actual excised tumour below. 
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4.8.5 In-vivo toxicity after Intravenous injection 
The observation of enhanced retention of polymersomes in tumour tissue of 12 
loaded polymersomes, provided the basis of the exploration of antitumor activity of 
multiple drugs loaded polymersomes by intravenous injection. Thus, Intravenous 
injection of combination drugs in solution and encapsulated in polymersomes formed 
the next part of the in-vivo studies. Similar to intratumoral study, mice with ectopic 
BxPC-3 tumours were divided randomly into groups receiving intravenous injection of 
combination drugs solution and other group receiving polymersomes loaded with 
combination drugs at the same concentration on Day 0 and Day 5 and compared to 
those that received no treatment. The graph of % tumour growth Figure 4-14 indicates 
a steady increase in tumour volume throughout the 7 days of treatment with the 
tumour volume increasing to 74.8% ± 11.8% in the control group and an increase of 
53.7±11.2% in the combination solution treatment group. Mice treated with 
combination polymersomes showed least increase in tumour volume with an increase 
of 40.1%± 10.8% from initial volume.  
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Figure 4-13 (A) Percentage increase in tumour weight after the study. (B) Estimated 
tumour doubling of different groups after intratumoral injection. N=3 represented as 
average±SEM, * indicates p<0.1. 
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As with the previous study, the body weights of all mice were recorded on a regular 
basis. There was a drastic effect on the mice body weight as indicated in Figure 4-15. 
The mice treated with combination free drug solution showed a marked decrease in 
the body weight from the first day of treatment which potentiated after the second 
treatment and the weight of mice fell down to 80.0%±4.01% from their initial weight 
indicating accumulated systemic toxicity and leading to the termination of the study 
on day 7. The mice were weary, distressed and unable to eat further causing the rapid 
weight loss. The mice in the untreated and polymersomes treated group were healthy 
with lesser change in their body weight.  
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Figure 4-15 Graph showing percentage body weight change after intraveneous 
injection for each of the three groups over the 7 days duration of experiment. 
N=3 represented as average±SEM, * indicates p<0.1, ** indicates p<0.01. 
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Figure 4-14 Percentage tumour growth of combination drug loaded 
polymersomes and combination free solution after intravenous injection. N=3 
represented as average±SEM, * indicates p<0.1. 
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The rapid weight loss of mice treated with free solution of combination drugs is 
indicative of acute cardiotoxicity of Dox and toxic effects of combination drug solution 
at the concentration administered in mice. Dox has been reported to exhibit acute 
cardiomyopathy which is dose dependant leading to congestive heart failure at higher 
doses406-408. Other effects of anticancer drugs such as 5-FU and Dox include nausea, 
vomiting, poor appetite, alopecia and hematopoietic suppression409, 410. Although 
cardiotoxicity of Dox remains the most feared side effect of chemotherapy, the 
encapsulation of Dox into liposomes and other NPs has helped reduce its 
cardiotoxicity, the most common example being the marketed pegylated liposomal 
Dox, Doxil® 411-413. The encapsulation of the combination drugs into polymersomes at 
the same concentration produced least toxic side effects in the mice indicating higher 
maximum tolerated dose.  
Following the premature end of the experiment, all the mice were euthanized and 
their tumours and hearts were excised. Figure 4-16 displays a photograph of one 
mouse from each group with the corresponding excised tumour.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-16 Photograph of one mouse from each group before 
tumour excision with the actual excised tumour below. 
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It can be seen from Figure 4-16, that the group treated with the combined 
polymersomal drugs displayed the largest reduction in tumour growth. This has been 
further quantified in Figure 4-17A which displays the % increase in tumour weight at 
the end of 7 days. It was found that the tumour weight of mice in the untreated group 
increased to 92.3±17.8% of the initial, whereas those in the combination solution and 
polymersomes treated increased by 53.8±13.0% and 40.1±12.5% respectively. Further, 
the calculation of tumour doubling time indicates that it would take 10.3±1.2 days and 
14.7±3.7 days for the untreated group and combination group tumours to double in 
size, however the polymersomes treated would take longer time of 21.3±7.9 days to 
double in size (Figure 4-17B). 
 
 
 
 
 
 
 
 
 
Further evaluation of systemic cardiotoxicity was carried out by the observation of the 
reduction in heart weights after the completion of the study (Figure 4-18). It was 
found that mice treated with combination solution showed an average heart weight of 
0.088±0.02 g which was lower than those of untreated and polymersomes treated 
groups having heart weights 0.12±0.02g and 0.10±0.01g respectively. 
 
Figure 4-17 (A) Percentage increase in tumour weight after intravenous study. (B) Estimated 
tumour doubling time of combination polymersomes and combination free drug solutions. 
N=3 represented as average±SEM. 
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Collectively, these observations demonstrate that we have prepared polymersomes 
having superior tumour toxicity against ectopic BxPC-3 tumours by encapsulation of 
multiple drugs as compared to combination free drug solutions at the same 
concentration.  
 
4.9 Conclusion 
Polymersomes are versatile drug delivery systems capable of encapsulating large 
extents of drug solutions proving ideal for multi drug delivery. Cancer chemotherapy 
using multiple drugs remains the foremost treatment strategy after surgery, for 
tumours that are hard to remove surgically and for multi drug resistant cancers. Even 
though liposomes are at the forefront of NP therapy for cancer, the problems 
associated with them provides the need for exploring other delivery vehicles.  In this 
research work, we have demonstrated excellent anticancer activity of polymersomes 
made of random copolymers which are facile to synthesize and able to simultaneously 
encapsulate three drugs namely 5-FU, Dox and LV within the aqueous core at 
therapeutic concentrations having particle size ~132nm and PDI of ~0.43 and good in-
vitro release within 4 hours. Polymersomes loaded combination drugs have better cell 
cytotoxicity than corresponding free drug solutions. These polymersomes have shown 
to largely collect in the tumour tissue with up to 6 fold accumulation in tumour as 
compared to reference 8 hours after injection and were present in the tumour after 
24 hours when observed after intravenous injection of fluorescently labelled 
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Figure 4-18 Average heart weight of each mouse in the three 
groups. N=3 represented as average±SEM.  
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polymersomes. They have shown better efficacy and higher maximum tolerated dose 
than free combination drug solutions after intratumoral and intravenous 
administration in mice having ectopic pancreatic BxPC-3 cancer tumours. 
Intratumorally injected polymersomes exhibited an approximately 2% decrease in 
tumour volume after 13 days as compared to free drug solutions which showed an 
approx. 60% increase in tumour volume in the duration of the study. Free drug 
solutions demonstrated extreme cardiotoxicity and weight loss of the mice whereas 
no toxicity was observed for polymersome encapsulated drugs. A smaller 40% 
increase in tumour volume was observed for polymersomes when compared to 
average 53% increase shown by free solutions after 7 days of treatment. These results 
further prove the hypothesis that multi drug single carrier systems can provide better 
tumour cytotoxicity and better tolerance than free drug solutions and polymersomes 
can be exploited to achieve better efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
5 Chapter 5 
Overall conclusion 
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5.1 Conclusion 
The work presented within this thesis demonstrates the prominence of amphiphilic 
random copolymers in the formulation of both single layered and bilayered systems 
for enhanced encapsulation of hydrophilic and hydrophobic molecules. These self-
assembling polymeric systems analogues of liposomes, have been employed for 
various applications ranging from simple drug solubilising agents to multifunctional 
nanocarriers responsive to various stimuli, discussed in detail in Chapter 1. 
In chapter 2, random copolymers having composition similarities to 
phosphatidylcholine with cholesterol and PEGs 500 and 2000 were designed to mimic 
structural similarities with conventional PEGylated liposomes. Correspondingly, 
monomers comprising of cholesteryl, oleic, octadecyl and PEG 500/2000 chains were 
integrated in specific molar ratios to form random copolymers by the freeze-thaw 
method using AICN as the free radical initiator. This is the first time that a random 
copolymer having composition resemblances to liposomes has been reported. 
Gaitzsch et al. discussed the ability of PEG based amphiphilic copolymers to form 
different types of morphological assemblies such as vesicles and micelles based on the 
hydrophilic fraction (f) of the fraction and its modulation over time at different 
temperatures414. They found an increase in the hydrophobic block created complex 
aggregates whereas increasing the chain length of the hydrophilic block destabilised 
the vesicle structure. It was interesting to note that these random copolymers lack the 
zwitterionic choline head group of phospahatidylcholine236, rendering them of neutral 
charge as compared to highly anionic liposomes. The method of preparation played an 
important role in the size and PDI of these polymersomes with the reverse phase 
evaporation method providing the lowest particle size with high uniformity as 
compared to the corresponding liposomes. The percentage encapsulation efficiency 
was not affected by the method of preparation. Furthermore, the polymersomes were 
capable of encapsulating various charged fluorescent dyes namely, negatively charged 
FITC-CM-Dextran, positively charged FITC-DEAE-Dextran and neutral FITC-Dextran and 
hydrophobic anthracene without significantly affecting the size, encapsulation 
efficiency and zeta potential. These polymersomes were also found to have a fast in-
vitro release of encapsulated cargo, hence proving further benefits as a DDS. 
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Alibolandi et al. compared the particle size, encapsulation efficiency and sustained 
release properties of PEG-PLA copolymers using PEG MW 2000 and 5000, comprising 
of hydrophilic fraction f value ~25% of the total polymer. Polymersomes were 
prepared by the thin film hydration method and it was found that polymersomes with 
PEG 2000 had a particle size of less than 100nm and low PDI415. Our results indicated 
particle size of approximately 160nm which was smaller than the corresponding 
liposomes having particle size approximately 240nm when encapsulating hydrophilic 
dye.  
The polymersomes were taken up by Hela cells mainly by clathrin mediated endocytic 
pathway and displayed better cellular uptake than liposomes. This is in agreement to 
research published by Swaminathan et al. who studied the effect of chemical 
inhibition of endocytosis using chlorpromazine on the cellular uptake of amphiphilic 
random copolymer micelles comprising of a decyl chain and PEG 500 loaded with 
Bodipy270. They found that after inhibition of endocytosis, the intracellular endocytosis 
was reduced, further confirming the prominently endocytic uptake mechanism of 
these polymersomes. The cytotoxicity of these polymersomes when observed in a 
cervical cancer cell line (HeLa cells), pancreatic cancer cell line (BxPC-3 cells) and non-
cancerous cell line (CHO cells) indicated that these amphiphilic copolymers were 
biocompatible up to 0.25mg/ml concentration after which they significantly reduced 
the cell viability. However this cytotoxicity can prove advantageous for application in 
cancer drug delivery where the vehicle can enhance the cytotoxicity of the 
encapsulated therapeutic compound. A recent example of this kind of cytotoxic 
enhancement is the formulation of Paclitaxel in cremophore EL vehicle (Taxol®). 
Cremophore EL itself imparts cytotoxicity to some extent and also enhances the 
toxicity of the encapsulated paclitaxel through micellar encapsulation416.  
Stability of nanoparticle formulations has been studied extensively throughout the 
years to establish their efficacy for storage for prolonged periods of time and different 
temperature conditions. Lipids used for the preparation of liposomes being obtained 
from natural sources have the tendency for fungal growth over prolonged periods of 
storage and the susceptibility of lipids to temperature causes particle aggregation and 
leakage of encapsulated material over time266, 281. Polymersomes loaded with 
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anthracene were observed to have lesser aggregation and better retention of 
encapsulated compounds upon storage for 8 weeks at 25°C when compared to 
liposomes at similar storage and temperature conditions.  
The third chapter of this research thesis involved the preparation of a micellar drug 
delivery systems using amphiphilic copolymers and to employ them for the delivery of 
dynamic compounds capable of triggered delivery and molecular communication 
through the FRET mechanism. Micelles prepared from amphiphilic copolymers have 
been investigated for their potential to simultaneously deliver multiple compounds 
encapsulated within their core212, 213. They have also been employed as 
multifunctional nanocarriers for combined delivery of therapeutic agent along with 
diagnostic/imaging application197-199. Park et al. developed multifunctional stimuli 
responsive micelles of phenylboronic acid-conjugated pluronic and lactose-modified 
chitosan Plu-CH, conjugated with spiropyran/boronic acid-conjugated 
poly(dimethylamino ethyl methacrylate-co-methacrylic acid) (S-PMA) which were 
responsive to acidic and higher redox environments and encapsulated hydrophobic 
paclitaxel within their core196.  
For this research, the micelles were made of an amphiphilic random copolymer 
comprising of a decyl chain attached to PEG 500. These micelles encapsulated the 
FRET pair compounds comprising of bodipy and either spiropyran alone or spiropyran 
attached to an API. The triggered ring opening of the hydrophobic spiropyran and its 
conversion to its hydrophilic merocyanine counterpart has been well established93, 305. 
Furthermore, merocyanine was utilized to establish a FRET relationship between 
bodipy, which upon excitation by UV light transfers its energy to merocyanine 
resulting in a quenching of the bodipy emission. The FRET efficiency between bodipy 
and merocyanine was observed and it was found that they have optimum FRET 
efficiency at bodipy: spiropyran molar ratio 1:6. Hence all micelles were prepared 
encapsulating the compounds at this ratio. It was also established that full conversion 
of spiropyran to merocyanine took 5 minutes. Additionally, the FRET efficiency 
between bodipy and merocyanine in HeLa cells in light and dark conditions was 
determined.  
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The most interesting observation was the quantification of spiropyran conjugated API 
release communicated in real time indirectly through bodipy fluorescence. A good 
correlation between the increase of bodipy fluorescence and the absorbance of 
spiropyran was observed after subjecting the micelles to UV exposure leading to 
release of merocyanine from the system. The largest amount of release was observed 
by UV stimulation in dark conditions since polar merocyanine prefers dark conditions 
and reverts back to hydrophobic spiropyran in visible light conditions. This release of 
merocyanine observed by decrease in absorbance was communicated through 
increase in fluorescence emission of bodipy. The negligible release of merocyanine in 
the absence of a UV trigger was communicated as insignificant change in bodipy 
fluorescence thus proving the potential of this super smart drug delivery system. Tang 
et al. demonstrated the efficiency of FRET carbon nanodots (Cdots) coupled systems 
for real time monitoring of drug release at different pH. They established excellent 
FRET communication between the PEG and folic acid conjugated Cdots and Dox 
adsorbed onto the Cdot surface which was regulated by the release of drug molecule 
from the Cdot surface, further cementing the application of FRET systems for real time 
monitoring systems of drug delivery417.  
The final part of this research involved application of polymersomes to observe 
enhanced cytotoxic effects on ectopic pancreatic tumours in mice. Amphiphilic 
random copolymers containing a decyl chain, cholesterol and PEG500 were prepared 
as reported by Martin et al. to show the highest uptake in HeLa cells128. These 
polymersomes prepared by reverse phase evaporation method encapsulated a 
combination of anticancer drugs namely Doxorubicin HCl, 5-Fluorouracil and 
Leucovorin calcium. Multidrug resistance plays an important role in the failure of 
cancer chemotherapy. The use of combination drugs have proved useful in fighting 
drug resistance. Polymersomes have been used as vehicles for multi drug anticancer 
therapy for the encapsulation and delivery of a vast variety of drugs214, 250, 390. The 
polymersomes indicated good encapsulation efficiency of all the anticancer agents 
with small and uniform particle size of less than 150nm after drug loading and fast in-
vitro release. Toxicity measurements in BxPC-3 cells indicated synergistic cytotoxicity 
of combination drugs encapsulated within the same polymersomes. 
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The in-vivo observation of polymersome toxicity after intratumoral and intravenous 
injection in pancreatic BxPC-3 ectopic xenograft mouse model form an important part 
of this chapter. Polymersome pharmacokinetics were first observed by imaging of 
fluorescently labelled polymersomes after intravenous injection in mice having 
tumours. Nomikou et al. employed ICG loaded PLGA NPs to study the effect of 
sonodynamic and photodynamic therapy by NIR imaging in ectopic mice RIF-1 
tumours. They observed the immediate accumulation of NPs in the tumour region 
which gradually declined after 6 hours of administration418. NIR imaging with ICG 
helped observe the kinetics of the polymersomes and it was found that the 
accumulation of polymersomes rapidly declined from the peripheral tissue, whereas 
polymersomes were present in the tumour tissue even after 24 hours of 
administration. The advantages of injecting anticancer agents in NPs intratumorally 
has been extensively reviewed by Torchillin405 however, intratumoral mode of 
injection has its own limitations.  Intratumoral injection of polymersomes produced 
better reduction on tumour growth in mice and more stable body weights throughout 
the experiment duration as compared to free drug solution. Nevertheless, intravenous 
mode of administration is the most common employed method for the administration 
of cancer chemotherapeutic drugs392. Additionally, anthracyclines such as Dox, have 
exhibited dose dependent acute cardiomyopathy. Swain et al. retrospectively studied 
the effect of doxorubicin on congestive heart failure of 630 patients in three different 
clinical trials406. They found that Dox related congestive heart failure occurs at greater 
frequency and at much lower cumulative dose.  Hence observation of multi drug 
loaded polymersomes by intravenous route formed the second part of the in-vivo 
studies. It was interesting to note that group of mice receiving intravenous free 
combination drug solutions exhibited peripheral toxicity by displaying a fast reduction 
in body weights even though they showed significant reduction in tumour volume. 
However, the group receiving combination drug polymersomes showed no marked 
change in their body weight and displayed good reduction in tumour volume.  
In summary, through this research work we have exhibited the flexibility and 
versatility of amphiphilic copolymers for different applications. Polymersomes are 
next generation drug delivery vehicles which are gaining rapid interest in research and 
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development. Even though polymersomes are different from liposomes, the general 
aspects of liposome design can be applied to polymersomes to achieve desired 
functionality. We can easily exercise control over the composition, size, and surface 
properties of polymersomes depending on their application. We have established the 
suitability of amphiphilic copolymers for two different types of applications and have 
confirmed their ability to encapsulate large amounts of drug solutions.  
 
5.2 Challenges and future perspectives 
Recent developments in the synthetic methods employed for polymer production 
have enabled the design of amphiphilic polymers with desirable properties. The 
numerous applications of these amphiphilic copolymers include the ability to 
encapsulate different types of drugs as well as being multi-stimuli responsive vesicles 
capable of performing a wide variety of functions. The future of polymer based drug 
delivery systems encompasses various fields of therapeutics. Several polymeric 
systems are in different phases of clinical trials and it won’t be long before they will 
form a significant part of the market of nanoparticulate drug delivery. However 
biosafety concerns remains a major challenge since these polymeric systems may have 
to be administered for long durations of time. Hence their long term toxicity and 
immunogenicity should be of utmost concern especially in the case of systemic 
administration. The translation of polymeric nanoparticle systems from bench to 
market is another area in need of a major breakthrough. Most nanoparticle studies 
are conducted under static conditions at a small scale with limited variability. The 
adaptation of these systems in complex scenarios at a large scale can truly confirm 
their potential as advanced therapeutics. Significant efforts for the design of these 
amphiphilic copolymers and their large scale synthesis and optimization such as 
assembly line synthesis have to be made. Besides this, there have to be tools for the 
exact spatial and temporal control of the polymeric units. Nevertheless, polymer drug 
delivery systems offer exciting new possibilities in the field of advanced drug delivery 
and it is only a matter of time before they will become indispensable tools in the 
design of new therapeutic systems.  
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6 Chapter 6 
Materials and methods 
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6.1 Materials  
Cholesteryl Chloroformate, Ethylene diamine, 1-Octadecanol, (N,N'-
Dicyclohexylcarbodiimide) DCC, 4-(Dimethylaminopyridine) DMAP, PEG-methacrylate 
(Mn 500), PEG-methylmethacrylate (Mn 2000), Methacrylic acid, methoxy PEG (550 & 
2000), 1 1'-azobis (cyclohexanecarbonitrile) (AICN), L-α-Phosphatidylcholine from egg 
yolk, FITC-CM-Dextran 4kDa, FITC-DEAE-Dextran, FITC-Dextran, anthracene, Dialysis 
membrane (MWCO 14,000), PBS tablets,  Fluorescence labelled TLC plates with 
aluminium backing, Dox, 5 Fluorouracil, Leucovorin Calcium, Indocyanine green were 
purchased from Sigma chemicals. Dichloromethane (DCM), anhydrous 
tetrahydrofuran, Chloroform, methanol, Ethanol and Hexane purchased as HPLC grade 
from Thermofisher Scientific, UK. Oleic acid, CDCl3 was purchased from TCI, Japan. 
DMEM, RPMI 1640, Hams F12, Trypsin-EDTA, PenStrep and Foetal bovine serum were 
sourced from Thermofisher Scientific, UK. Matrigel® basement matrix was acquired 
from Corning Inc. All synthesis were carried out in inert conditions under nitrogen gas 
unless otherwise stated. 
 
6.2 General methods 
6.2.1 Column Chromatography 
A glass column sealed at the bottom with cotton wool was utilized for column 
chromatography. Silica gel was dissolved in mobile phase (chloroform: methanol 18:2) 
and filled into the column while excessive solvent was removed from the bottom tap 
to ensure compact packing. About 2cm layer of mobile phase was maintained on top 
of the column. A fine even layer of sand was added on top of the silica gel packing. 
Synthesized sample was dissolved in a small amount of mobile phase and added on 
top of the sand. Roughly 5mL fractions were collected from the bottom of the column 
while maintaining the mobile phase layer on the top to allow separation of impurities 
by entrapment into the column. Thin layer chromatography was used to monitor the 
progress. 
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6.2.2 Thin layer chromatography (TLC) 
Fractions of separated compounds collected during column chromatography were 
analysed by TLC. This was to ensure acquirement of the right product according to the 
Rf values and obtain a pure sample with no other trace impurities. Sample solutions in 
mobile phase were filled in capillary tubes and spotted on fluorescence labelled TLC 
plates at 1cm distance from the bottom edge. These plates were placed in a TLC 
chamber filled to 0.5cm with mobile phase and the solvent was allowed to run up to 
1/3rd of the plate. The plate was then removed and dried and observed under a hand 
held UV lamp for the presence of the desired compounds and appropriate level of 
separation. 
6.2.3 Mass spectroscopy (MS) 
Molecular weight of all synthesized compounds was determined by mass spectroscopy 
using Thermo Finnigan LCQ Classic Ion Trap LC-MS. Briefly 1mg mL-1 compound was 
dissolved in methanol and analysed in positive electrospray mode. 
6.2.4 Nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectroscopy was conducted using Varian (500 MHz) NMR spectroscope by 
dissolving 5mg mL-1 synthesized sample in deuterated chloroform (CDCl3) in NMR 
tubes. 1H NMR Spectra were obtained on Tuneplus Version 1.0 SR1 and analysed on 
VNMRj 2.2 and Topspin 3.5 pl6 softwares.   
6.2.5 Dynamic light scattering (DLS) measurements 
Dynamic light Scattering measurements for particle size were conducted by placing 
diluted 100µl polymersomes/liposomes in 1mL PBS or undiluted 5mg mL-1 
polymersomes in disposable cuvettes and analysing using Malvern NanoZS Zetasizer 
Software V7.03.  
6.2.6 Zeta potential measurements 
Zeta potential for measurement of surface charge of liposomes and polymersomes 
was conducted using the Universal Dip cell electrode. Briefly, the electrode was 
dipped in the liposomes/polymersomes suspension and attached to the Malvern 
NanoZS Zetasizer and analysed.  
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6.2.7 Scanning Electron Microscopy (SEM) 
Particle morphology was observed using scanning electron microscopy (SEM), 
nanoparticle suspensions were air dried overnight on aluminium stubs and coated 
with ultra-thin Gold/Palladium layer at 18mA for 3 minutes using Polaron Equipment 
Ltd E5100 Sputter coater and observed under FEI Quanta 200 ESEM in high vacuum 
mode.  
6.2.8 Ultraviolet and Fluorescence spectroscopy 
Samples for ultraviolet (UV) and fluorescence spectroscopy were placed in glass 
cuvettes and analysed using Varian Cary Eclipse UV and Fluorescence 
spectrophotometers at the specific absorbance wavelength for UV and Excitation 
Emission wavelengths for Fluorescence spectroscopy mentioned in specific sections. 
6.2.9 Percentage encapsulation efficiency (% EE) 
Encapsulation efficiency of all polymersomes and liposomes loaded with hydrophilic 
drugs was measured by centrifugal filtration. Polymersomes/liposomes were placed in 
a dialysis tubing (MWCO 14,000 Da) tied at both ends and placed suspended in a 
centrifuge tube. These tubes were then centrifuged at 3000rcf at 4°C for 2 hours. 
Resultant filtrate was collected and measured and analysed for unencapsulated drug. 
Percentage encapsulation efficiency was calculated using the following formula, 
 
 
 
 
Encapsulation efficiency of hydrophobic drugs was analysed by dissolving 100µl 
Polymersomes/liposomes in appropriate organic solvent such as chloroform/ ethanol 
to break the nanovesicle assembly and release encapsulated compound and evaluated 
by UV/ Fluorescence microscopy for direct measuring of encapsulated compound. The 
percentage encapsulation efficiency was calculated according to the below formula, 
 
 
% Encapsulation efficiency = Theoretical drug-Unencapsulated drug 
       Theoretical Drug              X 100 
 
   % Encapsulation efficiency =  Encapsulated drug 
        Theoretical Drug   X 100 
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6.2.10 In-vitro release studies 
In-vitro release studies of polymersomes and liposomes were conducted by placing 
liposomes/polymersomes in dialysis tubes (MWCO 14,000 Da) tied at both ends and 
placing them in PBS maintained at 37°C and stirred using a magnetic stirrer. Aliquots 
were taken out at regular intervals of time and analysed by a relevant analytic 
method. The amount of sample removed was replaced by fresh PBS to maintain sink 
conditions. 
6.2.11 Maintenance of Cell lines 
Three different types of cell lines namely HeLa cells (cervical cancer cell line), BxPC-3 
(Human pancreatic cell line) and CHO cells (Non-cancerous Chinese hamster ovarian 
cell line) were used for various cell culture studies. The types of media and 
supplements for each cell line are outlined in table 6-1. 
Table 6-1 Media composition for cell lines 
 
 
All cells were obtained from in-house frozen cell repository. Briefly, cryovials 
containing cells were removed either from -80°C storage facility or liquid nitrogen, 
thawed to 37°C and centrifuged to remove old medium. The resultant pellet was 
resuspended in fresh media and incubated in HeraCell incubators at 37°C with 
constant influx of 5% CO2.  
Before each study, cells were confirmed to grow to more than 80% confluence level. 
After which, supernatant medium from cells was discarded, cells were dislodged using 
1x Trypsin-EDTA and incubated at 37°C for 5-7 minutes. After complete detachment 
from the flask surface, cell were added to centrifuge tubes with fresh media and 
centrifuged at 1000rpm for 5 minutes. The resultant pellet was resuspended in 5mL 
Cell Line Medium FBS (10%) PenStrep (1%) NEAA (1%) 
Hela  DMEM √ √ x 
BxPC-3 RPMI 1640 √ √ x 
CHO Hams F12 √ x √ 
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medium and counted using Invitrogen Countess Automated cell counter after staining 
cells with Trypan blue (1:1 ratio). 100µl of 5x104 mL-1 were added to 96 well plates and 
incubated overnight before all treatments. Different treatment conditions and 
controls are mentioned in relevant sections.   
6.2.12 MTT assay for cell viability 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
for analysing the cell viability after treatment. MTT assay was conducted by first 
removal of supernatant media from treated cells in 96 well plates. After which 20µl of 
5mg mL-1 MTT reagent pre-mixed with 100 µl fresh media was added to the cells and 
incubated for 3 hours. After which 85µl of medium was removed and 50µl DMSO was 
added to the cells and shaken for 5 minutes to ensure complete solubilisation of blue 
purple formazan taken up by live cells. Absorbance was recorded at 570nm using the 
Fluostar Omega microplate reader. 
6.2.13 Statistical analysis 
All data is reported as n=3 unless otherwise stated in figure legends. All values in 
tables are represented as average±SD and all graphs are represented as average±SEM. 
Statistical significance of groups was determined using Two tailed Unpaired Student’s t 
test in Graphpad Prism Version 5.01. * indicates p<0.1, ** indicates p<0.01 and *** 
indicates p<0.001 level of significance unless otherwise as stated in figure legends. 
 
6.3 Specific methods for Chapter 2 
6.3.1 Synthesis of Cholesteryl methacrylate (21) 
1.044mL (15.61 moles) of ethylene diamine (18) was dissolved in 5mL dry DCM and 
cooled in ice bath. 0.5007g (1.11 mmoles) cholesteryl chloroformate (17) dissolved in 
5mL dry DCM was added slowly to the above solution and stirred overnight. Product 
was washed 3 times with water and brine, traces of water from the organic layer were 
removed using anhydrous magnesium sulphate and the organic solvent removed to 
leave cholesteryl ethylene diamine conjugate (19). 0.9889g (2.09 mmoles) of the 
above product was dissolved in 20mL dry DCM with 0.1811gms (2.09 mmoles) 
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methacrylic Acid (20) and 0.0522g (0.20 mmoles) DMAP in a 3 necked round bottom 
flask in an ice bath. 0.5175g (2.09 mmoles) DCC dissolved in 20 mL DCM was added 
dropwise and stirred for 24 hours. Product was filtered and purified using column 
chromatography and characterised by 1H NMR and mass spectroscopy. 1H NMR shifts 
for 21 were 1H NMR (500 MHz, CDCl3, δ ppm): 7.34 (d, 2H), 5.73, 5.34 (s, 2H), 3.44-
3.36 (m, 4H), 2.32-1.82 (m, 7H), 0.8575 (m, 9H), 1.82-1.00 (m, 32H). 
6.3.2 Synthesis of Oleic methacrylate (24) 
3.088mL (48.0 moles) ethylene diamine (18) was dissolved in 10mL DCM. Separately 
2.208 g (7.81 mmoles) of oleic acid (22) was dissolved in 5mL DCM with 1.609 
(7.81mmoles) DCC and 0.095g (0.78 mmoles) DMAP to which ethylene diamine 
solution was added slowly and stirred for 48 hrs at 40°C. Product was washed 3 times 
with brine and dried to obtain oleic acid-ethylene diamine conjugate (23). 2.532 g 
(7.81 mmoles) of the above product was dissolved in 20mL DCM with 0.6729g 
(7.81mmoles) methacrylic acid (20) and 0.09550g (0.78 mmoles) DMAP in ice bath. 
1.612g (7.81 mmoles) DCC dissolved in 20 mL DCM solution was added drop wise and 
stirred for 24 hours. Resultant product was filtered and purified using column 
chromatography, washed 3 times using 0.1M hydrochloric acid using a separating 
funnel and dried to obtain the final product which was then characterised as above. 
The 1H NMR shifts for 24 were: 1H NMR (500 MHz, CDCl3, δ ppm): 6.08, 5.53 (s, 2H), 
4.12 (t, 2H), 1.95 (m, 3H), 1.65 (m, 2H), 1.25 (m, 30H), 0.88 (m, 3H). 
6.3.3 Synthesis of Octadecyl methacrylate (26) 
2.7g (9.98 mmoles) of 1-octadecanol (25) was dissolved in 30mL dry DCM with 0.244g 
(0.002 mmoles) DMAP and 0.86g (0.01 mmoles) methacrylic acid (20). 2.06 g (0.01 
mmoles) DCC solution was prepared in 20mL dry DCM and added drop wise to this 
solution and maintained overnight under constant nitrogen gas. The final product was 
purified and characterised as mentioned in the above procedure. 1H NMR (500 MHz, 
CDCl3, δ ppm): 5.75 (s, 1H), 5.33 (m, 3H), 3.45 (m, 2H), 3.38 (n, 2H), 2.18 (m, 2H), 1.98 
(m, 3H), 1.62 (m, 2H), 1.28 (m, 26H), 0.90 (m, 3H). 
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6.3.4  Synthesis of Polymers (28) 
Cholesteryl methacrylate (21), oleic methacrylate (24), octadecyl methacrylate (26) 
and PEG methacrylate (Mn 500) (27) or PEG methyl ether methacrylate (Mn 2000) 
(27) were taken in a reaction vessel in (1:1:1:1 molar ratio) for P500 and (1:1:1: 0.25) 
for P2000 in 20mL anhydrous THF with 5mg 1 1'-azobis (cyclohexanecarbonitrile) 
(AICN), freeze-thawed three times under vacuum using liquid nitrogen and kept at 
80°C for 72 hours. Polymer 28 was then precipitated out using hexane and washed 3 
times with hexane with centrifugation at 6000 rpm for 5 minutes. The final polymer 
was obtained as a yellow thick viscous liquid (P500) or white powder (P2000). 
Characterisation was confirmed by 1H NMR spectroscopy. The 1H NMR shifts of each 
polymer were, Polymer P500: 1H NMR (500 MHz, CDCl3, δ ppm): 0.01-2.16 (m, 152H), 
3.64 (s, 44H). Polymer P2000: 1H NMR (500 MHz, CDCl3, δ ppm): 0.7-2.16 (m, 84H), 
3.64 (s, 180H). 
6.3.5 Synthesis of CH-mPEG 2000 (30) and CH-mPEG 550 (30) for pegylated liposomes 
2g methoxy PEG 2000 (29) (0.001 moles) or 0.55g methoxy PEG 550 (29) (0.001 moles) 
and 0.449g (0.001 moles) cholesteryl chloroformate (17) were dissolved in THF in an 
ice bath with a constant influx of nitrogen. Solution was stirred at 45-50°C for 48 
hours, dried and washed with hexane to obtain final product. The 1H NMR shifts of 
both conjugates were, CH-mPEG 550: 1H NMR (500 MHz, CDCl3, δ ppm): 0.01-2.18 (m, 
48H), 3.64 (s, 44H). CH-mPEG 2000: 1H NMR (500 MHz, CDCl3, δ ppm): 0.7-2.16 (m, 
48H), 3.64 (s, 180H). 
6.3.6 Measurement of fixed aqueous layer thickness (FALT) 
Fixed Aqueous layer thickness (FALT) of polymers was calculated by the zeta potential 
measured in different concentrations of NaCl, plotted against k giving slope which is 
fixed aqueous layer thickness in nm. According to Gouy–Chapmann theory,  
ln (L) = ln A−kL,  
where A is a constant, k= √C/0.3 for univalent salts and C is molality of electrolytes419.  
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6.3.7 Preparation of liposomes and polymersomes by reverse phase evaporation method 
1mL of lipids egg phosphatidylcholine and CH-mPEG 550/2000 (2mg mL-1 15 and 30 in 
9:1 molar ratio) or 0.5mL polymer 28 (2mg mL-1) in chloroform were evaporated in a 
round bottom flask (RBF) to form a thin film. Anthracene (66µl of 1mg mL-1 in ethanol) 
was added at chloroform stage. FCD, FDD and F-D (100µl of 2mg mL-1 in PBS) were 
added to the RBF and evaporated to dryness. 0.5 mL chloroform was added and the 
solution was sonicated for 15 minutes. 1mL PBS was added to chloroform solution for 
liposomes or 0.5mL (2mg mL-1) polymer 28 in PBS with 0.5mL plain PBS was added for 
polymersomes and sonicated for 30 minutes after which chloroform layer was 
evaporated to form 1mL liposomes/polymersomes. Resultant nanoparticles were 
sonicated in a bath sonicator for 10 minutes after particle formation. 
6.3.8 Preparation of liposomes and polymersomes by emulsion evaporation method (EM-
EV) 
1mL of lipids (2mg mL-1) (section 6.3.7) or 0.5mL polymer 28 (2mg mL-1) in chloroform 
was mixed with 1mL PBS for liposomes and 0.5mL (2mg mL-1) polymer in PBS with 
0.5mL PBS for polymersomes. Anthracene (66µl of 1mg mL-1 in ethanol) was added in 
chloroform. Hydrophilic dyes (100µl of 2mg mL-1) were added in PBS. Resultant 
chloroform-PBS mixture was sonicated for 30-40 minutes to form an emulsion. 
Chloroform layer was evaporated to form nanoparticles instantly and bath sonicated 
for 10 minutes to form unilamellar particles. 
6.3.9 Preparation of liposomes and polymersomes by thin film hydration method (TFH) 
1mL of lipids (2mg mL-1) (as section 6.3.7) or polymer (28) (2mg mL-1) in chloroform 
was evaporated in a RBF to form a thin film. Anthracene loading (66µl of 1mg mL-1 in 
ethanol) was added in chloroform and 1mL PBS was added after making the thin film 
or hydrophilic dyes (100µl of 2mg mL-1 in PBS) were added with 900µl PBS after 
making the thin film and hydrated by sonication in a water bath for 45-60 minutes. 
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6.3.10 Characterisation of nanoparticles 
Encapsulation efficiency of all dyes was measured as mentioned in Section 6.2.9. 
Encapsulation efficiency of all dyes was measured by fluorescence spectroscopy. FCD 
was measured at Ex 490/Em 517 (y=32.318x, R² = 0.9982), FDD was measured at Ex 
490/Em 517 (y = 18.063x, R² = 0.9997), F-D was measured at Ex 490/Em 517 
(y=33.788x, R² = 0.999). Anthracene concentration was measured at Ex 355/Em 400 (y 
= 221.14x, R² = 0.9987). 
6.3.11 In-vitro release studies 
Release studies for FCD, FDD and F-D were conducted by tying nanoparticles into a 
dialysis bag (MWCO 14,000Da) and placing in a vial containing PBS at 37°C with 
constant stirring. Release of anthracene was determined in Ethanol: PBS 1:1 solution. 
Aliquots were taken at different intervals of time upto 24 hrs and replaced with fresh 
media to maintain sink conditions and analysed using fluorescence spectroscopy as 
stated above. 
6.3.12 Cellular uptake 
1x105 cells mL-1 (100µl) HeLa cells were seeded into 96 well plates and incubated 
overnight, to which FCD (250µg mL-1) or anthracene (50µg mL-1) liposomes/ 
polymersomes, sterile filtered using 0.45µ Millex MCE filters were added at a volume 
of 100µl in PBS and incubated for 4 hours at 37°C. After incubation cells were washed 
twice with PBS and measured using Fluostar Omega microplate reader at Ex 
480nm/Em 520nm for FCD and Ex 355nm/Em 460nm for anthracene. After 
fluorescence measurements, protein estimation of cells was done by lysing the cells 
and adding 25µl 0.1% Triton-X100 into each well with 15 minutes incubation at 37°C. 
Protein estimation was done using BCA Protein assay kit after incubation at 37°C for 30 
minutes and measuring absorbance at 562nm. Cellular uptake results are reported as 
fluorescence per mg of protein.  
6.3.13 Mechanism of cell uptake by inhibition of endocytosis 
For uptake mechanism, HeLa cells were incubated with 100µl of 30µM Chlorpromazine 
Hydrochloride in media for 30 minutes. After which the supernatant medium was 
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removed and cells were incubated with FCD loaded polymersomes/liposomes for 4 
hours as described above. Cells were then washed twice with PBS and analysed for 
FCD fluorescence as mentioned in Section 6.3.11. 
6.3.14 Observation of cells by Fluorescence microscopy 
For fluorescence imaging, HeLa cells were cultured on glass coverslips and allowed to 
adhere overnight. Cells were treated with liposome/polymersomes suspension having 
combination of FCD and anthracene at concentrations stated in Section 6.3.11. and 
incubated for 4 hours. Coverslips were then washed with water and observed 
immediately using Nikon Eclipse E400 microscope and analysed using NIS Elements 
3.22.01 software.  
6.3.15 Stability studies  
Nanoparticle suspensions were subjected to stability studies at 5°C (stored in 
refrigerator) and 25°C (incubator) for 8 weeks. Samples were taken at regular intervals 
and analysed for encapsulation efficiency and size.  
 
6.4 Specific methods for Chapter 3 
6.4.1 Preparation and characterisation of micelles 
Micelles were prepared by evaporating the desired amount of polymer 34 in CHCl3 in a 
round bottom flask along with 31 and 32 or 35 to form a thin film. The resultant film 
was hydrated with PBS to form the micelles. Micelles were characterised for particle 
size, PDI, Zeta potential, Encapsulation efficiency and SEM as mentioned in section 
6.2. 
6.4.2 Evaluation of phototransformation 32a to 32b 
0.5mL 32 (0.1 mg mL-1) was added to 0.6 mL polymer (34) (2.5 mg mL-1) and 
evaporated into a thin film and hydrated with 3mL PBS to form micelles. These 
samples were irradiated from a fixed distance of 4 cms at 365 nm (0.4 mW cm–2) with 
a Mineralight UVGL–25 lamp (UVP 95-0006-03 Model UVL-56 6 Watt). The UV-Vis 
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spectra was recorded at intervals of 30 seconds for 6.5 minutes until no further 
increase in absorbance of 32b (560nm) was observed. 
6.4.3 FRET efficiency 
Micelles were prepared as described in section 6.4.1. with 78 µL of 31 (0.08 mg mL-1) 
and varying volumes of 32 (0.2 mg mL-1) to obtain molar ratios 1: 0.5-10 of 31:32 and 
hydrated with polymer 34 with 3mL PBS to form micelles. The FRET efficiency was 
determined by allowing the photo-transformation of 32a to 32b while the 
concentration of 31 remained constant. Fluorescence emission spectra of 31 were 
recorded (Ex 525nm/Em 545 nm) before and after UV light exposure. 
6.4.4 In-vitro triggered release using Franz Diffusion cells 
Micelles were prepared as above using 0.176 mL of 31 (0.2 mg mL-1) with 0.6 mL of 32 
(0.5mg mL-1) and 2mL polymer 34 (2.5mg mL-1) and hydrated with 2mL PBS. Release 
studies were undertaken using Franz diffusion cells through dialysis membrane. 200µL 
of the micelle formulation was loaded into the donor compartment while the acceptor 
chamber comprised of PBS and was maintained at 37°C. The contents of the donor 
chamber were irradiated with UV light for fixed time periods of 2, 4, 6, 8, 10 and 12 
minutes and solutions were analysed using fluorescence spectroscopy at Ex360nm-EM 
637nm. Similarly, control studies were conducted in the absence of UV light. For 
determining stability and reproducibility of the system, micelles containing 31 and 35 
were loaded onto Franz diffusion cells and subjected to cycles of 5 minutes UV light 
and 20 minutes dark conditions during which samples were scanned for fluorescence 
emission of 31 at Ex 525nm-Em 540nm at 5 minutes intervals for 20 minutes. 
6.4.5 Observation of FRET in HeLa cells 
100µl, 5x104 mL-1 Hela cells were seeded in 96 well plates and allowed to adhere 
overnight. When 60 % confluency was reached, 2 mL micelle solutions were prepared 
containing either 31 (0.176mL of 0.2 mg mL-1) and 32 (0.6mL of 0.5mg mL-1) or just 31 
(0.176mL of 0.2 mg mL-1). 50µl of this solution were added to the wells and incubated 
for 18 hours. The cells were then washed twice with PBS and the fluorescence 
emission determined using an ELISA plate reader (Ex 485nm and Em 520nm). For 
confocal microscopy, cells were treated as mentioned above and imaged using a Leica 
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DMI6000b inverted microscope with a 40x oil immersion lens. All images were 
analysed using LAS AF v2.3.6 software. 
6.4.6  Comparative release study to quantify triggered release by FRET 
Release studies were conducted on Franz diffusion cells using dialysis membrane. 
Briefly micelles loaded with 31 and 35 were loaded into acceptor compartment and 
the donor compartment was filled with PBS maintained at 37°C. Micelles were 
irradiated with UV light for 5 minutes after which they were subjected to light and 
dark conditions for 20 minutes. Samples were taken at 5 minute interval and observed 
for UV absorbance at 345nm for 35a and fluorescence emission of 31 following a 20 
minute equilibration period in visible light conditions. Similar studies were conducted 
without UV trigger. 
 
6.5 Specific methods for chapter 4 
6.5.1 Preparation and characterisation of polymersomes 
0.5mL (5mg mL-1) polymer 41 in chloroform was evaporated in a round bottom flask to 
form a thin film. 100µl Dox (5mg mL-1 in water), 250µl 5-FU (8mg mL-1 in water) and 
50µl LV (5mg mL-1 in water) was added on top of the film and evaporated to form a 
layer on the polymer film. 1mL Chloroform was added to the round bottom flask and 
sonicated for 15 minutes, after which 0.5mL Polymer 41 (5mg mL-1) and 0.5mL PBS 
was added and sonicated again for 30 minutes to form an emulsion. The chloroform 
layer was evaporated to form polymersomes. Polymersomes were freeze dried and 
resuspended as per requirement. Resultant polymersomes were characterised using 
particle size, PDI, zeta potential, encapsulation efficiency and in-vitro release studies. 
Dox was analysed by fluorescence spectroscopy at Ex 485nm/Em 580nm (y = 91.324x, 
R²= 0.9881), 5FU and LV by UV spectroscopy at absorbance maximum 265nm(y 
=0.0581x, R² = 0.9992) and 285nm (y = 0.0543x, R² = 0.9998) respectively. 
6.5.2 Cell viability studies 
BxPC-3 cells were employed to observe cell toxicity of free solutions of individual 
drugs in solution, combinations loaded in polymersomes and blank polymersomes. 
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100 µl, 5x105 cells mL-1 were seeded in 96 well plates and allowed to adhere overnight 
after which 100µl of test solutions was added to the wells and incubated for 22 hrs. 
Free solution of individual drugs, combination free solutions or combination drugs 
encapsulated in polymersomes were loaded on cells at concentrations Dox 0.2mM, 5-
FU 4mM, LV 0.25mM, amphiphilic polymer 41 2.5mg mL-1  following sterilization with 
0.45µ Millex MCE syringe filters.  
6.5.3 In-vivo studies on ectopic xenograft mouse model 
Mixed gender NOD-SCID mice (NOD.CB17-Prkdcscid/NCrHsd) having an average 
weight of 23g, implanted with BxPC-3 tumours were employed for all in-vivo studies. 
BxPC-3 cells (5x106 per mouse) were resuspended in RPMI 1640 medium and 
Matrigel® in 1:1 ratio and implanted ectopically into the rear dorsum of the mouse. 
Well defined tumours were formed after 2 weeks of implantation and tumour volume 
was measured regularly using callipers and calculated using the formula (LxWxH)/2 
until the tumour volume reached 200-250mm3 after which animals were employed for 
in-vivo studies. All animals were treated humanely in accordance with UK Animals 
(Scientific Procedures) Act 1986.  
6.5.4 Observation of pharmacokinetics of polymersomes 
50µl polymersomes loaded with 0.2mg mL-1 ICG were injected into the tail vein of 
mice previously anesthetised with 150µl intraperitoneal injection of water for 
injection: hypnorm: hypnovel (2:1:1,) (VetaPharma Ltd., U.K.). Following 
administration, animals were placed in Xenogen IVIS® lumina imaging system chamber 
maintained at 37°C loaded with ICG filter set (Ex 705–780 nm; Em 810–885 nm) in 
fluorescence mode and images were taken at regular intervals up to 22 hours to 
observe pharmacokinetics of polymersomes in real time. After 22 hours, mice were 
euthanized and organs along with tumour were surgically collected and imaged for 
presence of ICG fluorescence. All data were analysed using Living Image® software 
version 2.60 and reported as arbitrary fluorescence unit’s ratio with respect to 
background.  
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6.5.5 In-vivo toxicity of polymersomes loaded with combination drugs 
After mice reached desired tumour volume, they were segregated into 5 groups-
untreated, free solution intratumoral, polymersomes intratumoral, free solution IV 
and polymersomes IV treated groups. Polymersomes loaded with Dox (5mg/kg), 5-FU 
(20mg/kg), LV (2.5mg/kg), polymer 41 (50mg/kg) were injected intratumorally and 
intravenously at 100µl volume on Day 0 and Day 5 of treatment in mice according to 
their respective groups whereas untreated group received no treatment. Mice in 
intratumor treatment group received hypnorm/hypnovel intraperitoneal anaesthesia 
before each treatment. Tumour volume and body weight was measured every day for 
13 days after intratumoral injection and 7 days after intravenous injection. Mice were 
then sacrificed and tumours and hearts were surgically removed for further 
observations. 
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Figure 8-2 Standard Calibration curve of FITC-DEAE-Dextran (FDD) 
by fluorescence spectroscopy at Ex 490nm Em 517nm. 
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Figure 8-1 Standard Calibration curve of FITC-CM-Dextran (FCD) by 
fluorescence spectroscopy at Ex 490nm Em 517nm. 
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Figure 8-3 Standard Calibration curve of FITC-Dextran (F-D) by 
fluorescence spectroscopy at Ex 490nm Em 517nm. 
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Figure 8-4 Standard calibration curve of anthracene by fluorescence 
spectroscopy at Ex 355nm Em 400nm  
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Figure 8-5 Standard Calibration curve of merocyanine using fluorescence 
spectroscopy at Ex 360nm Em 637 nm   
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Figure 8-6 Standard Calibration curve of Dox by fluorescence 
spectroscopy at Ex 485nm Em 580nm 
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Figure 8-8 Standard Calibration curve of LV by UV spectroscopy at 
absorbance maximum 285nm   
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Figure 8-7 Standard Calibration curve of 5- fluorouracil by UV spectroscopy 
at absorbance maximum 265nm 
218 
 
Appendix 2 
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
The integration of triggered drug delivery with real time quantiﬁcation
using FRET; creating a super ‘smart’ drug delivery system
Noorjahan Aibania, Paola Fontoura da Costaa, Jodie Mastersona, Nino Marinoa,
Françisco M. Raymob, John Callana, Bridgeen Callana,⁎
a School of Pharmacy and Pharmaceutical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland, United Kingdom
b Laboratory for Molecular Photonics, Department of Chemistry, University of Miami, 1301 Memorial Drive, Coral Gables, FL, United States
A R T I C L E I N F O
Keywords:
Real-time analysis
Photo-transformation
FRET
Hydrophobic drug delivery
Micelles
Stimuli responsive
A B S T R A C T
The ability to control drug release at a speciﬁc physiological target enables the possibility of an enhanced
therapeutic eﬀect with reduced oﬀ-target toxic side eﬀects. The discipline of controlled drug release has grown
to include most areas of medicine with examples in the literature of targeted drug delivery to the majority of
organs within the human body. In addition, a variety of external stimuli used to meditate the drug release
process have also been investigated. Nonetheless, the concurrent real time monitoring of drug release has not
been widely studied. In this manuscript, we present a novel micellar drug delivery system that is not only
capable of releasing its cargo when stimulated by light but also provides a real time analysis of the amount of
cargo remaining. Controlled drug release from the delivery system was mediated by physicochemical changes of
a spiropyran-merocyanine photochromic dyad, while drug quantiﬁcation was enabled using a Förster Resonance
Energy Transfer (FRET) relationship between the photochrome and a co-encapsulated BODIPY ﬂuorophore. The
percentage of drug released from the delivery system was signiﬁcantly greater (24%) when exposed to light
irradiation compared to an analogous control maintained in the dark (5%). Furthermore, the ﬂuorescence read-
out capability also enabled the drug-release process to be followed in living cells with a signiﬁcantly reduced
ﬂuorescence emission observed for those cells incubated with the delivery system and exposed to light irra-
diation compared to control cells maintained in the dark. Combined, these results highlight the utility of this
approach to theranostic drug delivery with the potential of light-triggered released together with a ﬂuorescence
read-out to enable quantiﬁcation of the drug release process.
1. Introduction
In order for a drug to produce a therapeutic eﬀect, it must not only
reach the site of action but also have the correct physicochemical
properties to allow it to be absorbed at an appropriate concentration. In
the past few decades, smart drug delivery systems (DDS) have evolved
to deliver an appropriate dose to meet the patients needs [1]. Delivering
the drug at a controlled rate, triggered drug release and targeted drug
delivery are some methods that have been extensively investigated.
Some examples of such systems include the development of bio-
pharmaceutical systems capable of interacting with intracellular com-
ponents that respond as a direct result to environmental stimuli [2] and
nanoparticles that speciﬁcally bind to tumour cells using receptor tar-
geted systems [3,4]. Among these, triggered release plays a substantial
role on controlling timing and location of drug release, since it can be
induced by several external stimuli acting on the intracellular vehicles
response [5]. Examples of stimuli used to facilitate drug release are
temperature [6], pH [7], magnetic ﬁeld [8], electric ﬁeld [9], ultra-
sound [10], enzymatic activity [11] and light [12].
Light responsive drug release is an attractive mechanism because of
the ability to control the spatial and temporal triggering of the release
process [13]. Numerous examples of photochromic materials capable of
transforming under the inﬂuence of activating radiation have been
explored over recent years [14]. However, the photo activating ability
of Spiropyran compounds was recognised as early as the1920s [15].
Spiropyran can undergo a reversible response to light and chemical
stimulations. The closed ring stable state of Spiropyran (a) can be
converted to its open form, Merocyanine (b), when irradiated with UV
light, which is converted back into its original state when irradiated
with visible light (Fig. 1).
This simple photochromic transformation has found many applica-
tions ranging from molecular sensors [16] to DNA-based logic
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operations [17] and bioimaging [18]. Here, we exploit diﬀerences in
the hydrophobic/hydrophilic balance between the two isomers to
mediate drug release from a micellar based delivery system. The spir-
opyran form, with its hydrophobic four-ring system preferentially fa-
vours a non-polar environment whereas its open ring zwitterionic
merocyanine counterpart prefers a more hydrophilic environment.
In addition to the triggered delivery mechanism there are also a
number of considerations to make when selecting the type of DDS. More
than 40% of newly discovered drugs have little or no aqueous solubility
(as determined by the Biopharmaceutical Classiﬁcation System): 90%
of drugs approved since 1995 have poor aqueous solubility, poor per-
meability or both [19]. The delivery of hydrophobic drugs can be
achieved in a number of ways. For example, a pro drug of the active
compound may be prepared to catabolize to the original drug. Alter-
natively, a speciﬁc functional group can be altered to create a synthetic
analogue with more appropriate hydrophilicity, or the compound may
be formulated in such a way as to enable delivery by enteric coating for
oral delivery or by an alternative method such as rectal or intravenous
administration. All of these approaches have proven successful in de-
livering hydrophobic compounds. However, these approaches can often
lead to enhanced ﬁrst pass eﬀects and thus the requirement for higher
dosage or enhanced expense or, depending on the dosage form, poor
patient compliance.
An alternative and successful method for the delivery of hydro-
phobic drugs is the use of polymeric drug delivery systems. These DDSs
can be formulated as, micelles [20], liposomes [21], nanoﬁbers [22],
dendrimers [23], colloids [24] or carbon nanotubes [25] with the
majority of them falling into the category of nanoparticle drug delivery
vehicles. It has been suggested that the polymeric nano carriers can
become concentrated preferentially in tumors, inﬂammatory sites, and
at antigen sampling sites by virtue of the enhanced permeability and
retention (EPR) eﬀect of the vasculature [26]. Once accumulated at the
site, these polymeric drug delivery vehicles can act as a drug depot,
providing a source of API to be released as and when required. This
leads to enhanced bioavailability, sustained/controlled release and
decreased toxicity caused by potential burst release of the API. There
are numerous examples where polymeric compounds are shown to
enhance drug delivery [27]. Among these systems Polyethylene glycol
(PEG) is frequently used as a polymeric component. We have previously
developed a PEG-micellar DDS and determined the size of our PEG
copolymers to have an average hydrodynamic diameter of 26 nm [18].
As a direct result of their size, these micelles can navigate through the
endothelium in inﬂammatory sites, epithelium tumors or penetrate
micro capillaries, allowing for uptake by a variety of cell types. We have
previously shown these micelles to eﬃciently cross the cell membrane
of Chinese hamster ovarian cells and distribute themselves in the cy-
tosol.
Finally, the ability to quantitatively monitor the amount of drug
release, from a DDS in real time using a simple but eﬀective approach is
an essential companion in the advance towards second-generation
health care. To this end, there have been a number of examples where
mesoporous silica nanoparticles (MSN) have been used as a cage for
drug delivery with the drug co-incorporated alongside a photochromic
compound [28], an oligonucleotide containing a recognition element
[29] or a redox active FRET pair [30] so that the system operates like a
molecular valve. In each case, the drug was prevented from exiting the
pores of the NP due to the large bulky groups surrounding the MSN. On
application of external stimuli, the outer layer (valve) was disrupted
and the inner cargo released from the MSN. In addition to the triggered
release, a Förster Resonance Energy Transfer (FRET) mechanism was
Fig. 1. Illustration of the phototranformation of spiropyran (a) to its merocyanine (b) counterpart and subsequent movement within the micellar environment before transformation back
under visible irradiation.
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utilised to enable real time monitoring of drug release.
In this manuscript, an alternative approach has been developed that
combines a triggered release of hydrophobic drugs encapsulated within
a polymeric micellar drug delivery system with real time analysis
through molecular communication. This was achieved using a FRET
mechanism whereby a FRET pair was contained within the hydrophobic
interior of a self-forming amphiphilic micelle. Upon application of an
external UV light trigger, one of the FRET pair, a Spiropyran moiety,
undergoes a photo transformation to the more hydrophilic merocyanine
isomer and transcends the micellar membrane into the aqueous external
environment. The other half of the FRET pair, a hydrophobic bodipy
ﬂuorochrome, remains within the non-polar environment of the mi-
celle. Thus, release of the merocyanine isomer from the micelle mod-
ulates the donor-acceptor energy transfer process enabling the release
process to be followed by ﬂuorescence spectroscopy, illustrated in
Fig. 2. A decrease in the quenching ability of the merocyanine for the
bodipy emission is observed relative to the amount of merocyanine
remaining within the micellar structure.
Indeed, the scope of this approach can be further extended by
conjugating an Active Pharmaceutical Ingredient (API) onto the
Spiropyran isomer enabling its release to be controlled and monitored
in real time. To illustrate this, we have attached ibuprofen to spiropyran
using an ester linkage, determined the release of this conjugated ibu-
profen-spiropyran compound from the micelle upon UV light irradia-
tion and compared these results to the release of unmodiﬁed spiropyran
from the micelle.
2. Materials and methods
2.1. Materials
All reagents and solvents were purchased from Sigma-Aldrich and
used without further puriﬁcation. 2,3,3-trimethylindolenine 98%, 1-
bromodecane 98%, 2-hydroxy-5-nitrobenzaldehyde 98%, Piperidine
≥99.5%, 2-bromoethanol 95%, Potassium Hydroxide 85% KOH Basis,
Triethylamine≥99%, Boron Triﬂuoride≥99.5%, Triﬂuoroacetic Acid
99%, 2,3-Dichloro-5,6-dicyano-p-benzoquinone 98%, 4-Formylbenzoic
acid 97%, 2,4-Dimethylpyrrole 97%, Phosphate Buﬀered Saline Tablets,
Dialysis tubing cellulose membrane ﬂat width 10 mm, Ibuprofen, 4-
(dimethylamino)pyridine, N,N′-Dicyclohexylcarbodiimide, Chloroform,
Acetonitrile, Ethanol, Dichloromethane, Diethyl Ether, Hexane, Ethyl
Acetate, Tetrahydrofuran.
2.2. Synthesis of compounds
The synthesis of hydrophobic spiropyran 1′-decyl-3′,3′-dimethyl-6-
nitro-spiro[chromene-2,2′-indol-1-ium] (HSP) (4) has been previously
described [18].
2.2.1. Synthesis of (10-(4-(decylcarbamoyl)phenyl)-5,5-diﬂuoro-1,3,7,9-
tetramethyl-5H-dipyrrolo[1,2-c:2′,1′-f] [1–3]diazaborinin-4-ium-5-uide)
(3)
Compound 3 was synthesized following a two-step procedure as
detailed below.
Step 1: Synthesis of (10-(4-carboxyphenyl)-5,5-diﬂuoro-1,3,7,9-tet-
ramethyl-5H-dipyrrolo[1,2-c:2′,1′-f] [1–3]diazaborinin-4-ium-5-uide)
(1) (S1).
To a solution of 4-formylbenzoic acid (0.5 g, 3.3 mmol) and 2, 4-
dimethylpyrrole (0.69 g, 7.3 mmol) in THF (90 mL) was added several
drops of triﬂuoroacetic acid. The mixture was stirred at ambient tem-
perature overnight, then a solution of 2,3-dichloro-5,6-dicyano-p-ben-
zoquinone (0.75 g, 3.3 mmol) in THF (120 mL) was added. The mixture
was stirred continuously for another 4 h. After the addition of triethy-
lamine (18 mL, 0.13 mol), BF3·OEt2 (18 mL, 0.15 mol) was added
dropwise to the mixture, which was cooled in an ice-water bath. The
mixture was kept stirring at ambient temperature overnight, then ﬁl-
tered through a celite pad. The residue was washed with CH2Cl2 (ca.
50 mL), then the combined ﬁltrate was rotary evaporated to dryness.
The residue was redissolved in CH2Cl2 (100 mL) and the solution was
washed with 5% aqueous NaHCO3 solution (100 mL) followed with
water (100 mL × 2). The organic portion was dried over anhydrous
MgSO4, then evaporated in vacuo. The crude product was puriﬁed by
silica gel column chromatography using CH2Cl2/MeOH 99/1 as the
eluent to give 1 as an red solid (0.615 g, 51%) (S2).
Step 2: Synthesis of compound 3 (Scheme 1).
A mixture of 1 (127 mg, 0.34 mmol), dodecylamine 2 (45 mg,
0.28 mmol), EDC (110 mg, 0.57 mmol), and DMAP (7 mg, 0.056 mmol)
was dissolved in 20 mL of CH2Cl2. After stirring at 27 °C for 1 h in the
dark the solvent was removed under vacuum. The obtained crude
product was puriﬁed by column chromatography (hexane/EtOAc 1:1)
to give 160 mg of 3 as an orange oil (yield 91%).1H NMR (CDCl3,
500 MHz): δ= 7.91 (d, J= 8 Hz, 2H), 7.39 (d, J= 8 Hz, 2H), 6.18 (br
s, 1H), 5.98 (s, 2H), 3.49 (t, J= 6 Hz, 2H), 2.55 (s, 6H), 1.65 (m, 2H),
1.4–1.2 (m, 14H), 1.35 (s, 6H), 0.87 (t, J= 6.5 Hz, 3H); ESIMS: m/z
506 [M− 1]−.
Fig. 2. Schematic representation of the UV triggered release caused by the photoisomerism of Spiropyran to the zwitterionic Merocyanine transcending the amphiphilic micelle and
concomitant quantiﬁcation using FRET with the simulated emission of the Bodipy donor moiety.
Scheme 1. Amidation of Bodipy compound 1 to increase the hydrophobicity of com-
pound 3.
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2.2.2. Synthesis of Spiropyran compound 2-(3′,3′-dimethyl-6-nitro-spiro
[chromene-2,2′-indol-1-ium]-1′-yl)ethyl 2-(4-isobutylphenyl)propanoate
(8)
The synthesis of compound 8 (SP-IB) was a two-step process. The
intermediate compound 2-(3′,3′-dimethyl-6-nitrospiro[chromene-2,2′-
indolin]-1′-yl)ethanol (6) was prepared following a literature procedure
[31] (S3). The SP-IB was synthesized by a modiﬁed method from
Baumann et al. [32]. Synthesis of SP-IB 8 is detailed in Scheme 2. A
mixture of 6 (100 mg, 0.28 mmol), Ibuprofen 7 (70 mg, 0.34 mmol),
EDC (108 mg, 0.56 mmol), and DMAP (7 mg, 0.056 mmol) was dis-
solved in 20 mL of CH2Cl2. After stirring at room temperature for 1 h in
dark, the purple solution becomes colorless and solvent was removed
under vacuum. The obtained crude product was puriﬁed by column
chromatography (hexane/EtOAc 4:1) to give 145 mg of 8 as a green oil
(yield 94%).1H NMR (CDCl3, 500 MHz): δ= 7.99–7.94 (m, 2H), 7.18
(t, J= 7.0 Hz, 1H), 7.14–7.12 (m, 2H), 7.07–7.06 (m, 3H), 6.89 (t,
J= 7.0 Hz, 1H), 6.79–6.66 (m, 2H), 6.26 (d, J= 6.5 Hz, 1H), 5.62 (t,
J= 11.0 Hz, 1H), 4.22 (m, 2H), 3.63 (m, 1H), 3.45–3.31 (m, 2H), 2.44
(t, J= 6.0 Hz, 2H), 1.83 (m, 1H), 1.45 (dd, J= 21.0 Hz, J= 7.0 Hz,
3H), 1.23 (s, 3H), 1.06 (d, J= 22.0 Hz, 3H), 0.90 (d, J= 6.5 Hz, 6H);
ESIMS: m/z 541 [M + H]+.
2.3. Preparation and characterisation of micelles
The synthesis of the random co-polymer has been extensively de-
scribed previously by the authors as both a hydrophobic [18] and hy-
drophilic [33] drug carrier and was prepared without further mod-
iﬁcation. It was comprised of two monomers (polyethylene glycol (PEG)
(Mn 500) and a decyl chain (C10)) both containing a methacrylate
functional group and polymerized using a free radical initiator in a
5:3 M ratio of PEG:C10 (scheme displayed in S5). The polymer has
previously been determined to be biocompatible with negligible toxi-
city at the concentrations used. Micelles were prepared by evaporating
the desired amount of polymer in CHCl3 in a round bottom ﬂask along
with 3 and 4 or 8 to form a thin ﬁlm. The resultant ﬁlm was hydrated
with PBS to form the micelles. Micelle size, polydispersity index and
zeta potential was analysed by dynamic light scattering using a Malvern
Nano-ZS Zeta sizer. Particle morphology was observed by scanning
electron microscopy (SEM) at high vacuum mode using FEI Quanta
ESEM. A particle suspension was air dried for 24 h on stainless steel
stubs and further coated with ultra-thin Gold/Palladium layer at 18 mA
for 3 min using Polaron Equipment Ltd. E5100 Sputter coater and
observed.
2.4. Evaluation of phototransformation of 4a to 4b
0.5 mL 4a (0.1 mg mL−1) was added to 0.6 mL polymer
(2.5 mg mL−1) and evaporated into a thin ﬁlm and hydrated with 3 mL
PBS to form micelles. These samples were irradiated from a ﬁxed dis-
tance of 4 cm at 365 nm (0.4 mW cm−2) with a Mineralight UVGL–25
lamp (UVP 95-0006-03 Model UVL-56 6 W). The UV–Vis spectra was
recorded using a Varian Cary Eclipse UV spectrophotometer at intervals
of 30 s for 6.5 min until no further increase in absorbance of 4b
(560 nm) was observed.
2.5. FRET eﬃciency
Micelles were prepared as described in Section 2.3 with 78 μL of 3
(0.08 mg mL−1) and varying volumes of 4 (0.2 mg mL−1) to obtain
molar ratios 1: 0.5–10 of 3:4 and hydrated with 3 mL PBS to form
micelles. The FRET eﬃciency was determined by allowing the photo-
transformation of 4a to 4b while the concentration of 3 remained
constant. Fluorescence emission spectra of 3 were recorded (Ex 525 nm
Em 545 nm) before and after UV light exposure using a Varian Cary
Eclipse Fluorescence spectrophotometer.
2.6. In vitro triggered release
Micelles were prepared as above using 0.176 mL of 3
(0.2 mg mL−1) with 0.6 mL of 4 (0.5 mg mL−1) and 2 mL polymer
(2.5 mg mL−1) and hydrated with 2 mL PBS. Release studies were un-
dertaken using Franz diﬀusion cells and dialysis membrane (MWCO
14,000). 200 μL of the micelle formulation was loaded into donor
compartment while the acceptor chamber comprised of PBS and
maintained at 37 °C. The contents of the donor chamber were irradiated
with UV light for ﬁxed time periods of 2, 4, 6, 8, 10 and 12 min and
solutions were analysed using ﬂuorescence spectroscopy at
Ex360 nm–Em 637 nm. Similarly, control studies were conducted in the
absence of UV light. For determining stability and reproducibility of the
system, micelles containing 3 and 8 were loaded onto Franz diﬀusion
cells and subjected to cycles of 5 min UV light and 20 min dark con-
ditions during which samples were scanned for ﬂuorescence emission of
3 at Ex 525 nm–Em 540 nm at 5 min intervals for 20 min.
Scheme 2. Synthesis of Spiropyran compounds hydro-
phobic spiropyran (HSP) (4) and Ibuprofen spiropyran
(IBSP) (8).
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2.7. Observation of FRET in HeLa cells
HeLa cells were incubated in modiﬁed DMEM with 10% FBS and 1%
Pen/strep in 96 well plates at a cell density of 5 × 103 cells in each well
and allowed to adhere overnight. When 60% conﬂuency was reached,
2 mL micelle solutions were prepared containing either 3 (0.176 mL of
0.2 mg mL−1) and 4 (0.6 mL of 0.5 mg mL−1) or just 3 (0.6 mL of
0.5 mg mL−1). 50 μL of this solution were added to the wells and in-
cubated for 18 h. The cells were then washed twice with PBS and the
ﬂuorescence emission determined using an ELISA plate reader (Ex
485 nm and Em 520 nm). For confocal microscopy, cells were treated as
mentioned above and imaged using a Leica DMI6000b inverted mi-
croscope with a 40× oil immersion lens. All images were analysed
using LAS AF v2.3.6 software.
2.8. Comparative release study to quantify triggered release by FRET
Release studies were conducted on Franz diﬀusion cells using dia-
lysis membrane. Brieﬂy micelles loaded with 3 and 8 were loaded into
acceptor compartment and the donor compartment was ﬁlled with PBS
maintained at 37 °C. Micelles were irradiated with UV light for 5 min
after which they were subjected to light and dark conditions for 20 min.
Samples were taken at 5 min interval and observed for UV absorbance
at 345 nm for 8a and ﬂuorescence emission of 3 following a 20 min
equilibration period in visible light conditions. Similar studies were
conducted without UV trigger.
3. Results and discussion
3.1. Synthesis of compounds
The synthesis of compound 1 was achieved by the synthetic pro-
cedure outlined in Scheme S1 (Supporting information). Successful
product formation was conﬁrmed by mass spectroscopy and 1H NMR
spectroscopy. Compound 3 was synthesized to increase the hydro-
phobicity of the FRET donor and hence ensure continued encapsulation
within the micelle. Synthesis was achieved by a modiﬁcation of a
previous procedure [18] with characterisation detailed in Section 2.2.1.
Compound 4 was synthesized as described in Scheme 2 and again
successful product formation was conﬁrmed by 1H NMR and mass
spectroscopy. Compound 8 is a novel compound and was formed by an
esteriﬁcation between 6 and 7 in a 1:1 stoichiometry with a yield of
94%. Successful product formation was again conﬁrmed by 1H NMR
and mass spectroscopy, as detailed in Section 2.2.2.
3.2. Preparation and characterisation of micelles
DLS measurements of micelles loaded with 3 and 4 indicate an
average particle size of 27.5 ± 0.98 nm with PDI 0.416 ± 0.009 and
surface charge of −1.67 ± 0.73 as determined by zeta potential
measurements. These observations were in agreement with those ob-
served previously by Yildiz et al. using the same polymeric micelle with
encapsulated cargo [18]. However when 4 was replaced by 8, the mi-
celle size increased to 45.93 ± 2.72 nm and PDI was 0.346 ± 0.04
with −2.05 ± 0.61 zeta potential. This slight increase in micelle size
may be attributed to the greater rigidity of 8 causing a larger hydro-
phobic internal core within the micelle. There was no major change in
the PDI and zeta potential values for micelles following encapsulation
with regards to content indicating successful incorporation of 8 inside
the micelle. Fig. 3a shows a representative particle size distribution
graph for micelles loaded with 3 and 4, while a scanning electron mi-
croscopic image of micelles loaded with 3 and 8 (Fig. 3b) show well-
formed particles with spherical morphology.
3.3. Quantiﬁcation of photo physical transformation of 4a to 4b
For eﬃcient FRET to occur between a donor-acceptor pair two main
criteria must be met. First, the donor and acceptor molecules must be in
close proximity to each other and secondly, the emission spectrum of
the donor must overlap eﬀectively with the absorption spectrum of the
acceptor. In the context of the micellar delivery system described
above, as both the donor and acceptor are originally conﬁned within
the micelle, a nanoscale distance between the two molecules can be
guaranteed [34]. In terms of spectral overlap, the absorbance spectrum
of 4a encapsulated within the micelle was determined to have a max-
imum absorbance centered at 360 nm. Upon activation by UV light, 4a
undergoes a ring opening of the spiro carbon to its corresponding
merocyanine, 4b (Fig. 1). The merocyanine is zwitterionic, and there-
fore more hydrophilic. It has also an elongated area of conjugation and
therefore induces a signiﬁcant bathochromic shift to a new absorbance
maximum at 550 nm which coincides with the emission wavelength of
3 (Fig. 4) when excited at 525 nm.
This spectral cohesion of absorbance and emission of 4b and 3 is
imperative for energy transfer from 3 (the ﬂuorescent donor) and 4b
(the photochromic acceptor. Nevertheless, the time required for con-
version of 4a to 4b can signiﬁcantly aﬀect the energy transfer from 3 to
4b. Hence we irradiated 4a with UV light and monitored the UV–Vis
spectrum at increments of 30 s in aqueous medium and found that it
required 5 min irradiation for complete conversion from 4a to 4b as
shown in Fig. 5.
After 5 min, the absorption reached a plateau beyond which there
was no increase in the absorption intensity. However complete con-
version of 4a to 4b took 12 min in DMF medium which can be ex-
plained by the polar nature of 4b enabling faster conversion in aqueous
medium (S4). The polar nature of 4b is fundamental to encourage its
release from within the micelle to the surrounding polar aqueous en-
vironment, enabling a triggered release of micellar content.
3.4. FRET eﬃciency between 3 and 4b
In order to identify the ratio of 3 to 4b which allows maximum
energy transfer between the ﬂuorophore and photochrome, the two
compounds were encapsulated into the micelles at diﬀerent molar ra-
tios and the observed decrease in ﬂuorescence emission of 3 following
irradiation with UV light for 5 min to facilitate the conversion of 4a to
4b. Fig. 6 shows the emission proﬁle of 3 at varying ratios of 4b. As
expected, the emission of 3 was highest when there was no 4b present
in the micelle (spectrum a). As the concentration of 4a in the micelles
increased, more 4a was converted to 4b upon irradiation with UV light
and quenched the emission of 3 at 540 nm proportionately (spectra
b–h).In addition, emission from 4b at 637 nm was observed to increase
upon increasing 4a concentration indicating a successful energy
transfer between 3 and 4b. However, the plot of percentage depletion
in ﬂuorescence emission of 3 (Fig. 6 insert) shows that a plateau was
reached after a ratio 1:6 of 3:4b suggesting a saturation concentration
was reached with no more 3 available for energy transfer. This suggests
that the optimal FRET molar ratio between donor and acceptor to allow
for quantitative analysis is 1:6. This is reﬂective of the diﬀerence in
extinction coeﬃcient between our donor and acceptor moieties. This
was the ratio chosen for all subsequent studies.
3.5. In vitro triggered release
UV light acts as a trigger for photoinduced transformation of 4a
which is hydrophobic with a closed ring system to an open ring 4b
which is polar in nature with higher solubility in aqueous medium. The
hydrodynamic properties of micelles allow 4b to easily come out of the
system permitting release of encapsulated cargo. Continuous photo-
activation of 4a within the micelle lead up to 24% release of 4b into the
surrounding environment within 12 min which was signiﬁcantly higher
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than the 5% release in the absence of photoactivation as seen in Fig. 7.
This design of a triggered fast release system is essential for successful
release of drugs attached to 4 for therapeutic applications.
3.6. Reproducibility of system
The integration of photoswitchable assemblies with ﬂuorophores
capable of resonance energy transfer allows the formation of a system
which has the ability to switch on and oﬀ on demand. Fig. 8 shows the
ﬂuorescence emission of 3 in the presence of 8 and subsequent photo-
chromic switching between the spiropyran form (8a) to its merocyanine
Fig. 3. A. Dynamic light scattering displaying the hydro-
dynamic radius of micelles. B. SEM image of micelles.
Fig. 4. Absorbance spectra of 4a and following photoconversion to 4b with the emission
spectra of 3 with Ex 525 nm.
Fig. 5. Absorbance spectra of 4b at λmax 550 nm increasing with increasing exposure to
UV light of 365 nm. Spectra displayed following exposure to 0, 0.5, 1.0, 1.5,2, 2.5, 3, 3.5,
4, 4.5, 5, 5.5, 6 and 6.5 min UV light at 465 nm from a ﬁxed distance.
Fig. 6. Fluorescence emision of 3 following exposure to
varying molar ratios of 4a and photoconversion to 4b. a: no
UV exposure and b-h: solutions were exposed to 5 mins UV
light at 365 nm from a ﬁxed distance and molar ratios of
compunds bodipy 3: merocyanine 4b 1:0.5; 1:1, 1:2, 1:4,
1:6, 1:8 and 1:10 consecutively. Insert: FRET eﬃciency of 3
and 4 following exposure to 5 mins UV light at 365 nm
from a ﬁxed distance. Concentration of 3 remains constant
at 3.64 μM. Percentage eﬃciency was determined by the
relation depletion in the emission of 1 at 545 nm, n= 3.
Fig. 7. In-vitro triggered release of 4b from micelles after continuous activation with UV
light for 12 min and no UV activation. ** indicates p < 0.005.
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counterpart (8b) indicating the reproducibility of the system.
Compound 8 was created as a prodrug, to contain an API
(Ibuprofen) covalently linked to the photochromic spiropyran moiety.
Once released from the internal core of the micelle it is anticipated that
it would be subjected to hydrolysis via esterase's enzymes and hence
release the API. When there was no 8b present in the system (in the
absence of UV light), there was a signiﬁcantly high emission of 3. This
emission was quenched upon photoactivation of 8a to 8b as the ab-
sorption signature of 8b overlaps with emission signature of 3. As 8b
slowly reverted back to 8a owing to its reversibility in heat and visible
light conditions, the emission of 3 slowly increased. The hydrophilic
nature of 8b encourages it to transcend the hydrophobic internal core of
the micellar system into the wider aqueous environment. Although the
system was kept in the dark, there were three cycles of 5 minute irra-
diation, allowing for signiﬁcant movement outside the micelle. This
movement was observed as a decrease in the quenching eﬃciency of 3
upon subsequent photoactivation cycles (Fig. 8 insert) as less 8b was
present within nanoscale distance for FRET to successfully take place
between the two molecules in each subsequent excitation. This decrease
in the quenching of emission of 3 is of similar magnitude to the %
release of internalised compound 4, observed in Fig. 7, with 19% re-
lease after 10 min of 8 when compared to the 15% release of 4 after
10 min displayed in Fig. 7. The increase in release is attributed to the
time lapse between UV stimulation and subsequent photoconversion
allowing for more hydrophobic 8b to leave the micelle. It is seen from
Fig. 8 that a further ﬂuorescence quenching of 74.4% is recorded after
15 min UV irradiation and would suggest that 25.6% of 8 has been
released. A similar eﬀect was seen in light conditions, but the % of
quenching of 3 was slightly less, due to the faster photoconversion back
to the original more hydrophobic spiropyran moiety (8a), ensuring that
less compound was released and hence more available for the sub-
sequent energy transfer to the donor (S6). Micelles loaded with only 3
did not show any changes in ﬂuorescence emission after photoactiva-
tion and after subsequent resting periods, in addition there was limited
photobleaching of 3 after UV irradiation.
3.7. Observation of FRET in HeLa cells
Encapsulation of cargo within micelles enables them to be trans-
ported across the cell membrane leading to better cellular uptake owing
to their biocompatibility and size. In order to determine the feasibility
of communication and triggered release from within the micelles, we
incubated HeLa cells with micelles loaded with 3 and 4a and enabled
the photoconversion of 4a to 4b present within the cells to conﬁrm
FRET communication between 3 and 4b. As seen in Fig. 9, ﬂuorescence
emission of 3 ﬂuctuated drastically according to status of 4b present
within the cells, as a direct result of molecular communication between
them. The ability of 4b to switch back to 4a in the presence of visible
light broke the communication between 3 and 4b allowing the emission
of 3 to be observed. These results in HeLa cells support our previous
observations in vitro conditions in Section 3.6. It can be seen that im-
mediately following 5 min UV irradiation there is a 82.5% quench in
the ﬂuorescence emission of 3, attributed to the energy transfer to the
acceptor moiety, 4b. Upon subsequent photoactivation cycles of 4b
there was signiﬁcantly less quenching of the emission from our donor
compound 3 (75.3% and 64.2% respectively). This can be attributed to
the more polar 4b form leaving the micelle DDS (24.7% and 35.8%
released after 10 and 15 min irradiation).
As expected the emission of 3 lapsed back faster in visible light
conditions compared with dark conditions (S7), further conﬁrming that
the photoconversion of 4b to 4a is faster in the presence of visible light
and is indirectly communicated in the form of higher emission of 3.
Additionally, the quenching eﬀect after subsequent UV irradiation cy-
cles in the dark was similar to that seen in light conditions. Similarly,
observations of cells by confocal microscopy indicated signiﬁcant re-
duction in ﬂuorescence emission of 3 on photoactivation of 4b con-
ﬁrming its presence within cells (Fig. 10).
3.8. Real time quantiﬁcation of encapsulated cargo
The photoswitchable nature of 8 and its molecular communication
with 3 can prove beneﬁcial in real time quantiﬁcation of release of
encapsulated materials from within the micellar environment. To
quantify this occurrence, micelles loaded with 3 and 8 were loaded on
to dialysis membranes in Franz diﬀusion cells and photoactivated for
5 min to allow conversion of 8a to 8b resulting in its release from the
micellar environment recorded over 20 min of resting time in both dark
and visible light conditions. Two parameters were measured simulta-
neously at various time points in an attempt to correlate the commu-
nication seen through 3 with release of 8. This was achieved by
Fig. 8. Bar chart: Fluorescence emission of 3 within mi-
celles loaded with 8a following cycles of UV exposure
(365 nm, 5 mins) leading to conversion of 8a to 8b and
subsequent resting time in dark conditions permitting re-
version of 8b back to 8a. Line graph: control with micelles
containing only 3. Insert: % quenching of 3 following UV
irradiation. ** indicates p < 0.005.
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monitoring the amount of 8a present within the micelles by absorbance
at 345 nm. Following removal of the sample for analysis a set period of
20 min was observed with the sample subjected to visible irradiation, to
ensure that all 8 was in the spiropyran form, 8a. The results of the
depletion in 8a absorbance can be seen in Fig. 11a. The simultaneous
measurement of bodipy emission (3) was collected, following the ori-
ginal 5 mins UV irradiation, each sample removed for analysis was
subjected to 20 min visible light before the emission of 3 was recorded,
the decrease in quenching is plotted in Fig. 11b. From Fig. 11 a good
correlation is seen between both the ﬂuorescence increase from 3 and
the absorbance of 8a. The largest magnitude of change is observed from
the UV stimulation in dark conditions, this is expected as 8b would
favour the more polar environment. Speciﬁcally, a 8.4% decrease in 8a
absorbance is observed after 10 min, indicting a transfer of 8 across the
dialysis membrane. This is indirectly communicated through a 7.0%
increase in the ﬂuorescence emission of 3 (Fig. 11b). Similarly a 17.4%
decrease in absorbance of 8a is seen at 20 min compared to 11.6%
increase in ﬂuorescence emission of 3 at the same time point. Visible
light conditions led to conversion of 8b back to 8a leading to lesser
release of only about 7% from micelles which was reﬂected as ap-
proximately 4% increase in ﬂuorescence emission of 3. However there
was negligible release in the absence of a UV trigger and is suitably
revealed as insigniﬁcant increase in ﬂuorescence emission of 3. This
close correlation between the FRET communication when compared to
the direct measurement of remaining spiropyran would suggest that
there is indeed potential to further develop these smarter DDSs.
4. Conclusion
The number of smart DDSs capable of real time communication with
concomitant stimulated drug release is increasing in response to the
nanotechnology revolution [35]. The need for variation between the
mechanism of stimulus, as well as the parameter involved in commu-
nication is paramount to the success of these advanced materials so to
allow these nano-platforms to reach the full echelon of their potential.
Recent examples illustrating this diversity can be seen by Huang et al.
[36], whereby they have incorporated the anticancer agent doxorubicin
into a supramolecular nanoparticle and also double up its use as the
FRET acceptor to allow self-communicating. Another interesting ex-
ample is seen by Du et al. [37] and their incorporation of ﬁve stimuli
responsive moieties on to their NP.
We have designed a photo-activated DDS capable of real time
communication using the photochromic properties of spiropyrans and
exploiting the diﬀerences in physiochemical properties. By adopting a
prodrug approach, we have developed an ibuprofen-spiropyran ana-
logue, which has displayed signiﬁcant stimulated release from within a
micelle environment. In addition, with the incorporation of a hydro-
phobic bodipy compound within the micelle hydrophobic core, we have
created a FRET communication between the two species present within
the micelle that has shown signiﬁcant potential for real time analysis of
content. In vitro analysis has conﬁrmed this system remains intact
within Hela cells. This smart DDS has the potential to be adapted for a
number of diﬀerent API, by simply linking the API with the spiropyran
Fig. 9. Bar chart: Fluorescence emission of 3 in HeLa cells
incubated overnight with micelles loaded with 3 and 4a
and following cycles of UV exposure (365 nm, 5 min)
leading to conversion of 4a to 4b and subsequent resting
time in visible light conditions permitting reversion of 4b
back to 4a. Line graph: control using micelles containing 3
only. Insert: % quenching of 3 following UV irradiation. **
indicates p < 0.005, * indicates p < 0.05.
Fig. 10. Confocal microscopic images of HeLa cells in-
cubated with micelles loaded with 3 and 4a showing (a)
Clear ﬁeld (b) Fluorescence emission of 3 (Ex 514 nm, Em
520–590 nm) before UV exposure (c) Fluorescence emis-
sion of 3 after UV exposure (365 nm, 5 min).
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through an ester or potentially an amide bond, thus increasing appli-
cation for such nanoplatforms to include a large number of drugs with
the only prerequisite being that they contain a suitable reactive func-
tional groups.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2017.08.013.
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Nanomedicine has evolved with the use of biological compounds such as proteins, 
peptides and DNA. These hydrophilic and often highly charged compounds require 
a delivery system to allow effective transport and release at the site of action. These 
new biological therapeutics have not replaced the more traditional smaller molecule, 
but instead are working synergistically to the benefit of the end user. To that end, drug 
delivery systems are now required to encapsulate both larger hydrophilic compounds 
as well as the smaller and generally more hydrophobic compound. This review 
highlights the emerging role in drug delivery of amphiphilic polymers that by their 
very nature can associate with compounds of differing physicochemical properties, in 
particular the role of micelles, polymersomes and nanocapsules.
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The requirement for delivering hydrophilic 
drugs has significantly increased in the past 
decade as medicine has evolved from the ‘one 
size fits all’ approach to drug development 
with thanks in part to the Human Genome 
Project (HGP) [1]. Since the completion of 
this landmark discovery there has been a 
pervasive increase and exploration of person-
alized medicine. The therapeutic use of siR-
NAs, proteins and enzymes has allowed for a 
revolution in healthcare regimes [2]. In order 
to reach its full potential, it is essential that 
such therapeutics can be delivered to their 
required site of action. The size and hydro-
philic nature of these compounds, combined 
with the fact they are often highly charged, 
presents a significant challenge from a formu-
lation perspective. One successful method of 
delivering these types of compounds to their 
target cells is through the use of liposomes. 
Since the late nineteenth/early twentieth cen-
tury scientists have appreciated that the cellu-
lar membrane consists of a lipid bilayer [3] and 
as such, most nonpolar compounds can read-
ily pass through this membrane to the inte-
rior of the cell. The translation of this mech-
anism for drug delivery purposes occurred 
in 1965 when Bangham [4] coined the term 
‘liposomes’ with a description of self-forming 
lipid vehicles capable of encapsulating com-
pounds for cellular transport. By mimicking 
the lipid bilayer, these vehicles, together with 
their content, could transcend the structur-
ally similar cell membrane and enter the 
interior of the cell. These self-assembling 
drug delivery systems (DDS) expanded from 
lipids to include both natural and synthetic 
polymers with the only prerequisite for suc-
cessful formation being the presence of both 
hydrophobic and hydrophilic units.
The use of biopharmaceuticals have not 
replaced traditional small molecule drugs; 
indeed, when prescribed together they often 
display a synergistic benefit to the patient. The 
advances in such combination therapies has 
led to the requirement of drug delivery sys-
tems to expand so that both hydrophobic and 
hydrophilic drugs can be delivered in the same 
vehicle simultaneously [5]. This can present a 
significant challenge as the physicochemical 
properties of these two classes of compounds 
are quite literally ‘polar opposites’.
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The development of drug delivery systems formed 
from amphiphilic building blocks has obvious bene-
fits when considering the delivery of compounds with 
distinctly different physical properties. These amphi-
piles can self-assemble in solution to form particles 
with both hydrophilic and hydrophobic regions that 
are capable of delivering a wide range of both polar 
and nonpolar compounds [6]. Often these particles 
have diameters in the nanometer range and provide 
improved stability for their cargo, have good bio-
compatibility with tissues and cells and due to their 
subcellular size display a relatively high intracellular 
uptake [7]. It has been established that nanocarriers 
can become concentrated preferentially in tumors, 
inflammatory sites and at antigen sampling sites by 
virtue of the enhanced permeability and retention 
(EPR) effect of the vasculature. Once accumulated at 
the site, these nanoparticles can act as a drug depot, 
providing a source of API to be released as and when 
required. This leads to enhanced bioavailability, a 
more sustained/controlled release and reduced toxic-
ity that can be caused by a ‘burst release’ of the API. 
Current nanoparticulate drug delivery systems being 
investigated include liposomes [8], micelles [9], nano-
spheres [10], nanocapsules [11], niosomes [12] and 
polymersomes [13,14] among others. Central to the 
development of these delivery systems is the flexibil-
ity offered by using polymers as the building block. 
In particular, amphiphilic co-polymers [15], that are 
formed from covalently linked polymer chains in 
blocks of two or more [16], have demonstrated sig-
nificant potential for the delivery of both large highly 
charged biological compounds as well as the more 
conventional small molecule and typically hydropho-
bic drug compounds. This article reviews the role 
amphiphilic polymers have played in creating 
such multifunctional delivery systems and in particu-
lar the recent developments in polymeric micelles, 
polymersomes and nanocapsules.
Amphiphilic polymers
Many examples can be found in the literature where 
amphiphilic polymers have been used for drug deliv-
ery applications [17]. Such polymers have the ability to 
form a variety of assemblies depending on both the 
number of monomers used in the polymer synthesis 
and the particular polymerization process chosen for 
their assembly [17,18]. The most common number of 
monomers used for the preparation of amphiphilic 
polymers is two, hence the term co-polymer [18], three 
monomers polymerized are known as ter-polymers [19], 
while one amphiphilic monomer can also create an 
amphiphilic homopolymer [20]. There are a vast num-
ber of hydrophobic and hydrophilic monomers used in 
the creation of amphiphilic polymers with some of the 
more common examples listed in Table 1. Co-polymers 
can form conformations with alternating [21], random 
[22], graft [23], star [24] or brush [25,26] type structures 
(Figure 1), with the particular type created dependent 
upon the method of polymerization chosen. The sim-
plest and most widely used of these structures is the 
random co-polymer, however these can be difficult to 
control in terms of reproducibility and so it is not sur-
prising that the brush copolymer and more recently 
the periodically grafted copolymers (PGCP) [27], 
which are a nonionic version of the ionenes, have gen-
erated significant interest. Once the polymer has been 
synthesized, it can then be assembled into a supramo-
lecular drug delivery system, using a number of differ-
ent techniques, such as the one step solvent evapora-
tion (simple emulsion evaporation [SEE]) method. In 
this procedure, the polymer is dissolved in an organic 
solvent and the drug added to the polymer solution. 
This solution is then combined with an aqueous phase 
to create an emulsion after which the organic solvent 
is removed, usually by heat or continuous stirring [28]. 
Although this method is the most common method 
used for NP preparation, it can be difficult to scale up 
for industrial applications and hence the use of super-
critical fluid technologies is also being investigated [29] 
among others [30]. This review will focus primarily on 
examples where amphiphilc polymers have been used 
to form polymeric micelles, polymersomes and nano-
capsules, as drug delivery vechicles, with a focus on 
block co-polymers. There is a high degree of diver-
sity within these formations depending upon both the 
polymer used and the method of formation. Figure 2 
illustrates a common formation of each of the DDSs 
to be discussed.
Key terms
Amphiphilic polymer: Co-polymers possessing both a hydrophobic and 
hydrophilic subunit.
Polymeric micelle: Self-assembling nanoparticles comprised of amphiphilic 
polymers with a hydrophobic core and hydrophilic corona.
Polymersome: Self-assembling nanoparticles comprised of amphiphilic 
polymers with a hydrophilic cavity, a hydrophobic interdigitated membrane and 
an outer hydrophilic corona.
Nanocapsule: Nano-sized self-assembling structures containing an amphiphilic 
polymeric wall surrounding a hydrophobic or oil core.
Hydrophilic compounds: Compounds belonging to Biopharmaceutics 
Classification System (BCS) class III, with high water solubility but low cell 
permeability. These compounds tend to be larger and often charged.
Hydrophobic compounds: Compounds belonging to BCS class II drug 
substances, with low water solubility and high cell permeability.
Simultaneous drug delivery: The incorporation of both a hydrophobic and 
hydrophilic drug into the same vehicle and subsequent drug delivery.
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Polymeric micelles
Polymeric micelles have been extensively studied due 
to their simple structure, ease of production and capa-
bilities of encapsulating and delivering hydrophobic 
drugs in their water insoluble core while their sur-
rounding hydrophilic surface enables the vehicle itself 
to be stored and administered in aqueous solution [31]. 
Polymeric micelles are formed by the self-assembly of 
amphiphilic polymers to from a hydrophobic core and 
hydrophilic outer layer (corona) as shown in Figure 2. 
They are typically very small in size (usually >100 nm) 
and enable protection of their cargo by limiting opso-
nin adsorption, which contributes toward a longer 
blood circulation time and better blood stability [32]. 
They have gained considerable interest in recent years 
because of their applicability to cancer therapy and 
their ability to incorporate a range of drugs with differ-
ent physicochemical properties. The hydrophobic core 
of micelles allows enhanced solubilization of hydro-
phobic drugs while the outer surface can be modified 
to attach specific ligands such as RNAs, DNAs and 
also other anticancer drugs [33] allowing for the simul-
taneous delivery of both hydrophobic and hydro-
philic compounds.
There are many interesting examples of where amphi-
philic polymer micelles have been used for the simul-
taneous delivery of both hydrophobic and hydrophilic 
drugs [34]. The most common approach is where the 
nonpolar core is used to encapsulate the hydrophobic 
drug while a charged outer corona (usually positively 
charged) is used to electrostatically interact with the 
biological component. Both Qian et al. and Bian et al. 
have successfully encapsulated doxorubicin in the 
core of the micelle and conjugated micro-RNA and 
green fluorescence labeled DNA [35,36] to the corona. 
Qian et al. used amphiphilic star branched copoly-
mers using polylactic acid (PLA) and polydimeth-
ylaminoethyl methacrylate (PDMAEMA) while 
Bian et al. used poly(ethylethylene phosphate)-block-
poly(e-caprolactone)-block-poly[2-(dimethylamino)
ethyl methacrylate (PEEP-b-PCL-b-PDMAEMA). 
The PLA and PCL chains formed the hydrophobic 
core whereas the PDMAEMA forms the positively 
charged outer corona to which the RNA/DNA was 
attached by electrostatic interactions. Another cationic 
monomer that has been used successfully to interact 
with miRNA is tetra-ethylene-pentamine (TEPA). 
Kumar et al. [37] created a co-polymer using TEPA, 
PEG, poly (2-methyl-2-carboxyl-proylenecarbonate) 
(PCC) and a decyl chain (DC) to treat pancreatic 
ductal adenocarcinoma with a hydrophobic hedgehog 
(Hh) inhibitor encapsulated within the center of the 
micelle and the tumor suppressant miR-let7b electro-
statically attached to the surface, both compounds 
were effectively delivered using the NP. Another 
polymer used to form of cationic polymeric micelles 
is branched polyethylenimine (PEI), in particular low 
molecular weight (LMW) PEI as it has reduced tox-
icity when compared to its higher molecular weight 
counterpart [38]. Gaspar et al. have incorporated PEI 
into a triblock copolymer to create a polymeric micelle 
capable of delivering minicircle DNA (mcDNA) [39]. 
These promising therapeutics are a class of nonviral 
gene expression vectors that present excellent charac-
teristics for future use in cancer therapy. Gaspar et al. 
combined the mcDNA delivery with hydrophobic 
DOX, which caused the zeta potential of the cationic 
micelle to reduce from +42.3 mV without the mcDNA 
to +21.9 mV after complexation. Mittal et al. [40] have 
also used cationic polymers to electrostatically bind 
with siRNA, however, instead of encapsulating a 
hydrophobic drug within the polymeric micelle, they 
chose to deliver the antimetabolite gemcitabine for the 
enhanced treatment of pancreatic cancer. Gemcitabine 
is a highly water soluble structure that if given orally 
suffers extensive first pass metabolism to inactive 
compounds. Its anticancer activity works by inducing 
S-phase arrest and inhibiting DNA synthesis. In this 
example, the authors conjugated the primary amine 
of gemcitabine onto the polymer backbone through 
amidation, which was released upon hydrolysis in vivo. 
They concluded that their cationic polymeric micelle 
achieved an 8–12% w/w gemcitabine loading and suc-
cessfully transfected and reversed chemo-resistance, 
invasion and metastasis in gemcitabine-resistant pan-
creatic cancer cells [40].
The alternative mechanism to utilizing a cationic 
corona is to create an anionic micelle. There are 
numerous examples within the literature whereby an 
anionic corona has been created thus attracting posi-
tively charged hydrophilic compounds for complex-
ation. One of the most common drugs to be electro-
statically attached to the corona is doxorubicin. As a 
chemotherapy agent DOX works by binding to DNA 
and inhibiting nucleic acid synthesis [41]. It can be 
combined with alternative chemotherapeutic agents 
that have different mechanisms of action, such as pacli-
taxel and curcumin. In the examples discussed above 
where DOX was the hydrophobic drug encapsulated 
within the micelle, it was in its free base state and 
therefore possesses limited solubility. However, when 
the primary amine becomes protonated it is both posi-
tively charged and water soluble which is why DOX 
is generally administered as its HCL salt form (DOX-
HCl). Sun et al. [42] have developed a micelle capable 
of encapsulating curcumin within the micelle and sub-
sequently binding DOX-HCl using a biodegradable 
poly(ethylene glycol)-poly(3-caprolactone) (mPEG–
18 Ther. Deliv. (2016) 7(1)
Figure 1. Different forms of copolymers that can be created from monomers (A and B) using different 
polymerization techniques.
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PCL) co-polymer. The resultant micelles were very 
small having a hydrodynamic radius of 25.3 ± 0.2 nm 
with a polydispersity index (PDI) of 0.065 ± 0.011 
and good encapsulation efficiency of 96.8 ± 0.30% 
and 99.3 ± 0.47% and drug loading of 4.85 ± 0.01% 
and 4.97 ± 0.02%, for DOX and curcumin, respec-
tively. The exact mechanism of DOX-HCl association 
is unclear, so it was presumed that hydrogen bonding 
must play a significant role as DOX has 12 hydrogen 
bond acceptors and six donors per molecule. Perhaps 
electrostatic interactions of the positive DOX are also 
involved, however the zeta potential for this micelle 
was not quoted. Lv et al. have also chosen DOX-HCl 
as the hydrophilic drug to deliver using polymeric 
micelles. They utilized micelles prepared from the neg-
atively charged poly (glutamic acid) to electrostatically 
bond to DOX-HCL with paclitaxel (PTX) encapsu-
lated within the core for synergistic anticancer activity 
[43]. Li et al. also describe DOX-HCl and PTX encap-
sulation using the polymer methoxy-poly(ethylene 
glycol)-b-poly(L-glutamic acid) (mPEG-b-PLG) [44]. 
In this example paclitaxel was covalently bonded to 
micelle via an ester bond while DOX-HCl attached 
using electrostatic and hydrophobic interactions. This 
system displayed increased release at both pH 6.8 and 
5.4 indicative of the pH found in tumor interstitial 
www.future-science.com 19
Figure 2. Simplified illustration of some types of nanoparticle that can form from amiphiphilic polymers.
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fluid and endosomes respectively as well as enhanced 
accumulation at tumor sites due to the EPR effect illus-
trating its potential for tumor delivery. When tested in 
human cancer cells (A549 and MCF-7) a synergistic 
effect was observed when both PTX and DOX were 
administered together while in vivo a 95.5% tumor 
suppression rate was observed which was significantly 
better than micelles containing free DIX (59.7%) or 
PTX (67.7%) showing its potential as a dual drug 
delivery system.
Tain et al. [45] have taken an interesting approach to 
dual drug delivery using micelles for the simultaneous 
delivery of two hydrophobic drugs. They prepared an 
amphiphilic PEGylated rapamycin micelle to solubilize 
the hydrophobic drug rampamycin and use the PEG-
rampamycin to further encapsulate another chemo-
therapeutic agent, in this case PTX. PEG-succinic acid 
(SA) was used to conjugate with the alcohol groups on 
the rapamycin, creating a PEG-SA-rapamycin amphi-
philic polymer which self-assembled and encapsulated 
PTX. The zeta potential of the overall system was -11 
mV and the novel nanomedicine offered a 20-fold 
improved potency over free PTX against a model mul-
tidrug resistant human breast cancer cell again reiterat-
ing the benefits of a synergistic approach.
The third and final option for the delivery of both 
hydrophobic and hydrophilic drugs by polymeric 
micelles is by the creation of neutral NPs. There are 
fewer examples of this type of micelle than either 
the cationic or the anionic forms; however the neu-
tral nature of the micelle will be beneficial when it 
comes to cell retention as it has been shown that 
the RES uptake of particles cannot be avoided if 
their zeta potential values are above -5 mV [46]. In 
these examples the amphiphilic polymers have the 
capability of encapsulating hydrophobic drugs and 
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further provide cross linking or conjugation of the 
micelles with another more hydrophilic drug. One 
such example of this was seen with the platinum-
based anticancer drug, cisplatin. Scarano et al. used 
a polycaprolactone-based amphiphilic copolymer to 
encapsulate curcumin and crosslinked the resultant 
micelles with cis,cis,trans-diaminedichloro disucci-
natoplatinum (IV) (Pt IV(COOH)
2
) derived from 
oxoplatin [47]. The resulting cross linked micelles 
had a very small size of about 38 nm explained by 
the loss of surface charge and possible contraction of 
micelles during cross linking. The resultant incorpo-
ration of both drugs in the same micelle provided a 
very high synergistic effect with the curcumin and 
platinum complex providing enhanced cytotoxicity. 
Another example using cisplatin was described by 
Li et al. [48] where the free carboxylic acid groups on 
the side chain of the polymer were cross linked with 
the cisplatin. As observed by Scarano et al., there was 
a significant reduction in the hydrodynamic radius 
of the micelle from 42 to 17 nm attributed to the 
cross linking within the micelle. Similarly, a synergis-
tic effect was again observed when the combination 
therapy was used. A further interesting example of a 
neutral delivery system was described by Noh et al. 
[49]. They used two separate micelles, and brought 
them together through electrostatic interactions to 
form a single delivery system; a muti-prodrug nano-
carrier (MPDNC). They achieved this by conjugat-
ing the hydrophilic drug gemcitabine (GEM) onto 
one polymer and the hydrophobic paclitaxel (PTX) 
onto another. To facilitate interaction between the 
two polymers a cationic charge was included within 
the hydrophobic carrier and an anionic charge on the 
hydrophilic carrier, thus ensuring the facile creation 
of a nanoparticle through electrostatic interactions 
between the two polymers and an overall nett neutral 
species.
All of the examples described above have used 
either encapsulation (dominated by hydrophobic 
interactions) or chemical conjugation to incorporate 
the hydrophobic drug compound within the micelle. 
The effect of each approach on the release kinetics 
of the drug has been explored by Li et al. [50]. They 
investigated PTX release from amphiphilic micelles 
where the drug was either encapsulated with or chem-
ically attached to the micelle. They concluded that 
at physiological pH (7.4) the encapsulated micelle 
resulted in a cumulative release of 16.3% after 48 
h compared to only 1.8% release for the covalently 
attached counterpart. However, in acidic solution 
where hydrolysis can facilitate release of the PTX an 
improved 25% cumulative release was observed. The 
overall zeta potential of this system was quoted as 
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-11 mV, which can be attributed to the folic acid used 
as a cell targeting moiety.
Table 2 provides a summary of some current poly-
meric micelles reported for the delivery of both hydro-
phobic and hydrophilic drugs.
Polymersomes
Polymersomes are polymeric capsules with an inter-
digitated membrane comprised of synthetic amphiphi-
lic block copolymers, Figure 2. Their macromolecular 
structure is similar to that of the liposome in that they 
are both composed of a bilayer of amphiphiles enclos-
ing an aqueous compartment [54]. However, the differ-
ence between these two vehicles is that most liposomes 
are naturally occurring phospholipids and as such have 
both a strong negative charge and lower molecular 
weight than the synthetic polymeric alternatives. This 
enhanced ability to specifically tailor polymersome for-
mulation methods, physicochemical properties, release 
mechanisms and even targeting chemistries make 
polymersomes an ideal platform for the encapsulation 
of a broad range of therapeutic molecules [16]. They can 
load hydrophilic, hydrophobic or amphiphilic com-
pounds allowing them to be exceptional in delivering 
bioactive molecules and combined loading of multiple 
drugs for synergistic therapy [55]. With the ability to 
tailor the properties of each polymer block as well as 
altering the hydrophilic to hydrophobic ratio a range of 
properties can be specifically tuned including size [56], 
encapsulation efficiency, pharmacokinetics including 
release rates, degradability and cellular entry as well 
as highly stable membranes avoiding drug leakage [57].
Another advantage of polymersomes is the ability to 
attach targeting moieties onto their surface to target 
receptors on cell membranes leading to site-specific 
delivery and so a more targeted release of payload. 
Targeting complexes such as RGD-containing pep-
tides, folic acid and carbohydrates have been used to 
recognize specific cancer cells [58,59]. It is not surprising 
therefore that one of the major avenues of research into 
polymersomes is focussed on cancer therapies. Interest-
ingly carbohydrates are known to be involved in many 
biomolecular recognition events such as cell adhesion 
and growth regulation; extracellular recognition as 
well as cancer cell metastasis and inflammation [59]. In 
a study by Das et al. [58] a glycopeptide-based polymer 
glycopeptide-b-poly(propylene oxide (GP-PPO) was 
used to form polymersomes to encapsulate both hydro-
philic and hydrophobic dyes calcein and rhodamine B 
octadecyl ester percholate (RBOE), respectively. Upon 
encapsulation of both complexes using the co-assembly 
method the hydrodynamic radius of the polymersomes 
Table 2. Recent examples of simultaneous delivery of hydrophobic and hydrophilic compounds in 
polymeric micelles and the polymers used in their preparation.
Hydrophobic Hydrophilic Copolymer Zeta (mV) PEG Ref. 
Monomer Drug Monomer Drug     
PLA DOX PDMAEMA mi-RNA Star +10 to +27 x  [35]
PCL DOX PDMAEMA/
PEEP
GFP-DNA Triblock terpolymer +18 x  [36]
PCC/DC GDC-0449 TEPA miR-let7b Copolymer with 
pendant chains
+5 √  [37]
PCC/DC ——— TEPA siRNA Gem Copolymer with 
pendant chains
+15 √  [40]
PEOz / PLA DOX PEI mcDNA Triblock copolymer +22 x  [39]
OA PTX PEI siRNA Graft copolymer +14 x  [51]
PCHLG Docetaxel PEI pDNA Trilock copolymer +33 x  [52]
PLL Docetaxel PEG siRNA Triblock copolymer +20 √  [53]
PCL curcumin PEG DOX-HCl Copolymer N/Q √  [42]
PLL/DOCA PTX PLG DOX-HCl Triblock copolymer -18 √  [43]
rapamycin PTX PEG-SA None Copolymer -11 √  [45]
PLG-PTX PTX PEG DOX-HCL Triblock copolymer -7 √ [44]
MPA/PLA PTX PEG/PAGE Cisplatin Block copolymer N/EQ √ [48]
PCL Curcumin PEGMEA/
PABPA
Oxoplatin Triblock copolymer N/EQ √ [47]
N/Q: Not quoted; N/EQ: Not expected or quoted.
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increased and encapsulation efficiencies (EE) were 
found to be on average 6.3% calcein and 23% RBOE. 
Although these EEs are relatively low it is important to 
note that a higher percentage of the hydrophobic agent 
has been encapsulated into the bilayer itself than the 
hydrophilic drug into the inner aqueous compartment. 
A similar observation was also reported by Xu et al. [60] 
who compared the uptake of DOX-HCl with its free 
base DOX using PEP polymersomes. The maximum 
encapsulation of hydrophilic DOX HCl was found to 
be 16.3% compared to a maximum 90% for DOX. 
These lower drug encapsulation efficiencies for the 
inner compartment of the polymersome could be due 
to the method of preparation of the nanoparticles, with 
the outer bilayer being more easily accessed than the 
inner cavity.
With drug resistance and toxicity a major limiting 
factor in cancer chemotherapy the idea of a combined 
treatment allowing the simultaneous delivery of multi 
anticancer drugs and or genetic components could 
overcome these issues as well as improve the pharma-
cokinetics of treatments for patient. Using the bio-
degradable amphiphilic copolymer mPEG-b-PLA to 
encapsulate small interfering RNA (siRNA) against 
the anti-apoptotic gene Bcl-xL and widely used DOX, 
Hyun-Ouk et al. [61] reported a marked increase in 
the cell death of two gastric cancer cell lines MKN-
45 and MKN-28 with the administration of these co-
loaded polymersomes, compared with free doxorubi-
cin, Bcl-xL-specific siRNA loaded Lipofectamine with 
doxorubicin as well as doxorubicin polymersomes. 
Release profiles for the co-loaded polymersomes at pH 
5.5 and 7.4 showed an initial burst release which was 
reflected in the results of the MTT study which show 
more than a 50% decrease in cell viability after 24 
h and a plateau of less than 30% viable cells reached 
after 48 h. This was compared with free doxorubicin, 
Bcl-xL-specific siRNA loaded Lipofectamine with 
doxorubicin as well as doxorubicin polymersomes 
which all displayed a much lower cellular toxicity after 
72 h of 60–70%.
The combination of the DOX-HCL and PTX has 
been found to be highly effective in the treatment of 
advanced breast cancer, however when administered 
alone or together without the aid of a nano-carrier, the 
severe dose-dependent side effects such as cardiotoxic-
ity, neutropenia and neuropathy along with multidrug 
resistance limit its use in the clinic [43]. This has led 
to extensive research into drug delivery systems for 
co-delivery of anticancer drugs. Table 1 displays some 
recent examples of where both these drugs have been 
combined within a polymeric micelle delivery sys-
tem. However, unlike micelles, polymersomes do not 
require either chemical conjugation or electrostatic 
interactions to combine both of these compounds, as 
they contain both hydrophilic and hydrophobic com-
partments. There are a few examples where these same 
drugs have been combined within a polymersome [57]. 
Iatrou et al. [62] have investigated two different poly-
mersomes for the independent delivery of DOX and 
PTX, comparing a tri block co-polymer with a ter-poly-
mer. They concluded that both forms of polymer were 
capable of encapsulating both drugs, but did not allude 
to whether the possibility of simultaneous delivery was 
to be investigated in the future but did anticipate the 
incorporation of genes with either of the anticancer 
drugs. Colley et al. reported the pH-sensitive poly2-
(methacryloyloxy)ethyl phosphorylcholine (PMPC)- 
poly 2-(diisopropylamino)ethyl methacrylate (PDPA) 
polymersome for both the combined and independent 
delivery of DOX and PTX [63]. They recorded com-
bined encapsulation efficiencies (%) of 42.7 ± 10.2 
and 37.1 ± 13.5 for PTX and DOX respectively with a 
hydrodynamic radius of 224.5 ± 43.5 nm, which is bet-
ter than some independent therapies. They conclude 
that the polymersomal combination of PTX and DOX 
in an in vitro tumor model displayed significantly less 
cell survival than any of the controls experiments.
As well as the research into polymersomes as dual 
drug delivery systems for cancer chemotherapy, they 
have more recently been investigated for a novel bac-
terial sensing application which allows the differen-
tiation between a serious pathogenic infection and a 
minor inflammatory response; in certain cases like 
bandage covered burn wounds, symptoms are often 
similar including elevated temperature and a decline 
in wound condition [64]. Haas et al. [65] described a 
hyaluronidase responsive amphiphilic block copoly-
mer which specifically targets the common Staphy-
lococcus aureus bacterium. Over 90% of strains of 
this bacteria secrete hyaluronidase and is known to 
be produced by Clostridium and Streptococcus spp, so 
by incorporating the naturally produced, biocompat-
ible, polysaccharide hyaluronic acid (HYA) into the 
polymer, Haas et al. have shown that in the presence 
of bacteria secreting this enzyme the polymersome 
itself was degraded. Enzymatic degradation begins 
slowly with only minimal reduction in size from 100 
nm after 10 min, however this lull is followed by a 
fast decrease, with degradation ceasing after 30 min 
with vesicles reducing in size to on average 30 nm. 
This 70% reduction in size of the polymersomes due 
to the enzymatic breakdown of its structure was then 
harnessed to allow the encapsulation of specific anti-
microbials. This allows the system to not only recog-
nize the bacterial infection but also release appropri-
ate therapeutics, as well as reporter dye molecules, at 
the correct sites to treat it.
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Dual delivery of silver nanoparticles with the 
hydrophilic antibiotic ampicillin using polymersomes 
have also recently been investigated by Geilich et al. 
[66] who found the co-administration led to syner-
gistic activity against the gram-negative genetically 
modified antibiotic-resistant Escherichia coli (E. coli) 
inhibiting or delaying its growth. Gram-negative 
bacteria are particularly problematic in relation to 
antibiotic resistance due to their outer selectively 
permeable lipopolysaccharide membrane, the pres-
ence of efflux pumps and the production of hydro-
lyzing β-lactamase. The co-delivery of reactive silver 
nanoparticles known to disrupt and indent the bacte-
ria cell wall leading to increased permeability as well 
as possible reactive oxygen species (ROS) release and 
ampicillin in a1:0.64 ratio led to complete growth 
inhibition in the resistant strain. Additionally, in the 
absence of silver nanoparticles no bacteriostatic effect 
was observed at any ampicillin concentration (free 
and polymersome loaded) suggesting its therapeutic 
efficacy is potentiated by the presence of the metal 
nanoparticles.
Table 3 summarizes recent examples where polymer-
somes have been used to deliver both hydrophobic and 
hydrophilic drugs as well as some interesting examples 
of single drug delivery.
Nanocapsules
One further nanoparticulate delivery system derived 
from amphiphilic polymers and discussed within 
this review is that of nanocapsules. These are nano-
sized structures containing an amphiphilic polymeric 
wall surrounding a hydrophobic or oil core (Figure 2). 
These vesicles are generally larger than micelles, typi-
cally ranging between 40 and 240 nm. They are com-
monly formed by an emulsification method [71] or the 
interfacial polymer deposition method [72]. There are 
a number of recent examples in the literature where 
nanocapsules have been used to deliver insoluble drugs 
such as naturally occurring compounds from plants 
such as polyphenols and carotenoids. These com-
pounds have gained increased interest due to their 
therapeutic potential [73,74–75] as antioxidants. Free 
radicals leading to oxidative stress are known to be a 
major cause of many disease states including degen-
erative and inflammatory conditions such as cancer, 
cardiovascular disease, diabetes, rheumatoid arthritis 
and age-related macular degeneration (AMD) [72,75]. 
Table 3. Recent examples of simultaneous delivery of hydrophobic and hydrophilic compounds in 
polymersomes and the polymers used in the preparation.
Hydrophobic Hydrophilic Copolymer Zeta (mV) PEG Ref.
Monomer Drug Monomer Drug     
EAB DOX PEG DOX-HCL Graft 
copolymer
N/EQ √ [60]
PPO RBOE GP Calcein Copolymer N/EQ x [58]
PCHLG ——— PEI + OA pDNA Brush 
copolymer
N/EQ x [67]
PCL Nile red HYA Calcein/gentamicin/
carboxy fluorescein
Copolymer N/EQ x [65]
PLA DOX PEG siRNA Copolymer N/EQ √ [61]
PBLG PTX PLL DOX-HCl Triblock 
copolymer
+ 45.3 - 
+48.2
x [62]
PBLG/PEO PTX PLL DOX-HCl Terpolymer +3.2 - + 5.4 x [62]
PNIPAM DOX amilFP497 PE545 (protein) Bioconjugate N/EQ x [68]
PLA/DAC ——— PEG Hb Graft co-
polymer
N/EQ √ [69]
PDLLA Ag NPs PEG Ampicillin Copolymer 0.3 √ [66]
PDPA PTX PMPC DOX-HCl Copolymer N/EQ x [63]
PLA DOX PEG Herceptin® Triblock 
copolymer
+27 √ [59]
PLA Atorvastatin PEG Lisinopril Tri block 
copolymer
-13 √ [70]
N/EQ: Not expected or quoted.
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Curcumin, resveratrol and lutein have all shown 
antioxidant, anti-inflammatory and chemotherapeu-
tic properties through their interactions with various 
molecular and cellular targets and most importantly 
their ability to neutralize harmful free radicals, how-
ever they display reduced bioavailability due to poor 
water solubility, rapid systemic clearance, inadequate 
tissue absorption and degradation at physiological pH. 
Nanocapsules have been studied in order to increase 
the water solubility of these compounds and subse-
quently increase their bioavailability enabling them to 
achieve their true therapeutic potential [74,75–76]. The 
nanocapsule can encapsulate these compounds within 
the hydrophobic protective inner core.
Nanocapsules derived from amphiphilc polymers 
that are capable of delivering two drugs with oppos-
ing solubility have not been widely studied. This is 
due to the oily core acting as the hydrophobic com-
partment while the hydrophilic polymers role is to 
impart polarity into the vehicle. There has been a sig-
nificant amount of research into the different oils that 
can be included within the center of these capsules 
and the synergistic co-encapsulation of hydrophobic 
drugs within. One example is the co-encapsulation of 
curcumin and resveratrol in lipid-core nanocapsules 
(LNC) by Friedrich et al. [73] and Coradini et al. [72] 
for the treatment of topical skin conditions and rheu-
matoid arthritis, respectively. They demonstrate that 
co-encapsulation of the polyphenols showed the most 
pronounced beneficial effect when compared with 
individually loaded nanoparticles or the free drugs in 
solution. In a similar study using curcumin encapsu-
lated in oil core nanocapsules (NC) for colon cancer 
treatment in vivo [77], it was discovered that altering 
the oil material in which the core was derived has a 
direct effect on size, zeta potential and encapsulation 
efficiency. Klippstein et al. looked at NCs derived 
from a PLGA-PEG conjugate (PLGA-NH-PEG-NH-
DTPA) with central cavities composed of either cas-
tor oil, soybean oil or miglyol 812 oil [77]. Nanocap-
sules with castor oil cores were found to be optimal 
as they showed the smallest size 150.5 nm ± 4.7 and 
the highest encapsulation and loading efficiencies of 
92.3 ± 1.6% and 18.4 ± 0.3% respectively as well as 
proving the most stable over a 28-day period with no 
significant changes in size. Miglcol 812 oil had the 
second highest encapsulation efficiency of 88 ± 0.4% 
and size of 205.5 nm ± 5.3 with soybean oil having 
the largest size (235.4 nm ± 9.6), lowest encapsulation 
efficiency (68.9 ± 2.9) and zeta potential (-45.3mV) 
of all three. Castor oil possesses the highest viscosity, 
surface tension and solubility of curcumin of all three 
oils and this is reflected in the characterization of the 
nanocapsules.
There is however a small number of reports high-
lighting the simultaneous delivery of hydrophobic and 
hydrophilic drugs (Table 4), such as the example pre-
sented by Chen et al. [78]. Similar to the mechanism 
adopted with polymeric micelles, they have used posi-
tively charged tertiary amine functionalized PLA as 
their hydrophilic monomer and allyl functionalized 
PLA as the hydrophobic counterpart creating a brush 
co-polymer. This positively charged nanocapsule can 
then electrostatically bind to negatively charged spe-
cies, in this case siRNA with the hydrophobic DOX 
encapsulated within the core. Using confocal micros-
copy they successfully visualized both DOX and fluo-
rescently labeled IL-8 siRNA in the same PC3 cells 
delivered using their nanocapsule.
Another example of simultaneous drug deliv-
ery is that by Hu et al. [81]. They have incorporated 
an additional triggered release into their nanocapsule. 
The release of drugs from nanocapsules has been 
shown to be slow, in particular for systems where a 
‘stealth’ property has been added by incorporation or 
adsorption of PEG or heparin onto the surface of the 
capsule [76,82]. The ability to actively control release 
of the payload by application of an external stimulus 
also has its advantages. A recent study by Hu et al. [83] 
showed that the encapsulation of magnetic nanopar-
ticles (MNPs) into the hydrophobic compartment of 
the capsules enabled a triggered release effect when 
Table 4. Recent examples of simultaneous delivery of hydrophobic and hydrophilic compounds in nanocapsules and 
the polymers used in their preparation.
Hydrophobic Hydrophilic Copolymer Zeta (mV) PEG Ref.
Monomer Drug Monomer Drug     
Allyl-PLA DOX Tert amine-PLA siRNA Brush copolymer +45 x [78]
PtBA DOX PEG Folate Brush copolymer N/Q √ [79]
PCL ——— PEO Rhodamine-dextran Star copolymer -16.3 √ [80]
PS Magnetic NPs PAA FITC-DNA Copolymer N/Q x [81]
N/Q: Not quoted.
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a magnetic field was subsequently applied. Amphi-
philic polymer PS
16
-PAA
10
 used to produce nano-
capsules through a simple scalable double emulsion 
method demonstrated that the release of hydrophillic 
FITC-labeled plasmid DNA and the hydrophobic 
dye pyrene could be increased by applying a high 
frequency magnetic field (HFMF) when co-encap-
sulated with MNPs. Release studies revealed FITC-
pDNA showed only 10–25% release after 10 days 
with pyrene less than 5% over the same time period; 
when HFMF was applied at different pulsed field 
strengths both showed initial burst release after 5 min 
with a total of 80% FITC-pDNA and 10% pyrene 
released after only 25 min at the highest field strength 
of 2.0 kA/m. Although the hydrophobic drug release 
rate overall was lower with and without the presence 
of a magnetic field the quantity released for pDNA 
and pyrene seems to be field strength dependent as 
the stronger the magnetic field resulted in more drug 
being released.
The use of nanocapsules for simultaneous delivery 
of hydrophobic and hydrophilic drugs is still rela-
tively new and with the efforts being made to develop 
new and advanced methods of preparation such as 
the melt dispersion technique described by Goven-
der et al. [83] or the use of organometallic coordination 
polymers to allow capsules to release cargo without 
themselves being damaged [84], these initiatives will 
allow for a rapid expansion in this particular field of 
drug delivery. Table 4 displays some recent examples 
of dual drug delivery using nanocapsules.
Triggered drug release
One of the fundamental problems associated with this 
area of drug delivery is that of drug release. The abil-
ity to only deliver the active component at the required 
site of action is the gold standard when considering 
therapeutic drug delivery. There have been signifi-
cant advances made in the quest to deliver this ‘sec-
ond generation health care’ such as the development 
of biopharmaceutical systems capable of interacting 
with intracellular components that respond as a direct 
result to environmental stimuli [85], lipid functionalized 
nanoparticles that specifically bind to tumor cells [86] 
and receptor targeted systems [87]. The use of stimulated 
release is also becoming more prevalent with amphiphi-
lic polymers and indeed in many reported examples have 
used external environmental changes to trigger the drug 
release, such as pH [73,79,88] redox [51,59,89, heat [59,68,90] 
and enzymes [59,65] among others [46,59].
Conclusion
This particular field of research, although having 
rapidly expanded in the past few decades, has still 
much to offer. The types of nanospheres available for 
assembly and encapsulation have increased to include 
more complex internal and surface structures such as 
those described by Sommerdijk et al. with their bio-
continuous polymer nanopheres (BPNs) [91] whereby 
the amphiphilic block copolymers are formed with 
a biocontinuous internal structure. This is achieved 
by the twisted hydrophobic phase intertwining with 
the hydrated hydrophilic moiety and could poten-
tially allow for the simultaneous controlled release 
of both hydrophobic and hydrophilic compounds. In 
addition to the changing morphologies, we are also 
developing a deeper understanding into the materials 
being used and how they can be manipulated for the 
benefit of therapeutics. Such examples are displayed 
by Swaminathan et al. [92] who have described the 
phenomenon of intercellular guest exchange using the 
Forster Resonance Energy Transfer (FRET) process. 
They describe two separate micelles showing intercel-
lular exchange of their hydrophobic cargo and this 
mechanism could potentially be further exploited for 
dual drug delivery. Another notable example has been 
the advances made to overcome the more complicated 
delivery routes such as using poymersomes as delivery 
systems to cross the blood–brain barrier (BBB) [93] 
and the use of nanocapsules in nose to brain drug 
delivery [94], as delivery across the BBB remains a 
major obstacle in the development of drugs targeted 
to the brain. One further example of the versatility 
of these compounds is presented by Wong et al. [68]. 
They have created a bio-conjugated thermorespon-
sive polymersome capable of encapsulating DOX and 
light harvesting proteins. However, a special feature 
of this work is the ability to clearly visualize where in 
the polymersome the cargo is situated so enhancing 
further our understanding of these systems.
In conclusion, there has been much progress made 
over the past decade in the development of delivery 
systems based on amphiphilic polymers for dual drug 
delivery applications. However, examples of where 
such systems have been used in the clinic are lim-
ited, with most trails to date focussing on the deliv-
ery of paclitaxel [95–97]. There is still much work to 
be done, in particular to improve the encapsulation 
and subsequent release of hydrophilic compounds. 
Nonetheless, few other drug delivery systems can 
rival the versatility offered by micelles, polymersomes 
and nanocapsules prepared from amphipilic polymers 
when it comes to exploiting these nanoparticles for 
simultaneous drug delivery. This is a relatively new 
area of research and no doubt more interesting exam-
ples will emerge in the coming years and we look for-
ward to reporting on these in due course.
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Future perspective
As the use of multidrug therapies continues to show 
improved efficacies, the role of drug delivery systems 
capable of transporting these combined therapies 
increases. This review discusses some of the most 
recent examples using amphiphilic polymers. A num-
ber of the DDSs discussed have patents associated 
with them [98,99–106] suggesting that translation into 
the clinic may be on the horizon. As a note of caution 
however, the fundamental and major limitation of this 
particular area of research is cost. Without a financial 
incentive the use of concomitant delivery of such drugs 
will remain the biggest rival to these advanced systems, 
and so the use of cheaper materials with facile scale 
ups and enhanced encapsulation capacities will be the 
future focus for such research.
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Executive summary
Amphiphilic polymers
•	 Amphiphilic polymers contain both a region of hydrophobicity and hydrophilicity.
•	 Depending on both number and type of monomers chosen as well as the method of polymerization they can 
be formed into a variety of different structures.
•	 Examples in the random, block and alternating copolymers as well as draft, star and brush-type polymers.
•	 These macromolecules have unique properties that they bestow on the final formulation, insuring that they 
can self-assemble into a large variety of nanoparticles utilized in drug delivery systems.
Micelles
•	 Self-assembling structure prepared from amphiphilic polymers and containing a hydrophobic core and a 
hydrophilic corona.
•	 Dual drug delivery is achieved by either electrostatically or covalently attaching hydrophilic compounds to the 
surface with hydrophobic compounds encapsulated within.
Polymersomes
•	 Self-assembling structure prepared from amphiphilic polymers with a hydrophilic cavity, a hydrophobic 
interdigitated membrane and an outer hydrophilic corona.
•	 The nature of these structures render them suitable for dual drug delivery with encapsulation of hydrophilic 
compounds within the central cavity and hydrophobic compounds dispersed within the hydrophobic 
membrane.
Nanocapsules
•	 Self-assembling containing an oily core surrounded by an amphiphilic polymer wall.
•	 Less commonly used for dual drug delivery than either the micelle or polymersome.
•	 Dual drug delivery has been achieved by electrostatically attaching a hydrophilic drug to the surface with the 
hydrophobic drug within the core.
Triggered drug release
•	 The use of an external or internal stimulant to trigger drug release at a particular time/region.
•	 Stimulated release is also becoming more prevalent with amphiphilic polymers.
•	 Examples can be found using pH, redox, heat and enzymes to trigger drug release.
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